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Abstract 
 
The burden of chronic inflammatory diseases, including inflammatory bowel diseases and asthma, is 
increasing around the world. An inverse relationship between early life exposure to microbes and larger 
pathogens and the prevalence of these chronic diseases is well supported. The human hookworm, 
Necator americanus, is one such pathogen which infects hundreds of millions of people worldwide. The 
hygiene and ‘old friends’ hypotheses propose that by removing hookworms and other pathogens we 
have eliminated an important factor in the normal development of the immune system. Many parasites 
have evolved to regulate host immunity through the production of excretory/secretory (ES) products. 
I hypothesized that the N. americanus ES proteome contains proteins which could be exploited ex vivo 
to limit inflammatory responses.  
Herein I describe, for the first time, the ES proteome of a human hookworm and utilize this data to 
carry out the first proteogenomic analysis of any parasitic helminth. This analysis significantly improved 
the available genome annotation, resulting in 3,425 fewer genes and increased numbers of introns and 
exons, total gene length and the percentage of the genome covered by genes. One hundred and ninety-
eight ES proteins were identified using liquid chromatography tandem mass spectrometry with the 
dominant families found to be SCP/TAPS and ‘hypothetical proteins’. In terms of sequence homology 
and families present, the findings compared well with closely related species including Ancylostoma 
caninum, Nippostrongylus brasiliensis and Heligmosomoides polygyrus.  
Using the Pichia pastoris expression system I expressed 4 of the SCP/TAPS proteins and tested their 
diagnostic screening potential as well as their therapeutic efficacy in the trinitrobenzenesulfonic acid 
(TNBS) model of murine colitis and the house dust mite (HDM) model of murine asthma. Vehicle-
treated mice that received TNBS experienced weight loss and significant colon pathology, and HDM-




  Page | 5 
serum IgE compared with controls. None of the recombinant SCP/TAPS proteins were found to be 
therapeutic when administered intra-peritoneally in the TNBS colitis or HDM asthma models.  
Ex vivo profiling of the recombinant ES proteins was carried out using peripheral blood mononuclear 
cells (PBMCs) isolated from the blood of healthy human volunteers. The hookworm recombinant 
protein NP17 consistently suppressed tumor necrosis factor (TNF)-α production by PBMCs that were 
stimulated with either LPS or PMA/ionomycin. A second protein, NP4, elicited pro-inflammatory 
responses in PBMCs in the form of elevated interleukin (IL)-6, IL-8 and TNF-α production. To provide 
insight into the potential binding partners of these proteins I used a human protein microarray. The 
results generated by probing of this array supported an immune regulatory role for at least some of 
these proteins in their interactions with host cells.  
The description of the N. americanus proteome offers a valuable source of information on the proteins 
in the N. americanus secretome, and at least one of the recombinant proteins shows promise as a novel 
biologic for the treatment of human inflammatory disorders. The future implications of this data are 
varied and may be useful for understanding the molecular basis of host-parasite interactions. It also 
provides a long list of potential vaccine candidates, diagnostic targets, and immunomodulatory 
biologics. Indeed, by profiling the impact of just four of these proteins on human PBMCs I have shown 
that at least one protein selectively suppressed the production of inflammatory cytokines. This 
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1  Chapter 1 - Introduction 
 
1.1 Inflammatory diseases 
 
Inflammation is a key immune response that occurs in defence against pathogens, cellular damage, 
irradiation and toxin exposure [1]. Typically, it acts to limit or remove damage in these circumstances 
and initiate the healing process [1]. However, in cases of chronic inflammation and dysregulated 
immunity, a number of immune-mediated diseases can occur. Immune diseases, encompassing allergy 
and autoimmunity, are on the rise in developed nations [2]. This has been attributed to a number of 
factors including improved diagnosis, lifestyle and genetic factors. Of particular note for their high 
prevalence and burden of disease are asthma and inflammatory bowel diseases (IBD).  
Atopic dermatitis, allergic rhinitis and asthma are common inflammatory diseases involving an 
inappropriate immune response to often harmless stimuli [3]. Asthma is a chronic, non-communicable, 
inflammatory disease characterised by repeated episodes of wheezing, chest tightening, coughing and 
shortness of breath [4]. Asthma affects people of all ages and demographics, and if left uncontrolled, 
these symptoms impose moderate to severe limitations on a person’s quality of life. While it usually 
begins in childhood, it has been shown to appear at any stage of life [5]. Asthma is often a lifelong 
condition. Half of the children with persistent asthma and three-quarters with severe asthma at age 6 
were shown to still be symptomatic at age 50 [6]. Given the global morbidity and health-care costs 
associated with asthma, the disease represents an area of great need. A number of studies have 
highlighted the association between asthma and IBD including both Crohn’s disease (CD) and ulcerative 
colitis (UC) [7].  
CD and UC are both idiopathic, immune-mediated inflammatory conditions affecting the 
gastrointestinal tract [8]. IBD typically begins in a person’s twenties or thirties with a majority of 
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degrees of mucosal inflammation extending proximally from the rectum [9]. This inflammation often 
results in severe superficial mucosal ulceration, fistulas, stenosis, and intestinal granulomas [10]. CD is 
similar in that it involves inflammatory driven lesions and ulceration however, it can manifest 
throughout the entire gastrointestinal tract [9]. The clinical manifestations of IBD can include 
abdominal pain, weight loss, haemorrhagic diarrhoea, anorexia and tenesmus [11].  
1.2 Epidemiology 
 
Asthma is the most common chronic disease in children and the most common respiratory disease 
worldwide, estimated to affect 334 million people [12,13]. Australia leads the world in terms of asthma 
prevalence with 1 in 9 of the population reporting asthma in 2014-15 [14]. Asthma affects twice as 
many children as adults and is one of the leading causes of missed school and work days, emergency 
department visits and hospitalisations [15]. While asthma prevalence is consistent or reducing in many 
developed nations, developing countries are seeing drastic increases as they become progressively 
westernised [16]. Migration studies reveal the importance of environmental factors in these global 
trends. Immigrants moving from low to high prevalence asthma countries begin with lower prevalence, 
increasing to similar proportions as duration of residence increased [17]. This effect was generally 
greater in second generation migrants and applied to multiple allergic diseases [17].  
IBD is primarily a disorder of the developed world. It afflicts more than five million people worldwide, 
including 1.4 million in the United States and three million in Europe [18]. The greatest increase in 
incidence however is being seen in traditionally low-prevalence regions including Asia and South-
America [19]. While some studies have reported gender distribution bias for IBD, others have described 
no such effect [20,21]. Although IBD onset has typically been middle-aged, the number of reported 
cases of paediatric IBD is increasing in northern Europe [22]. Further to this, prevalence gradients have 
been observed from north-south and west-east with higher rates in north-western countries [23,24]. 
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1.3 Aetiology and immunology 
 
Asthma 
Asthma entails a range of heterogeneous phenotypes for both children and adults afflicted. These 
phenotypes differ in presentation, pathophysiology and aetiology. Understanding the complex nature 
of the disease pathogenesis is key for the progress of treatment strategies as well as preventative 
measures. Research into asthma development highlights numerous genetic, host-environment 
interactions, in utero exposures, and immunological factors that contribute to the onset of asthma [16].  
From studies of twins, family history, familial aggregation and segregation, it is widely accepted that 
genetic factors contribute significantly to the development of asthma [25]. However, the exact 
contribution of genes when compared with environmental risk factors is significantly disputed. Some 
studies have reported heritability accounts for just 35% of the risk, whereas others claim the figure to 
be as high as 95% [25]. This disparity in the literature may be explained by the fact that asthma results 
from multiple gene interactions. While some of these genes are protective, others contribute to disease 
pathogenesis, with each gene having its own propensity to be influenced by environmental factors [25]. 
Genome-wide association studies have identified polymorphisms from both adults and children 
implicated in abnormalities in adaptive immunity as well as the epithelium barrier. The most notable 
of these are tim1, dpp10, opn3, ormdl3, phf11, gpra and pde4d [26]. While each of these genes will not 
be discussed individually in this review, their importance should not be overlooked. Asthma 
concordance in monozygotic twins is notably only 50%, highlighting the importance of other factors 
such as early-life exposures in asthma development [27]. These early life exposures, and the failure to 
account for them appropriately, is another likely reason for the inconsistencies in heritability risk 
percentages.  
A multitude of risk factors in the prenatal period have been implicated in asthma. These include 
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maternal smoking impaired lung function and was a consistent predictor for wheeze in the first year of 
life [29]. While the link between asthma and stress is less clear than maternal smoking, stress of a 
caregiver and infant immunoglobulin (Ig)E levels have been positively correlated [30]. Although roughly 
half of all infants experience wheezing, only 10-15% have diagnosed asthma by age 6 [31]. Exploring 
risk factors in childhood is essential for understanding this trend as well as potentially limiting disease 
frequency. Having multiple older siblings, consuming water with higher overall microbe content, 
attending early day care, growing up in close proximity with farm animals or cats and dogs, and living 
in a predominantly agrarian economy have all been reported to limit or reduce the risk of developing 
asthma [32-37]. Across these studies the impact was greatest in the first year of life and the reduction 
in the risk of sensitization observed was not allergen specific.  
When considering the immune responses involved in asthma pathogenesis, two distinct paradigms 
(adaptive and innate) are consistently reported. Both paradigms are similar in that they involve an 
aberrant immune response to non-pathogenic stimuli [38]. Early life allergen exposure is widely 
accepted as a key risk factor for subsequent development of allergic asthma [39]. When an allergen 
enters the airways it can directly interact with both airway epithelial cells (AECs) and conventional 
dendritic cells (cDCs) through pattern-recognition receptor (PRR) binding (Figure 1.1). Upon activation, 
AECs produce the chemokines CCL2 and CCL20, which attract immature pre-cDCs [39]. An array of 
signaling cytokines are also produced by activated epithelial cells to support the maturation of these 
immature cDCs to CD11b+ cDCs including granulocyte-macrophage colony-stimulating factor (GM-
CSF), IL-25, IL-1α, thymic stromal lymphopoietin (TSLP) and IL-33 [39]. These activated CD11b+ cDCs 
migrate to the draining mediastinal lymph nodes in an IL-13-dependent manner where they induce T 
cell differentiation and subsequent T helper type 2 (Th2) and T helper type 17 (Th17) responses [39]. 
Th2 cells secrete an array of pro-allergic cytokines including IL-3, IL-4, IL-5, IL-9, IL-13 and GM-CSF. 
These cytokines elicit responses that are dominated by eosinophils, but also contain mast cells, 
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the airways to allergens results in an early-type bronchoconstrictor response (EAR) which is driven by 
mast cells and typically lasts between 5-90 minutes. Specifically, IgE binds to mast cells to induce 
release of histamine, leukotriene C4 and prostaglandin D2. The late phase response (LAR) follows the 
EAR 3-12 hours post allergen exposure and is characterized by infiltration and activation of eosinophils, 
additional LTC4 generation, release of Th2 cytokines from mast cells and T cells, and an overall increase 
in airway responsiveness. While studies into EAR and LAR do provide a mechanism by which allergen-
induced exacerbations occur, they are not sufficient to explain the persistent inflammation seen in 
most instances of asthma. This Th2 type inflammation takes place in more than 80% of children and in 
a majority of adults with sensitization to pollen, pet dander, dust mites and fungi [40-42].  
 
 
Figure 1.1: Summary of epithelial cell and DC interactions and subsequent responses during 
sensitisation and challenge of experimental asthma. Airway epithelial cells and cDCs express pattern-
recognition receptors, directly activated by allergens which leads to the production of chemokines CCL2 
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cytokines including IL-4, IL-5, IL-9, IL-13 and GM-CSF. These cytokines lead to EAR and LAR characteristic 
of allergic asthma. Adapted from: [43] and [44]  
 
Asthma disease severity and duration are directly proportional to airway wall thickening. This airway 
remodeling is a key component of asthma pathogenesis to which numerous factors contribute. An 
increase in airway smooth muscle was first reported in 1922 as a key clinical feature in fatal asthma 
[45]. Since then a plethora of studies have reported on the varying contributors to airway remodeling 
and the underlying causes for this effect. Sub-epithelial basement membrane thickening in asthmatics 
results from the deposition of collagens type I, III, V, and VI along with fibronectin, tenascin, 
osteopontin and periostin [46,47]. These collagens are produced by a sheath of sub-epithelium 
myofibroblasts [4]. As a result of repeated injury from inflammation, an epithelial-mesenchymal 
trophic unit is established between the epithelial and smooth muscle layers of the airways [4]. Within 
this unit the epithelium is a significant source of platelet-derived growth factors, fibroblast growth 
factors, transforming growth factor-β (TGF-β) family members and functionally active periostin [48,49]. 
Furthermore, epidermal growth factors are produced by the epithelium, which play a key role in both 
smooth muscle proliferation and fibrosis [50]. Along with angiogenic factors and neurotrophin, these 
growth factors promote airway remodeling as a direct result of epithelial injury and impeded repair [4]. 
It is also important to note that defective resolution of inflammation pathways also play a role. By 
failing to effectively downregulate the inflammatory responses seen in chronic asthma, states of 
chronic inflammation contribute significantly to disease severity [51].  
 
Inflammatory Bowel Disease 
The aetiology of IBD is similar to asthma in that it is still poorly understood. While the triggers and 
underlying mechanisms are largely unknown, research points towards major contributing roles for 
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The number of gene loci associated with IBD is currently 163, with 110 linked to both CD and UC, 23 to 
UC specifically and 30 to CD [52]. These findings highlight the significant overlap between the two major 
forms of IBD which is particularly important for understanding their shared pathogenesis. Some of the 
most notable of these genes are nucleotide-binding oligomerization domain containing 2 (NOD2), 
autophagy related 16 like 1 (ATG16L1), and Immunity Related GTPase M (IGRM1), which play important 
roles in autophagy and immune responses [53-55]. Defects in the genes whose products are necessary 
for normal detection of the gut microbiota lead to an increased risk of IBD. In particular, NOD2 for 
bacterial sensing along with caspase recruitment domain-containing protein 9 (CARD-9) for fungal 
detection [56,57]. IL23R, the gene which encodes the receptor for the pro-inflammatory cytokine IL-
23, has been clearly linked with IBD for the role it plays in generation of Th17 cells [58,59]. Dysfunction 
in IL-10, a key immune regulatory cytokine, has also been linked with UC and CD [60]. IBD genetic 
research highlights a few key lessons in relation to the underlying disease mechanism. One is that there 
is an increasing number of gene loci implicated in IBD which emphasizes the important role genes play 
in disease pathogenesis. However, in terms of heritability, these variants only account for 20-25% in 
the aforementioned studies. This gap in explainable susceptibility loci is true for other polygenetic 
diseases such as asthma, and has been termed ‘missing heritability’ [61]. While many variants remain 
to be identified, considering gene-gene, gene-pathway and gene-environment interactions may help 
fill this gap [62]. 
Several environmental factors have been closely linked with an augmented risk of developing IBD 
including smoking, drugs, diet, stress and pollution. Of these factors, smoking is the most extensively 
explored prompter for IBD. A number of studies have shown a counter-intuitive protective effect of 
heavy smoking for UC as well as lower relapse rates, whereas for CD, smoking was found to increase 
the risk of development [63-66]. Prolonged, high-dose use of nonsteroidal anti-inflammatory drugs 
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use was particularly detrimental for risk of IBD when use occurred within the first year of life [69]. This 
effect of antibiotics points to the importance of considering gut microbiota in IBD pathogenesis. 
The human intestinal microbiome consists of more than 1,000 bacterial species with an individual 
person having approximately 160 species [70]. Differences, particularly reduced biodiversity, have 
been consistently reported between healthy individuals and IBD patients [71,72]. For CD these 
differences have been detected before the onset of disease, removing the possibility of IBD treatment-
induced variation [73]. While there is no definitive microbial community for someone with IBD, a 
number of species have been found to be comparatively reduced or increased [74,75]. Some of these 
differences include reductions in Bifidobacteriaceae and Erysipelotrichaceae families, with increases in 
Escherichia and Fusobacterium genera [76,77]. When inflamed and non-inflamed sections of colon 
were compared in people with IBD, abnormal flora was also present in many cases. This suggests that 
inflammation is not the only driver of microbial dysbiosis [78].  
The chronic inflammation experienced by patients with IBD is a hallmark of the disease and the main 
driver of clinical manifestations. The immunological mechanisms driving this inflammation, while 
poorly understood, vary across IBD types and occur in cycles of relapse and remission. In a healthy 
person, intestinal homeostasis is regulated by a careful balance of Th1, Th2, Th17 and regulatory 
responses. In IBD, dysfunction occurs at two key points: (1) impairment of the mucosal epithelial barrier 
and (2) inappropriate host acquired and innate immune responses. Although complex and often 
dissimilar across patients with IBD, the immunopathogenesis can be broken down into three distinct 
phases: (1) luminal contents penetrate into underlying tissue due to mucosal barrier defects, (2) limited 
clearance of this material due to inappropriate immune responses and (3) an acquired compensatory 
immune response which results in chronic inflammation and characteristic IBD associated lesions.  
As the intestinal lumen contains a plethora of microorganisms, one of the key roles of the mucosal 
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epithelial barrier in the initiation and worsening of IBD [79]. Indeed, the apical junction complex, 
consisting of tight and adherens junctions, is compromised in people with IBD [80]. As a result, many 
of these people experience increased gut permeability [81,82]. Moreover, mucin production by 
intestinal goblet cells is reduced in people with IBD meaning the protective mucus layer is suboptimal 
[83]. Innate immune cells, including DCs, macrophages, and epithelial cells, use PRRs to identify and 
respond to stimuli appropriately [84]. Loss of function polymorphisms in the bacterial sensing gene 
NOD2 (a PRR) is one of the strongest genetic associations linked with IBD [57]. When tolerance of self-
antigens is defective in the intestinal mucosa, either by genetic susceptibility or injury, it can contribute 
to IBD development [85]. These defects in the epithelium predispose people with IBD to increased 
antigen uptake, chronic immune activation and the resultant mucosal inflammation.  
With increased permeabilisation, the mucosal immune system and commensal flora come in contact 
much more frequently. Bacterial clearance was shown to be limited in these interactions due to 
defective cytokine production by macrophages [86]. When the host immune system is overexposed to 
commensal bacteria, a breakdown of tolerance can occur. DCs provide the interface been intestinal 
epithelial cells and T lymphocytes. They ensure tolerance to commensals is maintained by promoting 
T cell differentiation to regulatory phenotypes. Overactive DCs have been observed in IBD at sites of 
inflammation [87]. These DCs induce differentiation of effector lymphocytes as well as natural killer 
(NK) and NK T cells while eliminating regulatory responses [88]. A key contributor to overactive DCs is 
the abnormalities in PRRs such as the NOD receptors previously mentioned [88]. Indeed, 15% of 
patients with CD are heterozygous or homozygous carriers of a major NOD2 mutation [57]. These 
susceptibilities combine with a number of innate and adaptive immune alterations contributing to 
overall pathogenesis. 
In active IBD there is an imbalance between regulatory and effector Th cells and the respective 
cytokines [89]. In a healthy mucosa, macrophages are characterized by hyporesponsiveness to Toll-like 
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monocytes [90]. The acute phase of IBD involves dramatic increases in intestinal mucosa macrophages. 
In contrast to normal macrophages, these cells were shown to express a pro-inflammatory phenotype 
marked by increased production of IL-1, IL-6, IL-8, IL-12, TGF-β and TNF-α. TGF-β is a chemoattractant 
for additional macrophages, as well as neutrophils, and therefore increases recruitment of these cells 
[91]. IL-12 and TNF-α are potent inducers of pathogenic effector T cells [92]. Notably, the severity of 
UC and CD have both been correlated with increasing levels of serum TNF-α [93]. TNF-α augments 
production of other pro-inflammatory cytokines including IL-1β, IL-6, and IL-33, and has been shown to 
be involved in numerous pathological processes including increased epithelial permeability, granuloma 
formation and neutrophil recruitment [94-96]. For this reason it has become a key target for the 
treatment of both UC and CD with numerous anti-TNF drugs on the market [97]. 
1.4 Treatments and limitations 
 
Asthma 
Currently there is no preventative or cure for asthma itself. Instead, clinicians attempt to treat and 
prevent the symptoms to give patients the best quality of life possible. The first line of treatment for 
asthma is inhaled corticosteroids. Corticosteroids are the most efficient anti-inflammatory treatment 
available for numerous inflammatory diseases, including asthma [98]. Corticosteroids such as 
Budesonide work through the binding of glucocorticoid receptors (GR) found in the cytosol of most 
cells in the body [99]. Upon ligand binding and activation, the GRs are released from chaperone 
proteins (heat shock proteins) which then has three key anti-inflammatory effects within the cell [100]. 
Firstly the corticosteroid-receptor complex travels to the nucleus where it forms a homodimer and 
binds to the promotor region of DNA sequences called glucocorticoid response elements [100,101]. 
This binding trans-activates genes encoding anti-inflammatory proteins [101]. The second effect 
involves an interaction between the GR complex and other transcription factors – namely nuclear 
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suppress gene transcription of inflammatory molecules [100,101]. The final effect again takes place in 
the nucleus where the GR increases the expression of tristetraprolin, which binds to mRNAs encoding 
inflammatory cytokines, destabilizing them and therefore reducing their expression [100]. 
Although highly effective at treating the inflammation associated with asthma, glucocorticoids are not 
curative or disease limiting, even when started early in childhood [44]. Furthermore, there are 
significant limitations associated with long-term or high-dose glucocorticoid use. Some of the more 
serious effects include adrenal atrophy, hypertension, psychoses, immunosuppression, delayed wound 
healing, and foetal growth retardation [101]. Additionally, inhaled corticosteroids offer limited to no 
efficacy for virus-induced exacerbations or for asthmatics who smoke [44].  
Corticosteroids are commonly used with β2-adrenoceptor agonists (β-agonists) which upon inhalation, 
mediate smooth muscle relaxation. β-agonists work by binding to β2 adrenergic receptors (β2AR) 
[102]. The receptor is coupled with stimulatory G protein and adenylyl cyclase. Activation results in the 
formation of cyclic adenosine monophosphate which stimulates phosphate kinase A to phosphorylate 
myosin light chain kinase in bronchial smooth muscle cells, ultimately ending in relaxation of the 
airways [102].  
One of the major limitations of β-agonists is their short half-life, meaning continual drug re-
administration to maintain a therapeutic effect [44,98]. To combat their short acting nature, formoterol 
and salmeterol, two long acting β-agonists (LABAs) can be used. However, a large systematic review of 
mortality associated with formoterol in 2009 found that patients taking this drug are at a 2.0-3.2-fold 
increased risk of death due to asthma [103]. Other studies have highlighted that subsensitivity 
(tolerance) occurs with prolonged use of LABAs, meaning higher doses are required to achieve the 
same efficacy [104,105]. Further, mono-treatment with LABAs is not recommended as it may mask 
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Comparatively recent treatment for asthma has emerged in the form of monoclonal antibodies (mAb). 
The only currently approved and available mAb for treatment of asthma is Omalizumab, which was first 
registered in Australia in 2002 [107]. Omalizumab is an anti-IgE mAb which disrupts the interaction 
between IgE and its receptor FcεRI, whilst also decreasing the expression of FcεRI on mast cells and 
basophils [107]. The result is inhibition of mast cell degranulation and prevention of histamine release. 
This in turn precludes bronchoconstriction and mucous production which would have otherwise taken 
place [107]. Other mAbs have been developed to target multiple Th2 and inflammatory pathways 
involved in asthma including anti-IL4, anti-IL5, anti-IL13, anti-TSLP and anti-TNF-α. The large number of 
clinical trials involving these mAbs have found them to be less successful than Omalizumab [108]. 
Allergen specific immunotherapy (SIT) is an alternative method for treatment of allergic rhinitis, some 
drug allergies, venom hypersensitivity and bronchial asthma [44]. SIT induces immunological tolerance 
rather than sensitisation, and stimulates the production of blocking IgG4 antibodies through repeated 
exposures to allergens [44]. Despite being quite effective for a majority of asthmatics, induction of 
tolerance with SIT usually takes several months and in some cases even longer. A key drawback of SIT 
is the reporting that some people experience systemic, life threatening side-effects and even death 
[109-111]. This has caused some nations (e.g the United Kingdom) to restrict the availability of SIT for 
asthma [112].  
 
Inflammatory Bowel Disease 
Much like asthma, IBD has no cure. Instead treatment is aimed at reducing inflammation, dampening 
down the immune system, and inducing remission. The first line of treatment for UC is often 
aminosalicylates, while glucocorticoids are used for CD. When these prove unsuccessful, clinicians 
move on to other immunosuppressants and biologics such as antibody treatments. Treatment choices 
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other [93]. For example, 5-aminosalicylates (5-ASAs) are effective at maintaining remission in UC by 
reducing pro-inflammatory cytokine production as well as blocking neutrophil recruitment and 
inactivating NF-κB [113,114]. While they work well for people with UC, they have little effect in CD 
[115]. Corticosteroids are a first line treatment for CD and are commonly used to induce remission 
through similar effects as 5-ASAs [116]. Other classical immunosuppressive drugs used in IBD are 
methotrexate and cyclosporine-A which suppress inflammatory cytokines including TNF-α and induce 
apoptosis [117-119]. Glucocorticoids, while often effective at inducing remission in people with IBD, 
come with numerous side effects. The GR receptor is located on many cell types which results in non-
specific coverage, increased patient susceptibility to infections, and the other aforementioned effects 
as seen in asthma treatment.  
Given that a few key cytokines such as TNF-α and IL-1β play such key pathogenic roles in IBD 
progression, therapy targeting these molecules has been explored. Indeed, some mAbs have been 
shown to be highly successful for treatment of IBD. Specifically, anti-TNF agents such as adalimumab 
and infliximab work well in maintaining remission in both UC and CD [120,121]. By blocking the TNF 
receptor, these drugs limit the production of other pro-inflammatory cytokines, prevent regulatory T 
cell (Treg) apoptosis and promote wound healing through alternatively activated macrophages 
(AAMacs) [122]. Although anti-TNF agents have drastically improved outcomes for people with IBD, 
they are not effective for everyone [123]. Moreover, many people taking these drugs see a reduction 
in efficacy over time while others become intolerant [124,125]. When anti-TNF stops working it isn’t as 
simple as targeting other pro-inflammatory cytokines. Among other adverse effects, anti-IFN-γ and 
anti-IL-17A antibodies can also unexpectedly aggravate CD [126-128]. This attests to the complexity of 
the immune responses that result in IBD. Some traditionally pro-inflammatory cytokines may, in fact, 
have multiple functions. 
There is no question that treatments for patients with IBD have improved over the past few decades. 
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and improved quality of life. However, 30-40% of patients with CD and 20-30% with UC will still require 
surgery for their condition at some point [129]. This attests to the need for new therapeutics, 
particularly those that are better targeted and safer in the long term.  
1.5 Hygiene hypothesis 
 
The ‘hygiene hypothesis’, first proposed in 1989, came about in an attempt to explain the drastic rise 
in autoimmune and allergic diseases over the past few decades. The theory was based on observations 
from Strachan who found differences in the rates of atopy in children from rural versus urban settings, 
and from smaller vs larger families [130]. From this he concluded that those who grow up in relatively 
sterile environments were more likely to develop immune disorders [131].  
Much of the support for the hygiene hypothesis comes from studies comparing rates of allergic 
diseases among populations in urban vs rural environments. Multiple studies have found that children 
who grew up in a microbe-rich environment (such as a farm) had reduced risk of allergic diseases 
[132,133]. Among these children, the effect was magnified for those who were around livestock 
specifically. Further, protection was notably higher when that exposure occurred prenatally or within 
the first year of life [134].  
When looking globally at autoimmune disorders and allergy, there tends to be an inverse relationship 
between these afflictions and rates of infectious diseases [135]. Over the past few decades the 
prevalence of asthma, Crohn’s disease and type 1 diabetes have increased by more than 300% in 
developed settings while many infectious diseases have been completely ablated by vaccines and 
improved sanitation [135]. Given that the rise of immune diseases has occurred almost exclusively in 
developed or quickly developing countries, it raised the question of whether we were becoming too 
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In support of this, diseases such as asthma and IBD are more common in people exposed to antibiotics 
early in life [136-138]. Similarly, as aforementioned, early life exposures to environments higher in 
microbes (i.e. farmland and larger families) are linked to lower rates of allergy [132]. However, there is 
conflicting evidence which now suggests the hygiene hypothesis may be too simplistic. While lower 
socioeconomic nations tend to have higher rates of infection and lower rates of allergy and 
autoimmunity, it does not mean all infections are beneficial. For instance, repeated respiratory tract 
infections are associated with higher rates of asthma later in life [139].  
Although epidemiological data does not provide a mechanism, one explanation for these findings is 
that early life infections are important for the normal development of the immune system. A 
refinement of the hygiene hypothesis was offered by Rook in 2003, called the ‘old friends’ hypothesis 
[140]. Rook suggested that regular and early exposure to a wide range of harmless microorganisms he 
termed ‘old friends’ is necessary for training the immune system to respond appropriately [140]. The 
problem is not just about numbers of infections but rather the diversity, timing, and nature of 
exposures. The human immune system evolved in a time before antibiotics, sterile drinking water, 
effective waste removal and sanitation. It was therefore frequently exposed to numerous microbes 
and parasites which, with recent urbanization and industrialization, have drastically been reduced. It is 
likely that lack of exposure to these ‘old friends’ has removed necessary educational material for 
appropriate immune function [141]. In support of this, numerous studies have now shown that the 
microbiota is implicated in a range of health problems including diabetes, allergy, obesity and even 
mental health [142-144].  
1.6 Helminths, modified immunity, and regulatory T cells 
 
Despite being the largest organisms that infect humans, most species of helminths are capable of 
surviving for years without provoking an immune response that is sufficient to eliminate all of the 
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response required would likely be more detrimental to the host than tolerating light to moderate worm 
burdens. For this reason, regulatory mechanisms have evolved, either parasite or host-induced, which 
limit parasite expulsion while protecting the host from excessive immunopathology [145,146]. Indeed, 
it has been hypothesised that the Type 2 arm of the immune response evolved to combat helminth 
infections, as well as to limit and repair the damage they inflict during migration and feeding [147]. This 
immune response is characteristic of helminth infections and involves production of the cytokines IL-
4, IL-5, IL-9, IL-13, IL-25 and IL-33 [148]. Through various signaling cascades, these cytokines coordinate 
Th2 cell differentiation, B-cell class-switching to IgE, and inflammatory cell recruitment, all in an effort 
to kill or expel the parasite [149]. 
The Type 2 immune response to helminths and the immune response seen in allergy share significant 
similarities. Like a helminth infection, atopic asthma involves a Type 2 response, but results in mucus 
production in the lung, bronchoconstriction, smooth-muscle contraction and airway remodeling [43]. 
Logically, helminth infections — notably those where larval worms navigate through the pulmonary 
vasculature en route to the gut — should therefore augment asthmatic responses due to the similar 
nature of the immune responses they elicit; however, the opposite scenario may be true in some 
instances. This is likely because helminth infections promote a modified Type 2 response and 
concurrent regulatory immune responses that induce a state of hypo-responsiveness that prevents the 
development of allergic disease [149]. 
Tregs are an integral part of the immune system, responsible for regulating pro-inflammatory immune 
responses via the production of IL-10, IL-35 and TGF-β [150]. Studies have shown that Tregs from 
asthmatics are dysfunctional, which contributes to the exaggerated immune response to allergens 
[151,152]. Helminths on the other hand, have been shown to increase the number and enhance the 
functional capacity of Tregs during infection. For example, in cross-sectional human studies, chronic 
infection with schistosomes and filarial nematodes were associated with higher levels of IL-10 and 
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the intestinal parasites Trichuris trichiura and Ascaris lumbricoides were found to constitutively secrete 
more IL- 10 and TGF-[150]. The opposite effect has also been reported with anthelmintic treatment 
of humans, which resulted in a reduction in Treg cell numbers [155]. Evidence from animal models 
provides a similar picture. For example, frequencies and absolute numbers of Foxp3 + Tregs increase 
early in an infection with Heligmosomoides polygyrus, a rodent model of gastrointestinal human 
helminth infection, and this is associated with protection against lung inflammation [156-158]. This 
induction and persistence of Tregs is important for long-term parasite survival, as Treg depletion leads 
to a protective immune response and parasite expulsion [145]. There have also been a number of 
clinical trials utilising experimental helminth infections to treat immune diseases which will be 




Hookworms, along with whipworms and roundworms, make up three of the most pertinent and life-
limiting parasitic infections worldwide [159]. The Necator and Ancylostoma species of human 
hookworm infect more than 400 million people in tropical regions of Asia, Africa and South America 
[146]. The pathology caused by hookworm infection is predominantly due to blood loss caused by 
feeding adult worms. This blood loss is tightly correlated with worm burden. Chronic infection with N. 
americanus results in fatigue, abdominal pain, diarrhoea, weight loss and anaemia [160]. In children, 
anaemia can cause growth retardation and impairments in cognitive development [161]. In pregnant 
women, these infections lead to poor birth outcomes including low birth weight, increased perinatal 
morbidity as well as increased mortality [162,163]. Moreover, hookworm infections result in 3.2 million 
disability-adjusted life years (DALYs) lost every year [164]. Due to these effects, and as a result of their 
ubiquitous nature, these infections contribute significantly to widespread poverty in the majority of 
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The life cycle of N. americanus is direct, with no intermediate hosts involved. Eggs are passed out of 
the body in the faeces and, under favourable conditions, hatch releasing rhabditiform larvae. Parasites 
develop to infective L3, non-feeding filariform larvae that can penetrate the skin to infect a human host 
[166]. Upon infection the parasites migrate through the circulatory system to the lungs, where they 
move up the trachea, are eventually swallowed, and ultimately reach the small intestine where they 
can live for up to 10 years [146,166]. It is here in the small intestine where blood loss begins to occur, 
predominantly as a result of leakage around the feeding site of the worm [146]. 
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Diagnosis of hookworms are important to confirm infection for clinical purposes as well as mapping for 
transmission and targeted interventions. Examining faecal samples (molecular or microscopic) is key to 
diagnose infections. Given the above lifecycle, the faeces of infected persons include eggs, and often 
parts or whole larval stage parasites. For microscopic purposes, these must be processed fresh within 
24 hours before the eggs completely hatch and migrate out of the stool [146]. Diagnostics are 
particularly important in mass drug administration (MDA) campaigns. In this context it shows the 
effectiveness of these programs while also dictating whether other measures will become necessary. 
Microscope-based methods, while cheaper and more readily available, are inadequate in their ability 
to detect very low level infections and consequently fail to inform MDA action appropriately [167].  
Molecular based examinations are far more sensitive and are able to provide egg-per-gram 
measurements on frozen or fresh samples. While more costly and difficult to implement in the field, 
they are able to better differentiate hookworm species and obtain data on other parasitic infections 
simultaneously [168]. These tools are particularly useful for informing MDA approaches based on the 
risk of morbidity from infection. This kind of information is crucial for children and childbearing women 
who are most at risk of developing the iron deficiency anemia resultant from infections. The availability 
of ‘omics’ data, offers new tools for improving potential diagnostics as parasite antigens become 
increasing known [169]. 
 
1.7.1 Host-parasite interactions 
 
Parasites have evolved alongside humans for millions of years. As a result, they have developed 
mechanisms to evade, subvert and ultimately survive their host’s immune response. The ways by which 
parasites have achieved this immune evasion varies between parasites. One of the classic examples of 
parasite immune evasion is antigenic variation, which is employed by the unicellular parasites 
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multicellular blood fluke Schistosoma, where host cell surface proteins are adsorbed onto the parasite’s 
surface to make it undetectable by circulating immune cells [172-174].  
In gastrointestinal helminth infections, long-term infections with limited pathology are common. This 
fact combined with the finding that infected populations exhibit less allergic diseases has led to studies 
attempting to explain how these infections limit inflammation and associated disease. The three most 
common human gastrointestinal helminths, N. americanus, A. lumbricoides and T. trichiura, are 
strongly linked with immune hyporesponsiveness measured as changes in circulating cytokines and 
regulatory cells. Specifically, the regulatory cytokines IL-10 and TGF-β1 have been reported to be 
elevated in patients in direct proportion to burdens of infection [150,175].  
Despite the high prevalence of N. americanus infections globally, data on immune responses in human 
naturally acquired infections is limited. Nevertheless, experimental human infections with N. 
americanus and mouse studies with hookworm-like nematodes have been able to shed light on the 
immunopathological responses to these parasites. Initially, host immune responses are aimed at 
targeting invading parasites. These initial responses manifest as systemic and localized eosinophilia and 
mastocytosis [176,177]. The predominant response in experimental human infections is increased 
mucosal expression of Th1 cytokines such as IFN-γ, IL-2 and IL-15, and Th2 cytokines such as IL-4, IL-5 
and IL-13 [177]. Even with these immune responses, adult hookworms are rarely ousted from the 
human gut. Additionally, despite this distinct immune response caused by hookworms, infected 
individuals do not show signs of allergy to the parasite [146]. Conversely, infected individuals have been 
shown to be afforded protection from developing allergies to other antigens [178].  
Mouse immune responses to Nippostrongylus brasiliensis have been extensively explored because of 
its similarity to N. americanus. In this model there is significant evidence of host acquired immunity as 
well as clearance of the nematode from the lungs and gut. IgE-armed basophils have been shown to 
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brasiliensis elicits Th2 cell responses in the form of IL-4 and IL-13 as well as goblet cell hyperplasia which 
is effective in causing worm expulsion [180]. In contrast with this model, there is little evidence of 
immunological clearance of N. americanus from humans despite similar robust Th2 responses. In 
experimental human infection, some immunity has been described with both polyclonal and parasite-
specific IgE found to offer protection against hookworm infection [181]. Furthermore, a negative 
association between parasite-specific IL-5 concentrations and the likelihood of hookworm reinfection 
following treatment has been demonstrated [182]. While immunity to hookworm is not evident at a 
population level, this suggests an important role for eosinophils in the mediation of defence against 
these parasites [182].  
1.7.2 Live infections and ES products 
 
A number of clinical trials have explored using either N. americanus or Trichuris suis to treat 
inflammatory disease. These helminths, in some clinical trials at least, have been found to limit disease 
in patients with IBD. One such study found that T. trichiura led to UC remission and an increase of IL-
22+ CD4+ T cells of a single self-infected volunteer [183]. Another study showed promising results using 
T. suis ova (TSO) in the treatment of people with UC [184]. However, when large randomised controlled 
trials were carried out to confirm these findings, TSO therapy showed no statistical improvements for 
patients with either CD or UC [185,186].  
There has been mixed support for helminthic treatment for allergic rhinitis and asthma. Some studies 
have reported improvements in airway responsiveness and a reduction in the need for medication, 
while others found no improvement in any tested parameters [187,188]. More recently, experimental 
infection with N. americanus was found to restore gluten tolerance in people with coeliac disease. 
While the precise mechanism for this improvement is unclear, duodenal biopsy post-infection revealed 
intra-epithelial upregulation of CD3+ CD4+ Foxp3+ Tregs with increasing gluten exposure [189]. 
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T cells provides a potential mechanism by which N. americanus parasites limit disease outcomes. 
Multiple sclerosis (MS) patients infected with gastrointestinal helminths were found to have fewer 
relapses, lower disability scores and reduced MRI activity compared with uninfected MS participants. 
Following anthelmintic treatment, absolute numbers of CD4+ CD25+ Foxp3+ Tregs markedly decreased 
as did the number of IL-10- and TGF--secreting cells, and MS outcomes worsened [190]. 
While these studies show that helminth infection shows promise for suppressing immunopathology in 
some inflammatory diseases at least, a stigma exists around infections with a live pathogen to treat 
disease. This has led to more studies examining the molecular interface between host and parasite, 
with particular emphasis on the parasite secretome and its immunomodulatory properties.  
A number of studies have shown that crude excretory/secretory (ES) products from the dog hookworm, 
Ancylostoma caninum, protected mice against chemically induced colitis. In these studies adult stage 
hookworms were removed from their hosts and cultured to generate crude ES products which was 
subsequently injected into mice. ES-treated mice had decreased macroscopic inflammation scores, less 
inflammation and reduced myeloperoxidase activity [191-193] after administration of colitis-inducing 
chemicals. The ES products of A. caninum and N. brasiliensis have already been characterized, revealing 
313 and 315 proteins respectively [194,195]. These proteomic analyses not only validated these 
parasites as suitable model species for studying the human hookworm N. americanus but also 
identified a suite of proteins of unknown function. These proteins of unknown function represent an 
array of potentially immunomodulatory molecules which could be used to treat inflammatory disease. 
Characterisation of the N. americanus ES products, most likely due to the difficulty in acquiring 
sufficient material, is yet to be reported. A large proportion of the human hookworm proteins remain 
unknown in terms of identification and function. It is likely the profile of the ES products will be similar 
to the closely related aforementioned species. Of particular relevance in these publications has been 
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SCP/TAPS have also been labelled SCP/Ag5/PR-1/Tpx-1/Sc7 (Pfam: PF00188) and are a part of the 
cysteine-rich secretory protein (CRISP) “superfamily” [196]. SCP/TAPS proteins share a common 
primary structure usually including a signal peptide followed by the SCP domain [197]. SCP/TAPS 
homologues have been found in numerous invertebrates, particularly roundworms, flatworms, 
arthropods and plants. Despite their prevalence, attempts to define specific role classification for these 
proteins has been limited. In parasitic nematodes, Ancylostoma-secreted proteins (ASPs) were initially 
characterized from hookworms and later from related strongylid nematodes [197]. ASPs were found 
to be highly abundant in the ES products of L3 larvae. This finding has led to the belief that they play 
an important role in infection and transition from free-living to the parasitic adult stage of development 
[198,199]. Due to their immunogenic properties, ASPs have been and should continue to be explored 
for their potential as vaccine candidates [200,201].  
Defining SCP/TAPS has typically been based on the number and features of the SCP domains. Three 
classifications have broadly emerged namely: ‘double domain SCP/TAPS’ with two separate SCP-
domains, and ‘N-type’ and ‘C-type’ single domain SCP/TAPS [197]. Double domain and C-type single 
domain SCP/TAPS have been the dominant identified proteins in a range of parasitic nematodes [197]. 
Given the importance and abundance of SCP/TAPS in a wide range of eukaryotes, greater classification 
and functional information is needed. In particular functional data may aid approaches into control of 
infectious diseases (e.g. vaccines) or therapies based on immune regulatory roles.  
A number of publications have begun to elucidate the functions of specific hookworm proteins by 
producing recombinant versions. Recombinant A. caninum NIF (neutrophil inhibitory factor), a 
SCP/TAPS protein, inhibited Th2 cytokine production, eosinophil recruitment and infiltration, mucous 
secretion, and goblet cell hyperplasia in an OVA-induced mouse model of asthma [202]. In 2016, 
Navarro and colleagues showed that a single recombinant protein from the ES of A. caninum, termed 
AIP-2, suppressed airway inflammation in a mouse model of asthma [203]. AIP-2 was revealed to have 
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human DCs and inducing the expansion of mouse mesenteric CD103+ DCs which resulted in generation 
of Tregs that localize to the mucosa [203]. More recently, an ES protein from H. polygyrus (coined H. 
polygyrus TGF-beta mimic (Hp-TGM) with no homology to any TGF-β family member was shown to 
mimic the biological and functional effects of TGF-β [204]. This included binding to mammalian TGF-β 
receptors, and induction of both mouse and human Treg activity [204,205]. Another ES protein, 
H. polygyrus Alarmin Release Inhibitor (HpARI), was found to abrogate IL-33, eosinophilia, and group 2 
innate lymphoid cell responses to allergen in vivo [206]. It also limited eosinophilic responses to N. 
brasiliensis, augmenting parasite burden. HpARI was shown to bind directly to human IL-33, inhibiting 
release and thereby preventing type 2 responses [206]. These findings in particular highlight the 
potential for specific hookworm ES products to be harnessed as anti-inflammatory therapeutics. 
1.7.3 Hookworm ES products as vaccine candidates 
 
There is no natural protective immune response to hookworm infections in the human host [207]. 
Instead, infections can persist for many years due to the immunoregulatory capacity of these parasites. 
The plausibility of a human hookworm vaccine is supported by the canine hookworm vaccine which 
utilised radiation-attenuated infective larvae [208]. This was first marketed in the 1970s and while 
highly effective, was discontinued due to cost of production and a lack of scaling feasibility [208]. Given 
the enormous burden of disease the human hookworm poses, a vaccine would need to utilize a low 
cost expression system and show scaling potential [207]. The ES products of hookworm L3 larvae and 
adults have been explored for antigens to meet these necessities. Indeed, recombinant antigens have 
been identified from both stages of the parasite which have been used in animal models and show 
protection against challenge infections [207]. Development of Na-ASP-2, the leading L3-stage antigen 
against N. americanus, was discontinued following generalised urticaria in chronically infected subjects 
post vaccination [209]. Following this outcome, efforts have shifted towards targeting the blood-
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Using gut-expressed antigens as successful vaccine targets has been previously described for the 
ruminant parasite Haemonchus contortus [210]. In the human hookworm, two adult stage antigens 
that are currently being developed are the aspartic protease haemoglobinase (Na-APR-1) and the 
glutathione S-transferase (Na-GST-1) [211]. Both of these have shown efficacy in laboratory canines 
with Na-APR-1 having significant homology to APR-1 from A. caninum [211]. Na-GST-1 has since 
undergone a safety study in naïve and infected populations in Brazil with no adverse responses and 
significant antigen-specific IgG responses [212]. However, there are still a number of clinical trials and 
efficacy studies before the vaccine can be widely distributed.  
If the current leading antigens do not result in the desired protection against hookworms in their target 
population, other candidates will become necessary. For these means, proteomics analyses of ES 
products such as those carried out in N. brasiliensis and H. polygyrus (mentioned above) become highly 
valuable. ES products from the adult stage of the human hookworm, as will be presented in this thesis, 
hold a plethora of potential vaccine candidates which play important roles for parasite survival. 
Targeting one or many of these in future studies could provide additional efficacy for a human 
hookworm vaccine.  
 
1.8 Hypothesis underpinning this thesis 
 
The N. americanus hookworm has co-evolved with humans over thousands of years, specifically 
adapting to regulate host immunity to ensure its longevity. There is a large body of evidence to suggest 
that the ES proteins at the parasite-host interface represent the primary means by which the parasite 
does this. The secretomes of a number of parasitic helminths have been characterized, with some 
individual molecules found to possess immunomodulatory capacity. I hypothesise that some of the 
human hookworm ES proteins, through similar capacity, will be able to improve outcomes in 
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Despite their potential biotechnological utility, only a limited number of N. americanus ES proteins 
have been described to date, and most of them have been identified as cDNAs based on their homology 
to proteins from more readily accessible hookworm species that parasitise animals, such as 
Ancylostoma caninum [213]. In terms of vaccine antigens, a handful of N. americanus ES products 
including glutathione-S-transferases, aspartic proteases and sperm-coating proteins/Tpx-1/Ag5/PR-
1/Sc7 (SCP/TAPS), have been identified at the cDNA level, and vaccine efficacy of recombinant proteins 
assessed in animal models and phase 1 clinical trials [212,214,215]. SCP/TAPS, also referred to as 
venom allergen-like (VAL) or Activation-associated Secreted Proteins (ASPs) (Pfam accession number 
no. PF00188) have been reported from many helminths, but appear to be significantly expanded in the 
genomes and secreted proteomes of gut-resident clade IV and V parasitic nematodes, including the 
hookworms [169,194,195,216] 
The relative paucity of functional information on N. americanus proteins can be attributed, at least in 
part, to the difficulty in obtaining parasite material and the absence until 2014 of the published N. 
americanus draft genome. Analysis of the 244 Mb draft genome and the predicted 19,151 genes [169] 
provided important information about the molecular mechanisms and pathways by which N. 
americanus interacts with its human host. In agreement with published transcriptomes of N. 
americanus and genomes/transcriptomes of other hookworm species, a select number of protein 
families were over-represented, including SCP/TAPS proteins and different mechanistic classes of 
proteases with various functions including haemoglobinolysis and tissue penetration [217-222]. Of the 
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InterPro domain. Additionally, more than half of the total proteins had either no blast homology to any 
gene from the NCBI database (10,771 proteins) or shared identity with a ‘hypothetical’ protein (3,043 
proteins). These results highlight the importance of further annotation and refinement of the N. 
americanus genome [223].  
In general, the practicality of genomic sequence data is dependent on the accuracy of gene annotation 
as well as the availability of functional, expression and localization information [224]. The high-
throughput methods used when annotating a genome are prone to errors, therefore, to validate the 
predicted protein-coding genes, an analysis of the proteome is essential. Mass spectrometry provides 
useful data that can be used in a proteogenomic approach to improve genome annotation and identify 
novel peptides containing predicted protein sequences [225]. Methods including multiple fractionation 
techniques (in-gel and in-solution combination methods) improve the overall sensitivity and accuracy 
of our profiling [226].  
In this chapter I perform the first proteogenomic analysis of a parasitic helminth, while also significantly 
improving the genome annotation and comprehensively characterizing the ES proteome of adult N. 
americanus. The findings provide valuable information on important families of proteins with both 
known and unknown functions that could be instrumental in host-parasite interactions, including 
protein families that might be key for parasite survival and protection of the host against excessive 
immunopathology. Characterization of these proteins will be useful for the identification of vaccine 










Ethical approval for hamster animal experimentation to obtain N. americanus adult worms was 
obtained from the Federal University of Minas Gerais, Brazil (Protocol# 51/2013). Ethical approval for 
human experimental infection with N. americanus and subsequent culturing of L3 was obtained from 
the James Cook University Human Research Ethics Committee (ID# H5936). 
2.2.2 Parasite material 
 
Adult N. americanus were manually isolated from the intestines of experimentally infected golden 
hamsters (Mesocricetus auratus) upon euthanasia. For the isolation and purification of ES products, 
the worms were washed 3 times in phosphate-buffered saline (PBS) before being cultured overnight in 
a humidified incubator at 37°C, 5% CO2, in RPMI 1640 (100 U/ml penicillin, 100 μg/ml streptomycin 
sulphate, 0.25 μg/ml amphotericin B). The supernatant was collected the following day and debris was 
removed by centrifuging the concentrated samples at 1,500 g for 3 minutes in a benchtop microfuge. 
ES products were concentrated with a 3 kDa cut-off Centricon filter membrane (Merck Millipore) and 
samples were stored at -80°C until use. For somatic adult extracts, data was used from Tang et al [169]. 
This data was the mass spec results for the adult N. americanus whole worm digest that was later used 
in section 2.2.5 for database searching. In brief, whole worms were ground under liquid nitrogen and 
solubilized using lysis buffer (1.0% (v/v) Triton X-100 in 40 mM Tris, 0.1% (w/v) SDS, pH 7.4). The extract 
was filtered through a 20 µm filter before fractionation. 
For isolation of N. americanus L3, stool samples were collected from infected human volunteers and 
cultured as follows. dH2O water was added to the stool sample until a thick paste was formed. This 
paste was then distributed onto moistened filter paper (VWR, Standard Grade, 110 mm) in Petri dishes 
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plate were gently rinsed with RO water to obtain clean L3 preparations. Somatic extracts were 
prepared by adding 100 µl lysis buffer (3 M Urea, 0.2% SDS, 1% Triton X, 50 mM Tris-HCl) to 
approximately 6,000 larvae before repeated vortexing and sonication (4°C, probe sonicator, pulse 
setting) to digest the larvae. The extract was passed through a 0.45 µm filter (Millipore) before in-gel 
fractionation.  
2.2.3 Fractionation and digest 
 
SDS-PAGE fractionation and in-gel trypsin digestion 
A total of 30 µg of N. americanus adult ES products was buffer exchanged into 50 mM NH4HCO3, freeze-
dried and resuspended in Laemmli buffer (2% SDS, 10% glycerol, 0.002% bromophenol blue, 0.0625 M 
Tris-HCl, 5% dithiothreitol (DTT). The sample was boiled at 95°C for 5 minutes and electrophoresed on 
a 12% SDS-PAGE gel for 40 minutes at 150 V. The gel was stained with Coomassie Blue and 20 pieces 
(approximately 1 mm thick) were cut and placed into Eppendorf tubes. For the in-gel digestion, slices 
were de-stained and freeze-dried before incubating them at 65°C for 1 h in reduction buffer (20 mM 
DTT, Sigma, 50 mM NH4HCO3). Samples were then alkylated in 50 mM iodoacetamide (IAM, Sigma), 50 
mM NH4HCO3 for 40 minutes at 37°C, washed three times with 25 mM NH4HCO3 and digested with 20 
µg/ml of trypsin (Sigma) by incubating them for 16 h at 37°C with gentle agitation. Digestion was 
stopped and peptides were released from the slices by adding 0.1% TFA, 70% acetonitrile. This step 
was repeated 3 times with pooling of the corresponding supernatants to maximise peptide recovery 
for each sample. Finally, each sample was desalted with a ZipTip (Merck Millipore) and stored at -80°C 
until use. 
In-solution trypsin digestion and off-gel fractionation 
A total of 70 µg of each N. americanus extract (L3 somatic and adult ES products) was buffer exchanged 
into 50 mM NH4HCO3 before adding DTT to 20 mM and incubating for 10 minutes at 65°C. Alkylation 
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dark. Samples were digested with 2 µg of trypsin by incubating for 16 h at 37°C with gentle agitation. 
Following trypsin digestion, peptides were fractionated using a 3100 OFFGEL Fractionator (Agilent 
Technologies) according to the manufacturer’s protocol with a 24-well format as described previously 
[195]. In brief, Immobiline DryStrip pH 3-10 (24 cm) gel strips were rehydrated in rehydration buffer in 
the assembled loading frame. Digested peptides were diluted in dilution buffer to a volume of 3.6 ml 
and loaded equally across the 24 well cassette. The sample was run at a current of 50 μA until 50 
kilovolt hours (kVh) had elapsed. Upon completion of the fractionation, samples were collected, 
desalted with ZipTip and stored at -80°C until use. 
2.2.4 Mass spectrometry 
 
Both L3 and adult extracts from both fractionation methods were analyzed by LC-MS/MS on a 
Shimadzu Prominence Nano HPLC (Japan) coupled to a Triple Tof 5600+ mass spectrometer (SCIEX, 
Canada) equipped with a nano electrospray ion source. Fifteen (15) µl of each extract was injected onto 
a 50 mm x 300 μm C18 trap column (Agilent Technologies, Australia) at 60 µl/min. The samples were 
de-salted on the trap column for 6 minutes using 0.1% formic acid (aq) at 60 μl/min. The trap column 
was then placed in-line with the analytical nano HPLC column, a 150 mm x 100 μm 300SBC18, 3.5 μm 
(Agilent Technologies, Australia) for mass spectrometry analysis. For peptide elution and analysis the 
nano-HPLC pump was initially held at 2% solvent B for 6 minutes followed by a linear gradient of 2-40% 
solvent B over 80 minutes at 500 nl/minute flow rate and then a steeper gradient from 40% to 80% 
solvent B in 10 minutes was applied. Solvent B was held at 80% for 5 minutes for washing the column 
and returned to 2% solvent B for equilibration prior to the next sample injection. Solvent A consisted 
of 0.1% formic acid (aq) and solvent B contained 90/10 acetonitrile/ 0.1% formic acid (aq). The ionspray 
voltage was set to 2,200 V, declustering potential (DP) 100V, curtain gas flow 25, nebulizer gas 1 (GS1) 
12 and interface heater at 150°C. The mass spectrometer acquired 250 ms full scan TOF-MS data 
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mode. Full scan TOF-MS data was acquired over the mass range 300-1600 and for product ion ms/ms 
80-1600. Ions observed in the TOF-MS scan exceeding a threshold of 150 counts and a charge state of 
+2 to +5 were set to trigger the acquisition of product ion, MS/MS spectra of the resultant 20 most 
intense ions. The data was acquired using Analyst TF 1.6.1 (SCIEX, Canada).  
2.2.5 Proteogenomics 
 
The mass spectrometry raw data was searched against the N. americanus protein database [169] using 
SequestHT algorithm in Proteome Discoverer 2.1 (Thermo Scientific, Bremen, Germany). Trypsin was 
used as the protease, allowing a maximum of two missed cleavages. Carbamidomethylation of cysteine 
was specified as a fixed modification, and oxidation of methionine was included as variable 
modifications. The minimum peptide length was specified as 6 amino acids. The mass error of parent 
ions was set to 10 ppm, and for fragment ions it was set to 0.05 Da. Protein inference was based on 
the rule of parsimony and required one or more unique peptides. False Discovery Rate (FDR) of 1% at 
peptide and protein levels was applied. The unassigned spectra from the protein database search were 
further searched against the six-frame translated genome database of N. americanus [169]. The 
genome sequences were downloaded from WormBase ParaSite release 9 
(http://parasite.wormbase.org/Necator_americanus_prjna72135/Info/Index) in FASTA format and 
translated in all six frames using in-house python scripts. All the sequences greater than 10 amino acids 
between any two stop codons were added to the database. The search was again performed using 
SequestHT with precursor mass tolerance of 50 ppm and fragment ion tolerance of 1 Da. 
Carbamidomethylation of cysteine was specified as a fixed modification, and oxidation of methionine 
was included as variable modifications. Results were obtained at 1% FDR for both protein and peptide 
level.  
The identified peptides in the search against the six-frame translated genome were mapped back to 
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database were discarded. The filtered peptides were mapped to the N. americanus genome using the 
standalone tblastn program [169]. Peptide identifications that unambiguously mapped to a single 
region in the genome, also known as Genome Search Specific Peptides (GSSPs), were considered to 
perform proteogenomics-based annotation of novel coding regions. The known gene annotation GFF3 
was downloaded from WormBase ParaSite for N. americanus [169]. Using in-house scripts, GSSPs were 
characterized into various categories: intergenic, intronic, exon-extension, alternative frame, N-
terminal extensions or repeat regions with respect to the known regions from GFF3. Additionally, for 
all the intergenic peptides, a search was undertaken for potential open reading frames (ORFs) within 
the stretch of amino acids. Each of the spectra was further manually validated.  
2.2.6 Genome annotation 
 
The genome annotation from N. americanus [169] was updated using the MAKER pipeline v2.31.8 [227] 
in collaboration with Dr Makedonka Mitreva and colleagues at Washington Univertsity of St Louis. The 
genome assembly (GenBank assembly accession: GCA_000507365.1) was softmasked for repetitive 
elements with RepeatMasker v4.0.6 using a species-specific repeat library created by RepeatModeler 
v1.0.8, RepBase repeat libraries [228] and a list of known transposable elements provided by MAKER 
[227]. From the NCBI Sequence Read Archive (SRA), N. americanus RNA-Seq data [169] (Adult: 
SRR609895, SRR831085, SRR892200; L3: SRR609894, SRR831091, SRR89220) were obtained. After 
adapter and quality trimming using Trimmomatic v0.36 [229], RNA-Seq reads were aligned to the 
genome using HISAT2 v2.0.5 [230] with the --dta option and subsequently assembled using StringTie 
v1.2.4 [231]. The resulting alignment information and transcript assembly were used by BRAKER [232] 
and MAKER pipelines, respectively, as extrinsic evidence data. In addition, protein sequences from 
SwissProt UniRef100 [233] and WormBase ParaSite WS258 [234] (Ancylostoma ceylanicum 
PRJNA231479, Brugia malayi PRJNA10729, Caenorhabditis elegans PRJNA13758, Onchocerca volvulus 
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PRJEB125) were provided to MAKER as protein homology evidence. Following the developer’s 
recommendation [235], the protein-coding gene models of Tang et al. [169] were passed to MAKER as 
pred_gff to update the models by adding new 3’ and 5’ exons, additional UTRs, and merging split 
models. This method, however, cannot change internal exons nor create new annotations where 
evidence suggests a gene but no corresponding model is previously present. To address this 
shortcoming, additional ab initio gene predictions were generated using BRAKER v2.0.1 [232] and 
passed to MAKER so that the intron-exon model that best matched the evidence could be included in 
the final annotation set. Within the BRAKER pipeline, the gene prediction tools GeneMark [236] and 
AUGUSTUS [237] were trained utilizing the N. americanus RNA-Seq alignment and protein homology 
information from C. elegans. The GFFPs identified in the present study were used to confirm the validity 
of proposed annotation changes and resolve competing gene predictions through manual curation. 
Gene models with no evidence support were not included in the final annotation build to reduce false 
positives in the existing annotations. However, ab initio gene predictions that encoded Pfam domains 
as detected by InterProScan v5.19 [238] were rescued to enhance overall accuracy by balancing 
sensitivity and specificity [227,239]. The completeness of the annotated gene set was assessed using 





Mascot version 2.5 (Matrix Science), X!Tandem (The Global Proteome Machine Organisation) version 
Jackhammer and Comet v2014.02 rev.2 were used to analyze data from the mass spectrometer. 
Searches were carried out against a database comprised of either the updated genome annotation 
provided with this study, or the N. americanus genome [169], both appended to the common 
repository of adventitious proteins (cRAP; http://www.thegpm.org/crap/) database (to detect 
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trypsin; variable modifications, oxidation of methionine, carbamidomethylation of cysteine, 
deamidation of asparagine and glutamine; maximum missed cleavages, 2; precursor ion mass 
tolerance, 50 ppm; fragment ion tolerance 0.1 Da; charge states, 2+, 3+ 4+. A FDR of 0.1% was applied, 
and a filter of greater than 2 significant unique sequences was used to further improve the robustness 
of data. The mass spectrometry data have been deposited in the ProteomeXchange Consortium via the 
PRIDE partner repository with the dataset identifier PXD010669. 
Bioinformatic Analysis of Proteomic Sequence Data 
 
Gene ontology (GO) annotations were assigned using the program Blast2GO and Pfam analysis was 
performed using HMMER [241]. Pfam domains were detected at the p<0.001 threshold for the HMMER 
software. Putative signal peptides were predicted with SignalP v4.1, transmembrane domains with 
TMHMM v2.0, and non-classical protein secretion with the SecretomeP 2.0 server [242-244]. REViGO, 
an online tool, was used to summarise and plot GO terms [245]. UpSetR was used to group proteins 
based on whether they had a GO term with one, two or all of the GO categories (biological process, 
molecular function or cellular process) [246].  




A similarity analysis was carried out based on the Parkinson and Blaxter method using an in-house 
script [221,247]. Given the difficulty of working with N. americanus specifically (in terms of accessibility 
to samples and establishment of life cycle in other hosts), other hookworms are frequently used to 
model this human parasite. Data from the secreted proteome of adult N. americanus (described herein) 
was compared to the published secreted proteomes from adult stages of related nematode species 




  Page | 50 
 
 
Protein family similarity visualization 
 
H. polygyrus, A. caninum and N. brasiliensis SCP/TAPS and protease protein sequences were obtained 
from their respective published secreted proteomes [194,195,248]. These sequences were aligned with 
adult N. americanus homologous protein sequences using BLAST. Significant sequence alignments were 
visualized using Circos [249].  
Phylogenetic Analyses 
 
SCP/TAPS proteins were identified from published secretomes of 6 species of parasitic helminths 
including A. caninum, Ascaris suum, H. polygyrus, N. brasiliensis, Trichuris muris and Toxocara canis. 
SCP/TAPS proteins were identified from N. americanus ES products using the proteome data generated 
in this study. Sequences were sorted into single and double SCP/TAPS domain proteins for individual 
phylogenetic analysis due to distinct differences described previously [197]. A list of the proteins and 
their respective sequences used for this analysis can be found in Supplemental Data 1. A multiple 
sequence alignment was carried out using the alignment program MUSCLE. Outliers with poor 
alignment (long unaligned regions) were detected and filtered out using ODseek. PhyML, a phylogeny 
software, was used for a maximum-likelihood (ML) phylogenetic analyses of SCP/TAPS amino acid 
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2.3 Results 
 
The supplementary data for this chapter contains large datasets which are inappropriate for inclusion 
in this thesis. This has been uploaded to bioRxiv along with the rest of the data from this chapter and 
is available at: https://www.biorxiv.org/content/10.1101/406843v1.supplementary-material 
2.3.1 Proteogenomic analysis and genome annotation 
 
Different proteomes from two life stages (infective L3 somatic extract and adult somatic extracts and 
ES products) of N. americanus were analysed by mass spectrometry in a 5600+ ABSciex Triple Tof 
instrument to perform a proteogenomic analysis of the hookworm genome. After excluding peptides 
that mapped accurately to the existing protein database entry, a total of 218 novel peptides were 
identified that did not match any protein sequences of N. americanus contained in the annotations of 
Tang et al (11). Of these 218 novel peptides, 83 were found exclusively in adult somatic extracts, 50 
exclusively in L3, and 67 exclusively in adult ES, while 10 peptides were found in both the adult somatic 
extract and ES products, and 8 were found in both adult and larval somatic extracts. No common 
peptides were identified from adult ES products and larval somatic extract.  
Newly identified peptides could be grouped into the following six categories: (1) peptides mapping to 
intergenic regions; (2) peptides mapping to introns; (3) peptides mapping to alternative reading frames; 
(4) peptides extending gene boundaries (exon extensions); (5) peptides mapping to N-terminal 
extensions; and (6) peptides mapping to repeat regions (not gene) regions (Figure 2.1). Of the identified 
peptides, more than half belonged to group 1, 18% to group 2, 5% to group 3, 15% to group 4, 2% to 
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Figure 2.1: Depiction of the proteogenomic process as well as the types and numbers of peptide 
corrections identified. 
 
Group 1 peptides were further analyzed for an ORF including whether or not they contained a 
methionine; see Supplemental data 2. From this data, one-third of group 1 peptides were found to 
overlap with a viable ORF, with the shortest having just 21 amino acids and the longest 381 amino 
acids. The translated protein sequences with their respective peptides, six-frame translated genome 
(SFG) ID and ORF length are provided in Supplemental data 3. 
These results highlighted the need for improving the previously published gene models, so we updated 
the genome annotation of N. americanus using a new RNA-Seq based gene calling pipeline as outlined 
in the Materials and Methods (Table 2.1). The total number of predicted N. americanus genes 
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coding sequence (CDS) length increased by 2.22 Mb with the mean gene length (including introns and 
UTRs) nearly doubling from 4.3 kb to 8.1 kb. Furthermore, the percentage of the genome covered by 
genes increased by 18.3%, and the percentage of detected BUSCOs among the predicted genes 
increased from 95.7% to 97.4% (with 31% reduction in the number of fragmented BUSCOs). While 
these improvements are attributable in most part to the use of more sophisticated genome annotation 
methods utilizing RNA-Seq data and the inclusion of more extensive, up-to-date homologous protein 
databases, the peptide sequences generated in this study contributed directly to the refinement of 14 
gene models. The newly annotated, improved gene models were used in subsequent proteomic 
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  Original annotation Updated annotation 
Number of genes 19,153 15,728 
Number of exons 122,849 148,780 
Number of introns 103,696 133,052 
Number of CDS 19,153 15,728 
Overlapping genes 395 2,424 
Contained genes 2 386 
Total gene length (bp) 82,090,364 126,651,725 
Total exon length (bp) 15,470,227 24,553,753 
Total intron length (bp) 66,827,529 102,364,076 
Total CDS length (bp) 15,461,420 17,683,227 
Mean gene length (bp) 4,286 8,053 
Mean exon length (bp) 126 165 
Mean intron length (bp) 644 769 
Mean CDS length (bp) 807 1,124 
% of genome covered by genes 33.6 51.9 
% of genome covered by CDS 6.3 7.2 
Mean exons per mRNA 6.4 9.5 
Mean introns per mRNA 5.4 8.5 
Complete BUSCOs 82.84% 88.45% 
Fragmented BUSCOs 12.87% 8.91% 
Missing BUSCOs 4.29% 2.64% 
 
Table 2.1: Summary of the updated genome annotation of human hookworm. CDS – coding DNA 
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2.3.2 Analysis of the ES products from N. americanus adult worms 
 
A comprehensive analysis of the ES products from adult worms was carried out using in-gel and off-gel 
fractionation and the tryptic peptides were analyzed using LC-MS/MS. Mascot, X!Tandem and Comet 
searches were carried out against a database including the predicted proteins from the annotated N. 
americanus genome available in this study appended to the cRAP sequences available at 
http://www.thegpm.org/crap/. A total of 186 and 141 proteins were identified using Mascot and 
X!Tandem/Comet, respectively. All ES proteins were identified with at least two unique peptides, at a 
99.0% probability and FRD of 0.1%. The two search methods combined found a total of 198 proteins 
(Supplemental data 4). These 198 proteins were obtained using the updated genome annotation 
generated as part of this study. In comparison, using the first version of the annotated genome 
sequence we identified 203 proteins using the same analytical software. Using the exponential 
modified protein abundance index (emPAI) and the newly annotated genome, the most abundant 
proteins in the ES products of N. americanus adult worms were ranked, and the top 30 are shown in 
Table 2.2. One emPAI value was listed for each of the digestion methods used (in-gel and off-gel) and 
their combined value was used to rank the proteins.  
  






NumP     emPAI   
Accession In-gel Off-gel In-gel Off-gel In-gel Off-gel SP TD In-gel Off-gel Pfam domain 
NAME_05596 Hypothetical protein 19496 15287 1 1 11 11 N 0 867.19 308.05 No conserved domains 
NAME_07794 Hypothetical protein 21210 39596 1 1 18 22 Y 0 47.88 199.86 Single SCP  
NAME_11917 SCP 35077 43195 1 1 18 31 N 0 11.87 68.4 Double SCP  
NAME_13724 Hypothetical protein 7701 23099 1 1 5 7 N 0 7.06 64.55 No conserved domains 
NAME_15197 SCP 9446 12866 1 1 6 7 N 0 9.55 50.11 No conserved domains 
NAME_14329 SCP 10911 15142 1 1 10 15 N 0 14.34 43.25 Single SCP  
NAME_11146 SCP 21158 29296 1 1 24 27 Y 0 17.03 22.85 Double SCP  
NAME_10941 Hypothetical protein 983 3870 1 1 3 8 Y 0 2.6 33.23 Single SCP  
NAME_09098 SCP 6908 47379 1 1 13 25 Y 0 3.27 31.87 Double SCP  
NAME_05595 SCP-like protein, partial 0 23369 0 1 0 10 Y 0 0 26.61 Single SCP  
NAME_11145 SCP 19923 25558 1 1 18 22 N 0 6.35 16.62 Double SCP  
NAME_02907 Glu Leu Phe Val dimerization  6645 6095 1 1 20 22 N 0 6.82 7.63 Single ELFV_dehydrog_N 
NAME_10752 Nematode fatty acid retinoid  12416 3051 1 1 11 8 Y 0 9.76 4.65 Single Gp-FAR-1 
NAME_05865 Globin 3566 5667 1 1 6 10 N 0 2.63 9.67 Single Globin 
NAME_15231 SCP 117 1844 0 1 3 6 N 0 1.75 9.66 Single SCP  
NAME_05592 Hypothetical protein 0 4150 0 1 0 4 Y 0 0 11.02 Single SCP  
NAME_13132 Ferritin 1808 2833 1 1 7 8 N 0 3.39 7.31 Single Ferritin-like  
NAME_05794 Hypothetical protein 2681 2271 1 1 7 9 N 0 5.18 5.21 No conserved domains 
NAME_13809 SCP 8287 14385 1 1 7 9 Y 0 3.99 5.92 Single SCP  
NAME_07942 Copper zinc superoxide dismutase 4241 4469 1 1 4 8 N 0 1.41 6.25 Single Copper/zinc superoxide  
NAME_09181 Hypothetical protein 27774 68153 1 1 41 50 N 0 3.17 4.43 No conserved domains 
NAME_10294 SCP 6557 11684 1 1 7 9 Y 0 2.58 4.8 Single SCP  
NAME_02523 Histidine operon leader 23085 24957 1 1 66 63 Y 0 3.68 3.3 Many NPA  
NAME_13379 Flavodoxin 0 1089 0.9985 0 0 4 N 0 0 6.89 No conserved domains 
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NAME_02090 SCP 3916 12638 1 1 8 14 Y 0 1.35 5.47 Double SCP  
NAME_01069 SCP 3816 11201 1 1 10 12 Y 0 1.91 4.63 Double SCP  
NAME_12806 SCP 8094 8066 1 1 6 8 Y 0 1.62 4.42 Single SCP  
NAME_02548 Globin 887 1473 1 1 4 6 N 0 3.01 3.03 Single Globin 
NAME_05396 SCP 1339 5930 1 1 4 8 Y 0 1.48 4.13 Single SCP  
NAME_13850 SCP 3510 4006 1 0.9933 7 8 Y 0 1.97 3.07 Single SCP  
 
Table 2.2: Top 30 most abundant proteins identified with in-gel and OFF-GEL fractionation and ranked using summed exponential modified protein 
abundance index (emPAI) score. Blast2GO was used to obtain descriptions of each protein. Abbreviations key: NumP – number of significant peptides; SP – 
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The conserved Pfam domains of the 198 ES proteins identified were analysed. The most abundant 
protein family in the ES products was the SCP/TAPS family with 54/198 proteins containing a single or 
double cysteine-rich secretory protein family (CAP) domain (PF00188) (Figure 2.2B). The top 10 most 
abundant protein families are displayed in Figure 2.2B. Many of these proteins were described by 
Blast2GO as ‘SCP-partial’ or ‘SCP-like’, but for a more standardized annotation in my analysis they have 
been grouped and referred to as ‘SCP/TAPS’. The second most frequently represented group (with 42 
proteins) were proteins with one or more domains of unknown function (DUF). Other abundant 
families included Ancylostoma secreted protein related (ASPR) proteins and metalloproteases with 35 
and 9 of each identified, respectively (Supplemental data 5). Despite some published reports classifying 
ASPRs as SCP/TAPS proteins, they are a diverse set of secreted cysteine rich proteins based on Pfam 
annotation and therefore have been grouped separately (28). Of the 198 identified ES proteins, 51% 
contained a predicted signal peptide. Supporting the accuracy of the new gene model, 96 of the 
identified adult ES proteins were predicted to contain a signal peptide compared to just 75 using the 
previous genome annotation. Of the remaining 49% which did not have a signal peptide, 45% were 
predicted to be non-classically secreted by SecretomeP.  
The adult N. americanus ES proteins were annotated using Blast2GO (46). In total, 30 GO terms were 
identified (following the removal of parent child redundancy) belonging to one of the three GO 
database categories: biological processes, molecular function or cellular component (Figure 2.2A, for 
raw data see Supplemental data 6). Blast2GO returned biological process GO terms for 87/198 proteins, 
molecular function GO terms for 99/198 proteins and cellular component GO terms for 83/198 proteins 
(Figure 2.2A). The most prominent biological process term was proteolysis (Figure 2.2D), with 15% (29 
proteins) of total ES products being involved in a proteolytic process. The most prominent single 
molecular function term was “hydrolase activity” followed by “peptidase activity” and “metal ion 
binding” (Figure 2.2C). Interestingly, 50/198 proteins did not return any GO terms (Figure 2.2A). Of 
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cellular component. This highlights a significant knowledge gap surrounding SCP/TAPS produced by 
helminths.  
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Figure 2.2: Gene ontology (GO) and protein families of adult N. americanus ES proteins. (A) UpSetR 
plot displaying the number of each gene ontology (GO) term categories (cellular component, biological 
process, or molecular function) available (Blast2GO) for adult N. americanus ES proteins. Proteins with 
no available GO terms are broken down in a pie chart into ‘SCP/TAPS’ proteins ‘other’. (B) Top 10 most 
abundant protein families in the ES products of adult N. americanus. (C) Biological processes of adult 
N. americanus ES proteins ranked by nodescore (Blast2GO) and plotted using REViGO. Semantically 
similar GO terms plot close together, increasing heatmap score signifies increasing nodescore from 
Blast2GO, while circle size denotes the frequency of the GO term from the underlying database. (D) 
Molecular functions of adult N. americanus ES proteins ranked by nodescore (Blast2GO) plotted using 
REViGO.  
2.3.3 Similarity analysis of the ES products from different gastrointestinal nematode species 
 
A similarity analysis of ES proteomic data from N. americanus and three of the most commonly used 
animal models for human hookworms, A. caninum, H. polygyrus and N. brasiliensis was carried out 
(Figure 2.3). A total of 15, 10 and one N. americanus ES proteins had unique homology to ES proteins 
from A. caninum, H. polygyrus and N. brasiliensis, respectively. This included one SCP/TAPS protein 
(NAME_13724) which was similar only to an H. polygyrus protein, while 3 of the proteins were similar 
only to A. caninum ES proteins with domains of unknown function (NAME_07734, NAME_09181, 
NAME_09182). Seven proteins shared homology with only A. caninum and H. polygyrus proteins, 11 
shared homology with only A. caninum and N. brasiliensis proteins and 7 shared homology with only 
H. polygyrus and N. brasiliensis proteins. One hundred and twenty-two N. americanus proteins shared 
different degrees of homology with proteins from A. caninum, H. polygyrus and N. brasiliensis.  
From the 54 SCP/TAPS proteins found in N. americanus ES products, one (NAME_13724) shared 
homology with a protein found in only H. polygyrus, while another SCP/TAPS protein (NAME_15177) 
shared homology with proteins from both A. caninum and N. brasiliensis. Fifty-one of 54 SCP/TAPS 
proteins were similar to all compared species, leaving a single SCP/TAPS protein (NAME_11218) which 
did not have homology to any SCP/TAPS protein from the compared species. Twenty-five N. americanus 
ES proteins did not have homology to any proteins in the secretome of A. caninum, H. polygyrus or N. 
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brasiliensis. Notable proteins among these 25 were NAME_01848 (aspartyl protease) and 
NAME_05081 (zinc metalloprotease). 
Of the 26 proteases in the N. americanus ES products, 22 had homologs in all compared species, while 
one serine protease (NAME_06735) only had homologs in H. polygyrus and A. caninum and one 
metalloprotease (NAME_00535, peptidase family M1) only had homologs in the ES products of A. 
caninum, and N. brasiliensis. One zinc metalloprotease (NAME_05081) and one serine protease 
(NAME_01250) were only found in the ES products of N. americanus and therefore did not have any 
similarity to ES products from the other species.  
 
 
Figure 2.3: Similarity analysis of excretory/secretory (ES) proteins from helminths commonly used to 
model the human hookworm. Excretory/secretory (ES) products from Ancylostoma caninum, 
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Heligmosomoides polygyrus, and Nippostrongylus brasiliensis were compared with the ES proteome of 
Necator americanus and displayed in a Simitri plot. SCP/TAPS are represented by a teal square, 
proteases by an orange triangle and any other protein by a grey circle. Points on the diagram triangle 
represent sequences which only had similarity to the labelled species. Points along the edges of the 
triangle are sequences which had similarity to two of the three species (given at the respective ends of 
the edge). Any sequence in the middle area of the triangle represents a sequence with similarity to all 
three compared species.  
 
2.3.4 Homology analysis of SCP/TAPS and proteases in the ES products of N. americanus 
 
Since SCP/TAPS proteins and proteases from N. americanus numerically dominate the ES protein 
dataset and likely play key roles in infection, migration and parasite establishment, I performed an in-
depth comparison of these families of proteins from all four species of gastrointestinal nematodes. 
Adult N. americanus ES SCP/TAPS protein sequences were aligned with homologs from H. polygyrus, 
A. caninum and N. brasiliensis ES SCP/TAPS protein sequences using BLAST. Sequences which aligned 
with maximum scores >36 were visualized using Circos (Figure 2.4A). SCP/TAPS from N. americanus are 
more similar to A. caninum than to H. polygyrus or N. brasiliensis, as denoted by thicker, darker ribbons 
(Figure 2.4A). The sequences, their homologs and the corresponding blast scores are detailed in 
Supplemental data 7. As with the similarity analysis, NAME_11218 had no significant alignment to any 
of the compared species.  
A similar analysis was performed for the proteases from each of the aforementioned species (Figure 
2.4B). These proteases have been grouped together into their respective mechanistic classes: aspartyl 
(ASP), cysteine (CYS), metallo (MET) or serine (SER) proteases. In general, all three comparator species 
had high protease sequence homology to metalloproteases from N. americanus. Surprisingly, aspartyl 
protease sequences were more similar between H. polygyrus, N. brasiliensis and N. americanus than 
sequences from A. caninum. It is interesting to note that N. americanus contained more aspartyl 
proteases than the other nematode species analyzed (N. americanus – 8; A. caninum – 4; H. polygyrus 
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– 6; N. brasiliensis – 6). Serine proteases had the lowest sequence homology across all of the compared 
species and protease subclasses.  
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Figure 2.4: SCP/TAPS proteins in the excretory/secretory (ES) products of human hookworm are most 
closely related to SCP/TAPS proteins in the ES proteome of dog hookworm. SCP/TAPS (A) and 
protease (B) protein names are displayed in a circle with Necator americanus (purple), Ancylostoma 
caninum (blue), Heligmosomoides polygyrus (pink), and Nippostrongylus brasiliensis (green). Ribbon 
thickness is relative to the maximum score obtained in the BLAST search while darker ribbons denote 
higher sequence percent identity. The corresponding bars provide relative sequence length of each 
protein. Respective protease mechanistic classes: aspartic (ASP), cysteine (CYS), metallo (MET) or 
serine (SER).  
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2.3.5 Phylogenetic analysis of SCP/TAPS proteins  
 
SCP/TAPS sequences of 6 parasitic nematodes were obtained from published secretomes and 
compared to N. americanus SCP/TAPS identified in this study. Sequences were grouped by whether 
they had a single or double domain and then aligned using MUSCLE and PhyML. From the 7 total 
species, 232 SCP/TAPS were reported with 134 single-domain proteins and 98 double-domain. For the 
single SCP/TAPS-domain proteins an unrooted tree was generated. The analysis identified seven main 
clades. Three of these clades consisted entirely of sequences from N. americanus and A. caninum, while 
sub-clades in 3 of the other main clades followed a similar trend. A majority of T. muris single-domain 
sequences formed a sub-clade with A. suum and T. canis, grouping together the non-clade V helminths. 
An unrooted tree was also generated for double domain sequences. The analysis identified five main 
clades. N. americanus SCP/TAPS clustered almost exclusively with sequences from A. caninum again, 
representing one main clade and several sub-clades. H. polygyrus and N. brasiliensis also formed a 
number of distinct sub-clades. T. canis, the only non-clade V helminth, was reported to only produce 
one double-domain SCP/TAPS protein in its ES products which was not closely related to any of the 
compared sequences. Interestingly, no double-domain SCP/TAPS were reported for A. suum or T. 
muris. Another trend across both single and double domain trees was the diversity of evolution 
between SCP/TAPS within a single species. For example, the single-domain tree included a sub-clade 
of 7 N. americanus-only sequences while other N. americanus sequences had more similarity to mouse 
hookworm sequences. 
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Figure 2.5: Phylogenetic analysis of single and double domain SCP/TAPS proteins from various 
species of helminths. Phylogenetic relationships of (A) single-domain and (B) double-domain SCP/TAPS 
proteins determined with MUSCLE alignment software. PhyML was used for a maximum-likelihood 
phylogenetic analysis and results were visualized with The Interactive Tree of Life (iTOF) online 
phylogeny tool. Necator americanus sequences are highlighted in purple with comparator species each 
denoted by a different color (see key). 
 
  




The genome of N. americanus was sequenced in 2014, providing an important dataset to facilitate 
efforts to combat hookworm disease; however, the tools available at that time for annotating genes 
from parasitic helminths were limited. For instance, the number of proteins with a top hit to a 
‘hypothetical protein’ present in the original genome annotation was 3,043, corresponding to 15.8% of 
the total predicted proteins [169]. In addition, inferring gene and protein functions for parasitic 
nematodes is a major challenge as most species are genetically intractable and databases and 
algorithms are biased towards (free-living) model nematodes [223]. Proteogenomics is a relatively new 
approach in which proteomic data is used to improve genome annotation [225,251], and although it 
had never been applied to parasitic helminths (until now), its potential utility in this area has been 
suggested [252]. High-throughput sequencing and gene prediction tools are prone to false-negative 
and false-positive predictions which can lead to missed genes, false exons or exon boundaries and/or 
incorrect translational start/stop sites, so knowing the sequences of the proteins expressed by an 
organism will help to improve gene predictions. 
The proteogenomic analysis carried out in this study addresses some of these challenges by improving 
the characterization of predicted proteins from the annotated N. americanus genome. This study, while 
primarily focused on the ES products, provided an opportunity to update the N. americanus genome. 
For this end, I included L3 stage material to provide more data to add to this annotation. Overall, 121 
peptides were identified that mapped to intergenic regions in the first draft genome sequence for N. 
americanus. Peptides that map to intergenic regions are important as they can lead to identification of 
novel protein-coding genes or corrections of pre-existing models [225]. To investigate whether these 
peptides are likely to be new genes we checked for any potential ORFs where the peptides map. Thirty-
two [227] of the peptides identified mapped to alternative ORFs than those described in the current 
gene model. While these peptides map to known coding regions, they highlight out-of-frame ORFs 
which is likely to, once correctly annotated, result in an entirely different protein. Of the total newly 
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identified peptides, 39 of them mapped to introns. Peptides mapping to introns can lead to 
identification of novel splice isoforms or amendments in gene structure. Peptides mapping to exon 
extensions and N-terminal extensions were less abundant, with 10 and 4 peptides respectively. These 
groups of peptides suggest a possible correction in reading frame or an incorrect start site annotation.  
The decrease in gene number seen in this study is in line with other genome annotations. For example, 
the Schistosoma mansoni genome was originally thought to encode 11,809 genes, however further 
annotation has reduced this number to 10,772 [253]. Given that this is the first re-annotation of the N. 
americanus genome since the original draft was published, a substantial decrease in gene number was 
to be expected, and 15,728 genes is comparable with the predicted gene numbers of other nematode 
genomes [254]. Despite being a parasitic nematode, N. americanus has almost 5,000 fewer genes than 
its free-living relative C. elegans (https://parasite.wormbase.org/).  
Of particular importance in the characterization of parasite-specific genes is the presence of a signal 
peptide. Of the secreted ES proteins from N. americanus, 51% were predicted to have a signal peptide; 
this is also in agreement with ES proteomes from other parasitic nematodes [194,213,248]. The 
presence of extracellular proteins without predicted signal peptides in the ES products of N. 
americanus could be due to one of three reasons: (a) the protein is secreted via an alternative pathway, 
including release of parasite extracellular vesicles [255-258] or non-classical secretory signals; (b) the 
lack of full-length RNA transcript sequence to confirm gene model accuracy resulted in an error in the 
predicted sequence (i.e. truncation or ORF shift); (c) the pre-set D-cutoff threshold of 0.33 in SignalP 
results in false-negative predictions. In support of this, 45% of the sequences without signal peptides 
were predicted to be non-classically secreted. 
Helminth secretomes represent the molecular host-parasite interface [259], and provide useful insights 
into the biological strategies employed by these parasites to ensure longevity inside their respective 
hosts [259]. At this interface, ES products have been implicated in numerous roles from initial 
penetration/invasion and feeding to host immune regulation [259]. Obtaining sufficient ES products to 
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generate the proteome described in this study was time consuming due to the difficulty in culturing 
sufficient quantities of parasite material in hamsters. For this reason, human infection with N. 
americanus is frequently modelled using other hookworms and related nematodes that survive in 
rodents or larger animals, including Ancylostoma sp., H. polygyrus and N. brasiliensis. It should be noted 
that the N. americanus material employed in this study was obtained from parasites adapted to 
hamsters through many generations of selective pressure [260,261]. Adult stage N. americanus 
parasites obtained from hamster infection were smaller and less fecund than those from human hosts 
[262]. These phenetic differences may be associated with differences in transcriptional patterns. To 
date there have been no studies directly comparing the genomes or secretomes of N. americanus 
maintained in hamsters and those obtained directly from human infections. Such data would enhance 
the validity of the data obtained in this study.  
The protein family analysis of N. americanus ES products revealed a diverse number of known and 
unknown domains (391 domains total), which attests to the many biological functions of ES proteins as 
well as to the lack of information on these proteomes. The ES products of the three comparator species 
used here had similar protein family profiles with 458 (A. caninum), 434 (H. polygyrus) and 628 (N. 
brasiliensis) unique domains present. To assess the overall usefulness of these models, a similarity 
analysis was carried out on their ES products. This analysis relates relative protein sequence similarities 
in a plot where each of the identified N. americanus ES proteins is compared to the ES proteome of the 
comparator species [194,247]. The majority of the N. americanus ES proteins (173/198), including 
51/54 SCP/TAPS proteins, had homologs in the ES products of all three comparators, highlighting the 
relevance and usefulness of all three models. A total of 25 proteins did not have similarity to ES proteins 
from the other 3 nematodes analyzed. Since A. caninum, H. polygyrus and N. brasiliensis are animal 
parasites, these 25 N. americanus proteins might have evolved to such an extent that they target 
human-specific pathways. Two unique proteins of interest are the aspartyl protease NAME_01848 
(PF00026) and the zinc metalloprotease NAME_05081 (PF01546). Metalloproteases and aspartyl 
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proteases play crucial roles in host tissue penetration and parasite feeding, and as such, proteolytic 
enzymes from helminths may be of particular interest as vaccine and/or drug targets [263,264]. 
The most abundantly represented protein family (54/198; 27%) in N. americanus ES products was 
proteins containing a single or double SCP/TAPS domain (PF00188). This finding aligns with previous 
work that highlighted the abundance of this protein family in nematode ES products in particular 
[213,265]. For instance, a total of 45, 90 and 25 SCP/TAPS proteins were found in the ES products from 
N. brasiliensis (45/313; 14%), A. caninum (90/315; 29%) and H. polygyrus respectively (25/374; 12%). 
Interestingly, this family of proteins is also abundant in the extracellular vesicles secreted by different 
nematodes [255,258]. Given that SCP/TAPS proteins from N. brasiliensis are almost exclusively secreted 
by the adult developmental stage [194], these proteins are likely coordinating specific roles in the 
gastrointestinal tract of the host. In fact, it has also been shown that SCP/TAPS are overrepresented at 
the transcript level in N. americanus adult worms [169]. Serum-activated A. caninum L3 larvae were 
also shown to upregulate SCP/TAPS in culture [266]. While relatively little functional information is 
available for SCP/TAPS proteins, neutrophil inhibitory factor (NIF), an SCP/TAPS protein in the ES of A. 
caninum, was reported to abrogate neutrophil adhesion to the endothelium [267]. However, a N. 
americanus homolog of this protein was not detected in the current study, despite the presence of a 
NIF-encoding gene in the draft genome [169]. SCP/TAPS proteins are thought to play numerous and 
diverse roles at the host-parasite interface, from defense mechanisms, normal body formation and 
lifespan [197]. The diverse nature of N. americanus SCP/TAPS sequences is evidenced by their 
phylogenetic relationships (Figure 5A and B). Blast analyses presented in the Circos plot (Figure 4A) 
revealed varying degrees of sequence homology to SCP/TAPS proteins from A. caninum, H. polygyrus 
or N. brasiliensis. These SCP/TAPS proteins should be further explored to understand their roles in N. 
americanus-human host interactions. Given the limited availability of information regarding the 
function of helminth SCP/TAPS proteins in general, it was unsurprising that GO analyses revealed no 
known molecular function or biological process for 32/54 of the SCP/TAPS from N. americanus ES 
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products, and more studies should be performed to characterize the properties of this intriguing family 
of proteins. 
Despite the lack of functional information on the SCP/TAPS proteins in parasitic helminths, of the 
species we compared in this study, N. americanus proteins were generally most similar to those from 
A. caninum, which could simply be a reflection of the phylogenetic similarity between the two species. 
(Figure 5A and 5B). The trees generated in this study highlight strong clade-specific similarities between 
SCP/TAPS in the ES products of the compared species. In support of this, the vast majority of the 
SCP/TAPS proteins came from the four clade V species, while A. suum, T. muris and T. canis had only 2, 
5 and 2 SCP/TAPS proteins respectively. The clustering of A. caninum with N. americanus and H. 
polygyrus with N. brasiliensis supports the notion of host-specific roles for SCP/TAPS. Another trend 
across both single and double domain trees was the diversity of evolution between SCP/TAPS within a 
single species. For example, the single-domain tree included a sub-clade of 7 N. americanus-only 
sequences indicating an important human-specific role for this evolutionary cluster. This compares well 
with a number of other sub-clades that included proteins from the four predominant species. These 
SCP/TAPS proteins are more likely to share a common function, potentially in host-infection or parasite 
development within the mammalian host.  
The phylogenetic analysis strongly attests to the preferred use of A. caninum for studying hookworm 
molecular biology and ES products in general [268]. This finding is reinforced by the similarity analysis 
represented in the Circos plot of SCP/TAPS (Figure 4A). Not only was there a greater number of 
SCP/TAPS homologs in the ES products of A. caninum but these proteins also had relatively higher blast 
scores (denoted by link ribbon thickness) and higher percent identity scores (denoted by ribbon 
darkness). This type of analysis can prove useful since it also reveals which species to consider for 
investigating a specific Necator SCP/TAPS protein. For example, NAME_13850 has significant sequence 
homology to a SCP/TAPS protein from each of the compared species; however, the species with the 
highest sequence homology is A. caninum (ANCCAN_19759), making this protein the most relevant to 
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study as a model for NAME_13850. Prior to updating the draft genome, all three species of nematode 
used in this comparison had longer average gene sequence lengths than the N. americanus SCP/TAPS 
sequences. In the previous annotation, the average N. americanus SCP/TAPS sequence length was 244 
predicted amino acids, compared with 355 residues in the updated genome. This was likely due to 
some of the sequences being truncated, yielding similar results to the published H. polygyrus proteome 
[248].  
The Circos plot representing N. americanus proteases and homologous proteins from the three 
comparator species (Figure 4B) provides insight into the high degree of sequence similarity. Unlike the 
SCP/TAPS Circos analysis, all the N. americanus ES proteases had homologs with high similarity in the 
compared species (average 50% identity between N. americanus and comparator species protease). 
This finding supports the notion of using any one of these three parasites to study N. americanus 
proteases in general. We identified 8 aspartyl, 6 cysteine, 9 metallo and 3 serine proteases in the ES 
products of N. americanus. As the adult stage of N. americanus feeds on blood, the high abundance of 
aspartyl proteases was expected [219,269]. Yet when compared to other species, the human 
hookworm ES products included more of these proteases. Aspartyl proteases play a fundamental role 
in the digestion of host haemoglobin and have also been implicated in skin penetration, feeding, and 
host tissue degradation [270,271]. The finding that N. americanus has more of this mechanistic class of 
proteases than the other nematodes assessed here is likely due to split gene models and/or may be a 
true gene family expansion. Due to the vital role that aspartyl proteases play in parasite feeding, Na-
APR-1 an N. americanus aspartyl protease, was targeted as a vaccine candidate [211]. While we were 
unable to detect Na-APR-1 in the current ES proteome - probably because it is anchored to the gut 
epithelium [272] - 9 other aspartyl proteases were detected which could potentially be targeted as 
novel vaccine candidates. 
Cysteine proteases, particularly the group belonging to the papain superfamily, are common in 
nematodes [273]. They have been specifically described for their proteolytic activity against 
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haemoglobin, antibodies and fibrinogen in the N. americanus lifecycle [274]. Similarly, another study 
highlighted the importance of four cysteine proteases that were upregulated in the N. americanus 
transition from free-living larvae to blood-feeding adult worm, indicating that these proteins are likely 
to be important for nutrient acquisition [275]. Metalloproteases - particularly the astacins - identified 
in this study are most likely important for larval and adult migration and invasion through human host 
tissue [276]. In support of this, astacin metalloproteases were found to be upregulated in N. brasiliensis 
larvae when compared with adult stage parasites [194]. Interestingly, N. americanus metalloproteases 
were reported to inhibit eosinophil recruitment through the cleavage of eotaxin, a potent eosinophil 
chemoattractant [217]. The least abundant family of proteases in the adult N. americanus ES products 
was the serine proteases. Relatively little is known about these proteases from N. americanus 
specifically; however, a serine protease from the whipworm T. muris is involved in degradation of the 
mucus barrier to facilitate feeding [277]. Due to the importance of these various proteases in parasite 
feeding, infection, migration and defense, they represent potential targets for chemotherapies and 
vaccines to limit infection [278]. 
In this chapter, I have presented the first proteogenomic analysis of a helminth parasite, resulting in a 
more accurate genome annotation. While the above annotations are valuable additions to the current 
genome, further improvement requires access to substantially more parasite material including adult 
stage parasites which are difficult to obtain. Furthermore, I have carried out the first proteomic analysis 
of the ES products of the human hookworm N. americanus. The results presented herein offer 
significant insight into the validity of these model species while also highlighting differences between 
these important parasites.  
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3  Chapter 3 – Recombinant hookworm 





The proteomic results generated in chapter 2 includes the secretome of the human hookworm. Having 
access to this database helps to inform the direction and practice of numerous studies into the function 
of specific molecules from this parasite. To begin to explore these functions, the proteins must first be 
produced in recombinant form. This is due to the difficulty in obtaining sufficient quantities of purified 
parasite-derived proteins. Using the example of the human hookworm, ES product yields directly from 
the worm are very low, require a lot of parasites, and can be costly. The introduction of molecular 
cloning in the 1970s has afforded researchers the option of producing foreign proteins in a range of 
prokaryotic and eukaryotic cell lines. Among the many microbial systems, yeast combines the benefits 
of a unicellular organism (i.e. ease of growth and genetic exploitation) with the advantage of eukaryotic 
post-translational modifications and protein folding.  
P. pastoris is a methylotrophic yeast meaning it uses methanol to grow as a sole source of energy and 
carbon [279]. The alcohol oxidase gene AOX1, induced by methanol, was used in P. pastoris to develop 
an efficient organism for DNA transformations and subsequent protein production [280]. The main 
advantage of this system is a high secretory capacity in combination with the strongly inducible 
methanol-dependent promotor [281]. Additionally, the system has a distinct lack of endotoxin by-
products or viral DNA [282]. The disadvantageous come with industrial scale production including: high 
heat production, considerable oxygen demand, and the use of a flammable substrate [279]. As these 
disadvantageous are linked with very large scale production, they are not necessary to consider for 
smaller studies.  
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This system has been used successfully to express a number of helminth secreted proteins. Three 
glutathione S-transferases from N. americanus were expressed in P. pastoris with one taken forward 
as a potential vaccine candidate [283,284]. Notably, SCP/TAPS proteins including Na-ASP-2 and Ac-ASP-
7 have been expressed using this system and used for functional and crystal structure determination 
[285-287]. Given these studies with SCP/TAPS specifically, as well as the previously described 
advantageous of using P. pastoris, this method was ideal for use in this thesis. 
Based on the results of the proteomics analysis from chapter 2, eighteen proteins of interest were 
selected to be produced in yeast. Proteins were selected based on their abundance (emPAI), whether 
they were SCP/TAPS proteins and chosen based on dissimilarity to other SCP/TAPS proteins from the 
phylogenetic analyses. To improve the odds of selecting one of the key immunoregulatory molecules, 
the main aim in chapter 3 was to express SCP/TAPS proteins. I chose SCP/TAPS as they were abundantly 
represented in the ES products, but also because they are thought to play important roles in the 
modulation of host immune responses [197,288,289]. This chapter finishes with the testing the 
recombinant proteins as serodiagnostic markers of infection. This work was carried out to test whether 
ES antigens from the human hookworm could potentially be used to improve the currently available 






Gene of interest  
 
An initiator methionine and signal peptide were used to identify full-length ORFs. The signal peptides 
were removed and the ORF was designed to be fused in-frame with the encoded signal peptide in the 
pPICZα vector (Figure 3.1). Sequences were checked for restriction enzyme sites using the online tool 
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NEBcutter v2.0 available at http://nc2.neb.com/NEBcutter2/. If the sites EcoR1, Xba1 or Sac1 were 
present, a point mutation was carried out ensuring that the encoded amino acid sequence was not 
affected. The EcoR1 restriction site sequence (GAATTC) was placed at the N-terminus of the ORF while 
Xba1 (TCTAGA) was placed at the C-terminus. In order to retain the ORF, two guanines were inserted 
upstream of the Xba1 sequence, resulting in an additional glycine on the end of each recombinant 
protein (Supplementary data 7.1). Genes were synthesized by Integrated DNA Technologies (IDT) by 
following the instructions at www.idtdna.com. Sequences were automatically codon-optimised for P. 
pastoris using the optimization tool through the IDT ordering process.  
 








Aseptic technique using either a Bunsen burner or a fume hood was observed throughout the entirety 
of this protocol. Four micrograms of gene of interest (GOI) DNA in IDT generic cloning vector was 
obtained from IDT. Upon arrival, plasmid DNA was hydrated with dH2O, vortexed and centrifuged 
briefly. From this plasmid DNA, 0.2 µg was added to 100 µl Ca millilitre Cl2 competent E. coli cells 
(prepared as described below) and incubated for 20 minutes on ice. The cells were then heat shocked 
at 42°C for 45 seconds and placed back on ice for a further 2 minutes. After incubation on ice, 500 µl 
of LB low-salt media was added, the cells were incubated for 1 hour at 37°C, shaking at 220 rpm, before 
being plated onto LB low-salt plates with 100 µg/ml ampicillin. After overnight incubation at 37°C, 
single colonies were picked from the plate and cultured in 5 ml LB low-salt media (100 µg/ml ampicillin) 
in 50 ml tubes. These tubes were incubated O/N at 37°C, shaking at 220 rpm.  
Cloudy media indicated good bacterial growth. From this O/N culture 500 µl was added to a solution 
of 50% glycerol, mixed gently and stored immediately at -80°C. The remaining 4.5 ml of culture was 
miniprepped using the Nucleospin Plasmid Easypure kit (Macherey-Nagel). Miniprepping was followed 
according to the kit manual. Flow through (FT) was stored on ice, analysed for DNA content with a 
Nanodrop 2000 and stored at -30°C for later use. 
Using approximately 2 µg of plasmid DNA obtained from the miniprep, a digestion was carried out as 
follows. A master-mix (MM) was made by combining: 15 µl dH2O, 3 µl 10X CutSmart Buffer (B7204S, 
New England BioLabs), 1 µl EcoR1 HF (New England BioLabs), 1 µl XbaI (New England BioLabs). Twenty 
microlitres of MM was added to 10 µl of plasmid DNA (2 µg total) to give a final volume of 30 µl. The 
same format was used for digesting the pPICZα vector (ThermoFisher). Digestion reactions were heated 
for 2 hours at 37°C on a heat block. An agarose gel (1%) was prepared. Six microlitres of Gel Loading 
Dye, Purple (New England BioLabs) was added to each of the 30 µl digestion reactions, mixed, and each 
loaded to a separate well of the 1% agarose gel. HyperLadder 1kb (BioLine) was included as a size 
ladder. The gel was run for 45-60 minutes at 100 V. Cut plasmids and DNA inserts were viewed using a 
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Molecular Imager VersaDoc (BioRad). Using a scalpel blade, DNA inserts were cut from the agarose gel. 
An Isolate II PCR and Gel Kit (Bioline) was used to isolate the DNA inserts from the agarose gel. In brief, 
gel was solubilized by adding 200 µl of Binding Buffer CB per 100 mg gel, incubating at 50°C for 5-10 
minutes and vortexing. Solubilized gel was loaded into a kit column, centrifuged for 30 seconds at 
11,000 g, and FT discarded. Two washes were carried out by adding 600 µl Wash Buffer CW, 
centrifuging for 30 seconds at 11,000 g, and FT discarded. The membrane was dried by carrying out 
another 1 min centrifugation at 11,000 g. The collection tube was replaced, 15 µl Elution Buffer C added 
and the tube was incubated at room temperature for 1 min. The tube was then centrifuged for 1 min 
at 11,000 g to elute the DNA in a final volume of 15 µl. DNA was quantified with a Nanodrop 2000 
(ThermoFisher) before being stored at -30°C.  
Ligation 
 
DNA inserts were ligated into cut pPICZα plasmids (ThermoFisher) following the subsequent procedure. 
A MM was made by combining: 8.5 µl dH2O, 1.5 µl 10X T4 DNA Ligase Reaction Buffer (New England 
BioLabs), 1 µl T4 DNA Ligase (New England BioLabs) and 1 µl cut pPICZα (~300 ng/µl, ThermoFisher). 
Three microliters of DNA insert was added to 12 µl of MM and left at room temperature for 2 h to 
ligate. Ligated pPICZα was transformed into E. coli and subsequently miniprepped as previously 
described to a total amount of 15 µg plasmid with GOI. A restriction digest was carried out, as 
previously described, to confirm the presence of the DNA insert. 
Digest and clean-up 
 
Plasmid with GOI was digested to a linear form and cleaned up in preparation for electroporation using 
the following procedure. MM was made by combining: 7 µl dH2O, 6 µl 10X CutSmart Buffer (New 
England BioLabs), 2 µl SacI HF (New England BioLabs). Subsequently, 45 µl of pPICZα with GOI (~350 
ng/µl) was added to 15 µl of MM and left for 4 h, at 37°C. Following linearization, plasmid DNA was 
cleaned up using an Isolate II PCR and Gel Kit (Bioline). The method followed was the same as previously 
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described with the exception of the initial step. One hundred and twenty microlitres of Binding Buffer 
CB was added to the 60 µl linearized plasmid with GOI, mixed and loaded into the column. 
Electroporation 
 
Competent P. pastoris was prepared following the subsequent procedure. P. pastoris was streaked on 
a YPDS plate and allowed to grow until colonies formed. A single colony was picked and grown in YPD 
media rotating at 200 rpm, 30°C, O/N. From the O/N culture, 500 µl was inoculated into 100 ml of fresh 
YPD and grown to an optical density (OD) between 1.3-1.5. Throughout the remainder of this protocol 
the cells were kept on ice as much as possible. The cells were centrifuged for 5 minutes at 1,500 g, 4°C, 
the supernatant (S/N) discarded, and the pellet resuspended in 50 ml ice-cold dH2O. The cells were 
centrifuged for 5 minutes at 1,500 g, 4°C, the S/N discarded, and pellet resuspended in 25 ml ice-cold 
dH2O. The cells were centrifuged for 5 minutes at 1,500 g, 4°C, the S/N discarded, and the pellet 
resuspended in 10 ml ice-cold 1 M Sorbitol. The cells were centrifuged for 5 minutes, 1,500 g, 4°C, the 
S/N discarded, and the pellet resuspended in 1 ml ice-cold 1 M Sorbitol.  
Eight microlitres of cells were mixed with 10 µl linearized DNA with GOI (from Digest and Cleanup stage) 
and transferred to an ice-cold 2 mm electroporation cuvette (Bio-Rad). The cell-DNA mixture was 
incubated on ice for 5 minutes before being pulsed on a Bio-Rad Gene Pulser Xcell (settings: 2,000 V, 
25 µF, and 200 Ω). One millilitre of 1 M sorbitol was added to the sample before it was transferred to 
a 15 ml falcon tube and incubated for 1.5 h at 30°C. Incubated cells were pelleted gently at 300 g for 2 
minutes. Nine hundred microlitres of S/N was removed, the cells were resuspended in the remaining 
100 µl, and streaked on a YPDS plate with 100 µg/ml Zeocin. Plates were incubated for a minimum of 
3 days at 30°C in the dark. Single colonies were picked from plates and patched on to a YPDS plate with 
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Small scale expression 
 
A single colony was stabbed from the YPDS plate with 1 mg/ml Zeocin and put into 5 ml YPD media 
(100 µg/ml Zeocin) in a 50 ml tube. The colony was cultured O/N at 30°C, rotating at 200 rpm. One 
hundred microlitres of O/N culture was aliquoted into 5 ml fresh BMGY media and cultured O/N at 
30°C, rotating at 200 rpm. The remaining YPD culture was centrifuged briefly for 5 minutes at 2,000 
rpm before the S/N was aspirated. The cell pellet was resuspended in 15% glycerol, transferred to a 
cryovial and stored immediately at -80°C. The O/N BMGY culture was centrifuged briefly for 5 minutes 
at 500 g and resuspended to an OD of ~1 with BMMY. Five millilitres of OD1 BMMY culture was 
incubated at 30°C for 72 h, rotating at 200 rpm. At 24 h and 48 h of the culture period, 25 µl of 100% 
methanol (Sigma-Aldrich) was added to give a final concentration of 0.5% v/v. One hundred microlitres 
of BMMY culture was collected at 24 h, 48 h and 72 h for use in a dot blot and western blot. The 100 µl 
culture was centrifuged briefly at 500 g for 5 minutes, and the S/N stored at -30°C until use.  
Dot blot 
 
Nitrocellulose membrane (GE Healthcare) was cut and boxes were drawn lightly with a pencil. Two 
microlitres of clarified BMMY S/N from each time point (24 h, 48 h and 72 h) was blotted separately 
onto the membrane. Each dot was allowed to dry for 10 minutes before another 2 µl of the same S/N 
was added on top of the original dot. This process was repeated 4 times to a final volume of 8 µl. Five 
percent skim milk in PBST was prepared and the dried membrane was left to block O/N, rocking gently 
at 4°C. Blocking buffer was decanted and 20 ml anti-c-myc mAb (Sigma-Aldrich) in PBST diluted 1: 3,000 
was added and incubated for 2 hours at room temperature with gentle rocking. The membrane was 
washed 3 times in PBST for 5 minutes each with gentle rocking. Goat anti-mouse IgG peroxidase 
(ThermoFisher) diluted 1:2,000 was added and incubated for 1 hour at room temperature with gentle 
rocking. The membrane was washed 3 times in PBST for 5 minutes each with gentle rocking. The final 
wash was removed and the membrane was left in PBS until detection. Enhanced 
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Chemiluminescence (ECL) Western Blotting Substrate (ThermoFisher) was prepared according to the 
manufacturer’s instructions by mixing equal volumes of reagent A and B and incubating the membrane 
in the solution for 1 minute. The blot was viewed using a Molecular Imager VersaDoc (BioRad) 
Western blot 
 
Fifteen microlitres of S/N from the small scale expression was mixed with 5 µl of 4x SDS Protein loading 
buffer, heated for 5 minutes at 95°C and added to a 12% SDS-PAGE gel locked in an XCell SureLock Mini 
Cell electrophoresis chamber (ThermoFisher). SDS Running Buffer was used to fill the middle chamber 
and half the outside chambers. Five microlitres of unheated protein ladder (ThermoFisher) was added 
to a single lane. The loaded gel was run at 80 V for 20 minutes and then 120 V until the dye front 
reached the bottom of the gel.  
A weigh boat was filled with 4°C western transfer buffer. Three pads were soaked in the buffer before 
being placed into the transfer cassette. Three Whatman Grade 3MM Chr Blotting papers (GE 
Healthcare) were soaked and added to the cassette. The completed gel was removed from the holder, 
trimmed and added to the cassette. Nitrocellulose membrane (GE Healthcare) was soaked and added 
on top of the gel. Three sheets of Whatman paper and pads were added before the lid was attached 
and the cassette was placed into the electrophoresis chamber. The middle and outer chambers were 
filled with western transfer buffer before placing the whole system into ice and running at 20 Amps for 
2 h.  
Five percent skim milk in PBST was prepared and the membrane was left to block O/N, rocking gently 
at 4°C. Blocking buffer was poured off and 20 ml anti-c-myc mAb (Sigma-Aldrich) in PBST diluted 1:3,000 
was added. The primary antibody was allowed 2 hour to incubate at room temperature with gentle 
rocking. The membrane was washed 3 times in PBST for 5 minutes each with gentle rocking. Goat anti-
mouse IgG peroxidase (ThermoFisher) diluted 1:2,000 was added and incubated for 1 hour at room 
temperature with gentle rocking. The membrane was washed 3 times in PBST for 5 minutes each with 
gentle rocking. The final wash was removed and the membrane was left in PBS until detection. ECL 
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Western Blotting Substrate was prepared as described above. The blot was viewed using a Molecular 
Imager VersaDoc. 
Large scale expression 
 
The best expressing clones from the small scale expression were selected for large scale expression. 
The glycerol stock was stabbed and placed into culture with 25 ml BMGY in a 250 ml baffled flask 
(Edwardsco), incubated O/N at 30°C rotating at 200 rpm. The 25 ml O/N culture was added to 225 ml 
fresh BMGY in a 2 L baffled flask (Edwardsco), incubated O/N at 30°C rotating at 200 rpm. The O/N 
BMGY culture was centrifuged briefly for 15 minutes at 1,500 g and resuspended to an OD of ~1 with 
500 ml BMMY. The BMMY culture was incubated at 30°C for 72 h, rotating at 200 rpm. At 24 h and 48 
h time points, 2.5 ml of 100% methanol (Sigma-Aldrich) was added to give a final concentration of 0.5% 
v/v. At 72 h the S/N was harvested by centrifuging the culture at 3,000 g for 15 min and filter-sterilised 




An ÄKTA Start (GE Healthcare) fast protein liquid chromatography (FPLC) system including lines A, B 
and sample were washed with 1 M Sodium hydroxide for 30 minutes. The NaOH was rinsed out for 10 
minutes with dH2O. A 5 ml HisTrap excel column (GE Healthcare) was attached and flushed with dH2O 
for 10 minutes. Line A was placed into 4°C Buffer A, line B into 4°C Buffer B and the sample line into 
the 4°C sterile-filtered S/N from the large scale expression. The following settings were used for the 
protein purification: Flow rate – 5 ml/min, Equilibration volume – 10 ml, Sample volume – 500 ml, Wash 
column – 50 ml, Elution starting B concentration – 0%, Elution fixed fractionation volume – 3 ml, Elution 
target B concentration – 100%. Fifteen millilitre tubes (Greiner) were used for fraction collection. Three 
kDa Amicon Ultra-15 Centrifugal Filter Units (Merck Millipore) were used to concentrate protein-
containing fractions from the large scale expression.  
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Endotoxin quantification and removal 
 
Endotoxin concentration was quantified using a Pierce LAL Chromogenic Endotoxin Quantification Kit 
(88282, Thermo Fisher). The assay was carried out according to the manufacturer description. 
Absorbance was measured at 405-410 nm on a FLUOstar Omega plate reader (BMG Labtech). 
If the sample contained detectable levels of endotoxin in the above assay (>0.1EU/ml), the following 
procedure was carried out to remove it. Triton X-114 (Sigma-Aldrich) was added to the protein sample 
to a final concentration of 1%. Samples were left at 4°C O/N on a tube rotator. Samples were incubated 
on a heat block at 37°C for 10 minutes before being centrifuged at 16,000 g for 5 minutes. The top layer 
was collected into a fresh microcentrifuge tubes. Samples were incubated on a heat block at 37°C again 
for 10 minutes before being centrifuged again at 16,000 g for 5 minutes. Samples were re-quantified 
to ensure the concentration of endotoxin was below the limit.  
3.2.2 Enzyme-linked immunosorbent assays using human sera 
 
The diagnostic potential of each SCP/TAPS protein was assessed by indirect IgG ELISA using a cohort of 
hookworm-positive (grouped according to World Health Organisation stratification: heavy infection - 
≥4,000 eggs per gram of faeces (epg), n=10; moderate infection - 2,000-3,999 epg, n=11; or light 
infection - ≤1,999 epg, n=44), hookworm-negative (n=7) and hookworm-negative/Ascaris-positive 
(n=12) samples from a hookworm-endemic region in Minas Gerais, Brazil. Microlon high-binding 96-
well microtiter ELISA plates (Greiner) were incubated overnight at 4C with each antigen (2 μg/ml in 
0.1 M Na2CO3/NaHCO3, pH 9.6). Somatic extract of N. americanus L3 was similarly used as a positive 
control antigen. After washing with PBST the plates were blocked for 2 hours at room temperature 
with 100 μl of PBST/5% BSA. One hundred microlitres of sera (1:200 in PBST/1% BSA) were added to 
the wells and incubated overnight at 4C, then the plates were washed with PBST and 100 μl of goat 
anti-human IgG-HRP (Sigma) (1:5,000 in PBST) was added to the plates. Plates were incubated for 2 
hours at room temperature and then washed with PBST. Plates were developed by adding 100 μl of 
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3,3’,5,5’-tetramethylbenzidine and incubating for 30 minutes at room temperature in the dark. One 
hundred microliters of 1 M HCl was added to stop the colorimetric reaction, which was read at a 
wavelength of 450 nm on a Polarstar Omega (BMG Labtech) microplate reader. The assay was 
performed in triplicate with two technical replicates and blank-corrected values were plotted using 
Graphpad Prism 7. The same software was also used to generate single and multi-antigen Receiver-
Operating Characteristic (ROC) curves. Reactivity cutoffs were determined as the average plus 1 SD of 
the values of the hookworm-negative group and the frequency of recognition (FoR) of each antigen 
was determined using this cutoff. An unpaired Student’s t test was used to compare differences in 






Selected cDNAs of interest 
 
Eighteen cDNAs were selected for protein expression and were uploaded to IDT for synthesising (Table 
3.1). The nucleotide sequences for each of these as well as their modifications, and translations are 
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NP1 NECAME_01191 Single 579 21462.38 6.07 
NP2 NECAME_06164 Double 1074 39572.86 1.11 
NP3 NECAME_01366 Double 1332 48821.8 1.6 
NP4 NECAME_01369 Double 1383 49434.93 2.05 
NP5 NECAME_07493 Single 363 13224.36 15.78 
NP6 NECAME_09334 Double 1389 50936.8 1.71 
NP7 NECAME_07497 Single 612 22695.06 27.05 
NP8 NECAME_15063 Double 1182 42595.39 16.92 
NP9 NECAME_15467 Single 444 15919.3 1.2 
NP10 NECAME_15644 Double 1143 41768.52 128.67 
NP11 NECAME_16121 Double 1143 41745.98 0.5 
NP12 NECAME_02290 Single 480 17203.11 0 
NP13 NECAME_16708 Single 858 31436.05 5.55 
NP14 NECAME_17155 Single 975 34766.46 0.84 
NP15 NECAME_17854 Single 516 18953.28 0.55 
NP16 NECAME_18970 Single 303 10413.93 50.11 
NP17 NECAME_07690 Single 630 23129.11 4.13 
NP18 NECAME_16753 Double 1107 41214.65 0.23 
Table 3.1: Summary of the genes selected to clone and express.  
 
Transformation into Top10 E. coli 
 
All colonies transformed with IDT ampicillin resistant plasmid with respective gene of interests were 
successfully propagated on LB ampicillin (100 µg/ml) plates evident by numerous colonies the day after 
transformation and plating. An example is shown in Figure 3.2. The single colonies chosen from these 
plates for upscaling all grew well in 5 ml LB broth ampicillin (100 µg/ml) confirmed by visually inspecting 
the turbidity of the media.  
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Figure 3.2: Top10 competent cells transformed with gene of interest in plasmid with ampicillin 
resistance. Transformed cells were Escherichia coli grown on a Lysogeny broth plate with ampicillin 
(100 µg/ml) (A). This is contrasted with a negative control (B) which includes the same cells without 
transformed resistance to ampicillin.  
Digest for GOI 
 
Concentrated DNA was run on an agarose gel to confirm the presence of and isolate each GOI insert 
for ligation into the expression vector. The uncut vs cut DNA is shown below in Figures 3.3 and 3.4. 
From the gel it can be clearly seen that all of the DNA preps were successfully digested with the 
exception of NP5. The uncut lanes of each different prep shows three distinct bands (supercoiled, coiled 
and nicked plasmid): one at approximately 3,000 bp, one at approximately 6,000 bp and the last above 
the highest molecular size standard. The cut lanes show three bands at different locations: one at the 
position reflective of the size of the GOI, another at approximately 2,500 bp (cut plasmid) and the last 
above the scale. A GOI band was not detected for NP5 in the digest lane (lane K) of Figure 3.3. In 
addition, the uncut banding pattern visible in lane J was unchanged, indicating that restriction digestion 
was unsuccessful. Digested samples separated using an agarose gel had inserts excised and purified 
using a Bioline Isolate II PCR and Gel Kit. These inserts were quantified using a Nanodrop 2000.  
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 Figure 3.3: Comparison of uncut vs cut plasmid (1-9) with gene of interest. The 1% poured agarose 
DNA gel was visualised with ethidium bromide and a Molecular Imager VersaDoc (BioRad). Nine 
individual plasmids (1-9) were run across lanes B-S and the second of each pair was cut with 





Figure 3.4: Comparison of uncut vs cut plasmid (10-18) with gene of interest. The 1% agarose DNA 
gel was visualised with ethidium bromide and a Molecular Imager VersaDoc (BioRad). Nine individual 
plasmids (10-18) were run across lanes B-S and the second of each pair was cut with restriction 
enzymes EcoR1 and Xba1. One hundred nanograms total DNA was loaded into each well.  
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Ligation into pPICZα 
All colonies transformed with GOI + pPICZα expression vector were successfully propagated on LB 
Zeocin (100 µg/ml) plates evident by numerous colonies the day after transformation and plating. An 
example is shown in Figure 3.5. The single colonies chosen from these plates for upscaling all grew well 
in 5 ml LB broth Zeocin (100 µg/ml) confirmed by visually inspecting the turbidity of the media. The 
DNA was concentrated using a Nucleospin Plasmid Easypure kit.  
 
 
Figure 3.5: Top10 competent cells transformed with gene of interest in plasmid with Zeocin 
resistance. Transformed Escherichia coli were grown on a Lysogeny broth plate with Zeocin (100 µg/ml) 
(A). This is contrasted with a negative control (B) which includes the same cells without transformed 
resistance to Zeocin.  
 
Linearisation for electroporation 
 
Concentrated GOI in pPICZα was linearised with Sac1 and run on an agarose gel to confirm adequate 
linearisation. The circular vs linearised DNA is shown below in Figures 3.6 and 3.7. From the gel it can 
be clearly seen that all of the DNA preps were successfully linearised.  
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Figure 3.6: Comparison of circular vs linearised plasmid (NP1-9 excluding NP5) with gene of interest. 
The 1% poured agarose DNA gel was visualised with ethidium bromide and a Molecular Imager 
VersaDoc (BioRad). Eight individual plasmids were run across lanes B-S and the second of each pair was 
cut with restriction enzyme Sac1. One hundred nanograms total DNA was loaded into each well. Lanes 




Figure 3.7: Comparison of circular vs linearised plasmid (NP10-18) with gene of interest. The 1% 
poured agarose DNA gel was visualised with ethidium bromide and a Molecular Imager VersaDoc 
(BioRad). Nine individual plasmids were run across lanes B-S and the second of each pair was cut with 
restriction enzyme Sac1. One hundred nanograms total DNA was loaded into each well.  
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Electroporation into P. pastoris 
 
Approximately 5-10 P. pastoris colonies were observed for each of the GOIs on each respective plate 
72 hours post electroporation and plating. An example of this growth is shown in Figure 3.8 with some 
individual colonies highlighted with black circles. The single colonies chosen from these plates for small 
scale expression all grew well in 5 ml YPD broth Zeocin (100 µg/ml) confirmed by visually inspecting the 
turbidity of the media. 
 
 
Figure 3.8: Electroporated yeast cells with gene of interest in pPICZα with Zeocin resistance. 
Transformed Pichia pastoris cells were grown on a Yeast Extract Peptone Dextrose Agar with Sorbitol 
(YPDS) plate with Zeocin (100 µg/ ml) (A). This is contrasted with a negative control (B) which includes 
the same cells without transformed resistance to Zeocin.  
3.3.2 Protein expression 
 
Small scale expression 
 
Three colonies were selected from the electroporation plates for small scale expression, grown in 5 ml 
YPD Zeocin (100 µg/ml), and the supernatant tested using a dot blot with anti-c-myc mAb to detect 
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protein expression. The results for each protein are shown in Figures 3.8 and 3.9. The negative control 
protein, untagged BSA, was not detectable (I48, Figure 3.9). The positive control, an in-house produced 
and sequenced N. americanus c-myc tagged protein, elicited a strong signal (I72, Figure 3.9). NP1 (Row 
A, Figure 3.9) was the only protein for which expression was undetectable from the selected colonies. 
The remaining proteins NP2-9 (Figure 3.9) and NP10-18 (Figure 3.10) displayed varying levels of protein 
expression detected by dot blot. Across all proteins a strong trend was apparent for greater protein 
expression over time, with 72 h yielding the most intense signal for each of the tested colonies and 
proteins.  
 
Figure 3.9: Dot blot of small scale expression of hookworm recombinant proteins (NP1-9, excluding 
5) expressed in yeast. Image shows three separate colonies (C1-C3) at three time points (24 h, 48 h, 72 
h) of eight different proteins expressed in Pichia pastoris (A-H). A-H represent NP1-9 respectively, 
excluding NP5. I72 is the positive control, an established c-myc tagged protein while I48 is a negative 
control – untagged BSA. Intensity of dot reflects relative protein concentration, probed using anti-c-
myc mAb conjugated to horseradish peroxidase and visualised using a Molecular Imager VersaDoc. 
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Figure 3.10: Dot blot of small scale expression of hookworm recombinant proteins (NP10-18) 
expressed in yeast. Image shows three separate colonies (C1-C3) at three time points (24 h, 48 h, 72 
h) of nine different protein expressed in P. pastoris (A-I). A-I represent NP10-18 respectively. Intensity 
of dot reflects relative protein concentration, probed using anti-c-myc mAb conjugated to horseradish 
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A - NP10 C1 – 72 h 
B - NP2 C2 – 72 h B - NP11 C2 – 72 h 
C - NP3 C3 – 72 h C - NP12 C2 – 72 h 
D - NP4 C3 – 72 h D - NP13 C3 – 72 h 
E - NP6 C3 – 72 h E - NP14 C2 – 72 h 
F - NP7 C3 – 72 h F - NP15 C3 – 72 h 
G - NP8 C1 – 72 h G - NP16 C3 – 72 h 
H - NP9 C1 – 72 h H - NP17 C3 – 72 h 
I - controls N/A I - NP18 C3 – 72 h 
 
Table 3.2: The best expressing colonies and time points selected for large scale expression based on 
the dot blots from small scale expression.  
 
Large scale expression 
 
Successfully produced proteins from the small scale expression were taken forward to large scale 
expression to produce workable quantities. Proteins were purified over a HisTrap excel column and 
fractions were run on a SDS-PAGE gel to assess purity. Figure 3.11 shows an example of the elution 
profile of recombinant NP17.  
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Figure 3.11: Coomassie stained SDS-PAGE gel showing individual fractions of concentrated protein 
(NP17).The protein was purified using an ÄKTA Start fast protein liquid chromatography system and 
HisTrap excel column. The concentration of protein, evident from the gel, decreases with each 
progressive fraction from the ÄKTA. Lane A is the first elution fraction and each consecutive lane is the 
successive fraction with increasing levels of imidazole.  
 
Each protein was confirmed for correct size by running concentrated fractions on a SDS-PAGE gel. 
Figure 3.12 is an SDS-PAGE Coomassie stained gel showing NP1-NP9 (C-L). Only proteins NP3 and NP4 
were able to be detected via SDS-PAGE. Lane B was a positive control (BSA) present at the correct 
size/location of approximately 66 kDa.  
Figure 3.13 shows the results for NP10-18 (C-L). From the SDS-PAGE gel it can be seen that NP12 and 
NP17 produced detectable protein, while the remaining proteins were undetectable. These protein 
bands, were confirmed by Western blot (Figure 3.14). 
To test the validity of these results a number of factors were explored as detailed below: 
1. All colonies from the original electroporation were trialled for large scale expression 
2. Electroporation was repeated and the resultant colonies also tested 
3. Large scale expression conditions were explored including varied MeOH concentrations, 
expression volume, different supernatant collection time points 
4. Large scale supernatants were checked pre- and post- purification to determine if there was a 
column binding issue 
5. Cells were lysed to check for a protein secretion issue 
6. Both c-myc and histidine tags were explored through Western blotting 
Despite this troubleshooting (data not shown) none of the modifications resulted in purification of 
sufficient protein.  
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Figure 3.12: Coomassie stained SDS-PAGE gel showing individual concentrated proteins NP1-9 (C-K). 
The protein was purified using an ÄKTA FPLC workstation and subsequently concentrated before 
running on the gel. Only proteins NP3 (lane E) and NP4 (lane F) returned detectable protein quantities. 
Lane B is a positive control, BSA (1 µg), at the correct size of approximately 66 kDa. 
 
 
Figure 3.13: Coomassie stained SDS-PAGE gel showing individual concentrated proteins NP10-18 (C-
K).The protein was purified using an ÄKTA FPLC workstation and subsequently concentrated before 
running on the gel. Only proteins NP12 (lane E) and NP17 (lane J) returned detectable protein 
quantities. Lane B is a positive control, BSA (1 µg), at the correct size of approximately 66 kDa. 
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Figure 3.14: Western blots showing proteins NP1-9 (lanes B-K). The protein was purified using an ÄKTA 
FPLC workstation and subsequently concentrated before running on the gel and carrying out the 
transfer. Only proteins NP3 (lane E) and NP4 (lane F) returned detectable protein quantities. Lane B is 
a positive control, a protein with a known c-myc tag, at the correct size ~24 kDa. Blot was visualised 
using a Molecular Imager VersaDoc. 
 
The protein was purified using an ÄKTA and subsequently concentrated before running on the gel and 
carrying out the transfer. Lane A is a positive control, a protein with a known c-myc tag, at the correct 
size ~24 kDa. Blot was visualised using a Molecular Imager VersaDoc. 
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Figure 3.15: Western blots showing proteins NP10-18 (lanes B-K).The protein was purified using an 
ÄKTA FPLC workstation and subsequently concentrated before running on the gel and carrying out the 
transfer. Lane B is a positive control, a protein with a known c-myc tag, at the correct size ~24 kDa. Blot 
was visualised using a Molecular Imager VersaDoc. 
3.3.3 Immunogenicity and diagnostic potential of SCP/TAPS proteins 
 
Using the recombinant N. americanus SCP/TAPS proteins expressed in this study (and N. americanus 
L3 extract as a comparator), antibody responses in the serum of N. americanus-infected individuals 
were profiled against each recombinant protein (Figure 3.16A-E) and the AUC generated from the ROC 
curves were used to determine the sensitivity and specificity of each antibody response, and the 
predictive value of infection (Table 3.3). Antibodies to all antigens were significantly reactive in subjects 
with a heavy hookworm infection (≥4,000 epg) compared to hookworm-negative controls. Further anti-
NP3 and anti-NP4 IgG responses were also significantly elevated in subjects with a light hookworm load 
(≤1,999 epg) compared to uninfected individuals. For the L3 extract and three of the recombinant 
antigens, IgG reactivity in the hookworm-negative/Ascaris-positive group was higher (not significantly 
so) compared to the hookworm-negative group with no Ascaris infection, which is likely explained by 
cross-reactivity between N. americanus and Ascaris antigen. Of the recombinant antigens tested, the 
highest positive predictive value of infection (PPV) in hookworm-positive vs hookworm-negative 
subjects was generated by the antibody response to NP4 (AUC = 0.77). Hookworm-positive subjects 
with antibody levels against a particular antigen above the reactivity cut-off were recorded as positive 
for recognition of that antigen and, because the recognition pattern of each antigen among the 
infected populations was different, a combination of antigens was assessed to determine the frequency 
of recognition (FoR) and/or PPV among hookworm-positive subjects compared to any one antigen 
alone. A minimum combination of three SCP/TAPS proteins (NP4 + NP3 + NP17) increased the FoR to 
82% of hookworm-positive subjects, compared to an FoR of 60% and 66% for NP4 and L3 extract, 
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respectively (Table 3.3). Further, this antigen combination gave a PPV of 0.83, which was comparable 
to 0.86 obtained for the L3 extract.  
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Figure 3.16: Serological diagnosis of hookworm infection by hookworm extract and recombinant 
SCP/TAPS proteins. Scatter plots showing the (A) anti-N. americanus L3 extract IgG response, (B) anti-
NP12 IgG response, (C) anti-NP3 IgG response, (D) anti-NP17 IgG response (E) anti-NP4 IgG response. 
Hookworm-positive subjects were characterized (WHO stratification) as either having a heavy (≥4,000 
epg), moderate (2,000-3,999 epg) or light (≤1,999 epg) infection. “HW -ve” = hookworm egg negative 
subjects from an endemic area, “HW -ve/ASC +ve” = hookworm egg negative, Ascaris egg positive 
subjects from an endemic area. Differences in responses between groups were analysed by Student’s 
t test. *P≤0.05, **P≤0.01. The recognition cutoff was defined as the average response of the HW -ve 
group + 1SD. # represents the minimal antigen combination (NP4, NP12 and NP17) which gives the 
highest frequency of recognition. AUC = area under receiver operator curves generated for each 
antigen and the antigen combination, which determines the positive predictive value of infection. 
 
Antigen FoR (%)$ AUC& 
N. americanus L3 extract 66 0.86 
NP12 43 0.68 
NP3 52 0.74 
NP17 41 0.64 
NP4 60 0.77 
NP3 + NP4 + NP17# 82 0.83 
# the minimal antigen combination (NP4, NP12 and NP17) which gives the highest frequency of recognition. 
$ the recognition cut-off was defined as the average response of the HW negative group + 1SD. 
& area under receiver-operating characteristic curves generated for each antigen and the antigen combination, 
which determines the positive predictive value of infection. 
Table 3.3: Frequency of recognition and area under receiver-operator characteristic curves 
determined for the human hookworm L3 extract and recombinant SCP/TAPS proteins in the 
diagnosis of hookworm infection.  




In this chapter, P. pastoris was utilised for recombinant N. americanus protein expression. This system 
was chosen for a number of factors including: growth rate, high cell density, capacity to produce large 
quantities of secreted protein, as well the fact that it was a well-established method within our 
research group [203]. Eighteen proteins were originally chosen for a number of reasons: firstly because 
I expected that some would not express in this system; second because it was an ambitious but 
manageable target within the scope of this project; third because these eighteen gave a good 
representation based on phylogeny and abundance for the greater number of SCP/TAPS proteins. 
Despite the widespread use of this method of protein production, many proteins of interest are unable 
to be secreted by or produced in P. pastoris [290]. In total, 4/18 selected proteins of interest from the 
N. americanus secretome were successfully produced in this study. The main factors explored to 
improve this rate were culture conditions such as methanol concentration and collection time point as 
well as colony selection for varied gene copy number. Increasing methanol concentration has been 
shown to improve protein production rate and final concentration [291], but despite testing methanol 
total concentrations of up to 3% (data not shown), usable quantities of protein could not be produced 
for 14/18 proteins assessed. Many colonies were also screened for each individual protein of interest. 
In many cases it has been demonstrated that higher gene copy number results in increased product 
yield [292,293]. However, this trend is not always the rule and in fact it may be protein dependent. 
High copy number dosage of recombinant secretory proteins was demonstrated to overload host cell 
physiology and limit secretion of desired proteins [294-296]. In this study, the amount of protein 
secreted by each colony seemed to vary based on the individual colony as seen from the small scale 
expression dot blot. For example, colony 1 (C1) from NP9 (H) showed a substantial amount of c-myc 
tagged protein at 72 h when compared to colony 3 at the same time point. This disparity is likely to be 
due to differences in the uptake of GOI plasmid during electroporation. 
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The time point of supernatant collection was shown to be important in maximising the amount of 
protein produced. From the dot blot it can be clearly seen that most protein was present after 72 h of 
culture time. It may be beneficial in future studies to extend culture time beyond the 72 h time point, 
as protein concentration in the supernatant may continue to increase over time. Another aspect that 
may be explored is the temperature of induction. Lower-temperatures have been shown to reduce 
proteolytic degradation while limiting oxygen stress [297].  
Looking back at the results of chapter 2 reveals a number of points about the four successfully 
expressed SCP/TAPS. Firstly, I ended up expressing two single and two double domain proteins. This 
grouping provides a point of difference for the proteins in the chapters to follow and may highlight a 
functional difference specific to domain number. Secondly, each of the proteins was found to have 
significant blast scores from an SCP/TAPS protein from all three compared species in section 2.3.3 in 
chapter 2. This emphasises that these proteins are conserved among similar species and are likely to 
play related roles. 
In a demonstration of the potential translatability of the “omics” data generated herein, four of the 
SCP/TAPS proteins identified in this study were expressed in recombinant form and their potential to 
diagnose hookworm infection was assessed using sera from human subjects resident in a hookworm-
endemic area of Brazil. Serum IgG levels to each antigen were measured in individuals who were 
positive for the presence of parasite eggs in the faeces, the current gold standard for diagnosis. When 
the diagnostic performance of the antigens was assessed individually, each molecule was found to be 
an accurate predictor of infection as each cognate antibody response generated an AUC value above 
0.5, where an AUC of 1.0 is a perfectly accurate test [298]. The L3 extract was used as a control because 
obtaining adult ES and/or adult somatic extracts is very difficult. Regarding individual recombinant 
antigens, NP4 displayed the highest FoR (60%) among the infected population but this value was 
increased by over 20% when the FoR of a combination of antigens (NP4, NP3 and NP17) was calculated, 
due to the varying recognition patterns of each antigen among hookworm-positive individuals. Further, 
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this antigen combination had an FoR that exceeded, and an AUC that was comparable to, that of the 
L3 extract, which could be considered the gold standard for serodiagnosis of hookworm disease, given 
the widespread use of parasite extracts as markers of helminth infection. The negative correlation of 
antibody titer and the infection intensity makes these antigens potentially useful vaccine targets. 
While the PPV of infection of the L3 extract slightly exceeded that of the antigen combination 
(understandable given the complexity of the preparation, and so it’s ability to capture the breadth of 
the anti-hookworm immune response) the advantages of a defined, recombinant antigen preparation 
lies in its reproducibility and sustainably as a resource, compared to, especially in the case of human 
hookworm, the limitations of generating sufficient reagent for use.  
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4  Chapter 4 – Assessing the therapeutic 
properties of hookworm SCP/TAPS proteins 




IBD and asthma are immune-mediated diseases which may share similar pathology as well as common 
environmental and genetic risk factors [299]. Neither condition can be cured and currently available 
treatment options are not effective for all patients. Both of these conditions have a large burden of 
disease in Australia and worldwide, and therefore represent a significant unmet need in the lives of 
many people. The ‘old friends’ hypothesis contributes to the rise of inflammatory diseases in 
increasingly urban settings by the decreased exposure of people to infectious organisms. The human 
hookworm is one such organism which has been negatively correlated with a number of allergic and 
auto-immune diseases including IBD and asthma [146]. Given that established mouse models of both 
of these diseases were operating in our lab, it was logical to employ them in exploring the potential 
therapeutic effects of ES molecules from the human hookworm. Mouse models of inflammatory 
diseases are valuable tools for exploring the efficacy of potentially novel therapeutics. In the case of 
both IBD and asthma, many models of each disease exist, each with various advantages and 
disadvantages that should be considered [300,301].  
Animal models of intestinal inflammation have been used for decades to better understand disease 
pathogenesis as well as test novel therapeutics. The complexity of human IBD dictates that no single 
model is adequate to replicate all aspects of the disease. Therefore a number of models are commonly 
used which include knockout (KO) mice, chemically-induced models such as dextran sulfate sodium 
(DSS) colitis and 2,4,6-trinitrobenzene sulfonic acid (TNBS) colitis, as well as adoptive transfer colitis. 
Each of these models tends to be employed to study a particular mucosal immune function/therapy, 
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and range from acute models where disease is induced in just days to chronic models that take months 
[302].  
For TNBS colitis an intrarectal (i.r.) injection of the chemical TNBS is given with ethanol to one of a 
number of susceptible mouse strains [303]. The ethanol plays an essential role in permeating the 
intestinal barrier, allowing the TNBS to infiltrate further [303]. TNBS is thought to haptenise colonic 
and microbiota proteins, rendering them immunogenic. This initiates a mucosal immune response from 
the host that is primarily driven by Th1 cells and is characterized by infiltration of neutrophils, CD4+ T 
cells, and macrophages [302,303]. The cytokine response that drives the inflammation in this model 
has been found to depend on the microbiota and genetic strain of mouse used [301,304]. The effects 
of TNBS on mice include diarrhoea, weight loss, and inflammation of the colon with ulceration and 
oedema [303]. These clinical manifestations are a key strength of the TNBS colitis model as they overlap 
significantly with the human disease [302]. While there are advantages to using other, more chronic 
models, the acute TNBS model means many proteins can be screened for potential therapeutic effects 
in a short time frame.  
In the case of asthma the models differ with respect to type, duration and dose of allergens used to 
stimulate allergic responses in the airways. The most commonly used allergens are ovalbumin (OVA), 
cockroach antigen, moulds and house dust mite (HDM) [305-307]. Utilising a variety of asthma-inducing 
stimuli is useful for studying different asthma subtypes as well as varying aspects of the disease. These 
factors, along with the timeline chosen mean that some models more closely mimic human 
sensitisation and disease pathology, while others are more cost effective and higher throughput.  
OVA is the most widely used allergen for the study of asthma. It is produced from chicken eggs in large 
quantities and is effective at inducing intense allergic airway inflammation in mice [300,308]. Despite 
its widespread use, OVA does not induce pulmonary inflammation in humans [308]. This fact alone has 
meant it has been scrutinised in terms of relevance to human disease. HDM has become an increasingly 
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clinically-relevant allergen as exposures are common in the home and up to 85% of asthmatics are 
allergic to HDM [309].  
Although different allergens are often employed, the same basic model of a sensitization and a 
challenge phase tends to stay consistent. The timeframe of these phases dictates the clinical 
manifestations. For example, acute models of allergic asthma are often induced in less than 3 weeks. 
This type of model has been shown to successfully reproduce many features of clinical asthma including 
airway inflammation, increased IgE, epithelial hypertrophy, goblet cell hyperplasia and airway 
hyperresponsiveness (AHR) [300,310]. However, when compared to chronic models there are also 
some drawbacks. Many of the airway lesions and remodeling associated with chronic asthma are 
missing. In addition, it has been noted that the key features of the acute model such as AHR and 
inflammation tend to resolve within a few weeks of the final challenge [311]. Acute models are 
beneficial to use in preliminary tests such as this study where novel therapeutics are being tested for 
the first time. Chronic models involve sensitisation windows of up to 12 weeks, and are therefore much 
less cost effective but better represent human disease pathology for the aforementioned reasons 
[300]. One of the key criticisms of animal models of asthma is that they do not mimic the way that 
humans develop allergic responses [308]. Allergic asthma in humans involves repeated exposure to 
aeroallergens through ventilation, which leads to airway inflammation over time. Many models of 
asthma have traditionally involved intraperitoneal or subcutaneous administration of allergens such as 
OVA to sensitise animals. To combat this disparity the use of intranasal and intratracheal instillations 
have become increasingly common [307,312].  
Dosage and route of administration for this study were selected based on similar experiments from the 
literature. A single intraperitoneal dose (1 mg/kg) of the hookworm recombinant protein Ac-AIP-1 
significantly limited pathology in a TNBS mouse model of colitis [313]. Similarly, multiple doses of Ac-
AIP-2 (1 mg/kg) during the challenge phase, suppressed airway inflammation and induced regulatory 
responses in a mouse model of asthma [203].  
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It is important to highlight that no animal model perfectly reflects the complex interaction of genetic 
and environmental factors that manifests in human disease. Given this, determining the appropriate 
model needs to be based on the desired outcome. For studies such as this thesis where the goal was 
to screen many proteins, the timeframe of models was of primary concern. As both the acute HDM 
model and the acute TNBS model include many of the fundamental features of their respective 





Ethical approval was obtained from the James Cook University Animal Ethics Committee. Two separate 
applications were approved: (1) TNBS chemically induced colitis model (ID#A2305) and (2) HDM acute 
asthma model (ID#A2307).  
4.2.2 TNBS colitis 
 
An overview of the procedure employed for TNBS colitis is presented in Figure 4.1. 
 
Figure 4.1: An overview of the experimental design for TNBS colitis including mouse strain, 
treatment concentrations and outcomes. i.p. – Intraperitoneal; i.r. – Intrarectal 
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Mice 
6-week-old BALB/c mice were ordered from the Animal Resources Centre, weight matched (18-19 g), 
and randomised into groups of six animals per cage. All experiments were repeated three times with 
six mice in each group. Mice were housed in the JCU animal facility with a 12 hour light/dark cycle, 
maintained at 22°C with unrestricted access to food pellets and water as per the Australian animal 
rights and regulation standards.  
Treatments 
Twenty-four hours prior to TNBS administration, trial compounds in sterile PBS were delivered 
intraperitoneally (i.p). at a dose of 1 mg/kg to six mice per group. Eight experimental groups were 
included in the study: (1) healthy naïve; (2) PBS vehicle (colitis control); (3) sulfasalazine (drug control); 
(4) recombinant human albumin (irrelevant recombinant protein control); (5) NP3; (6) NP4; (7) NP12; 
and (8) NP17. A 500 mg sulfasalazine tablet was crushed with a mortar and pestle to a fine powder 
before reconstitution in dH2O to a final concentration of 20 mg/ml. Two milligrams in 100 µl was 
administered to mice using an oral gavage. Recombinant NP proteins (produced from chapter 3) that 
had been frozen at -80C were electrophoresed on a SDS-PAGE gel prior to administration to check for 
protein degradation. Endotoxin was confirmed to be below the level of detection using a Pierce LAL 
Chromogenic Endotoxin Quantification Kit. 
Induction of colitis 
Mice were anaesthetised using xylazine (5 mg/kg, Bayer, Germany) and ketamine (50 mg/kg, Pfizer Inc., 
USA). 2,4,6-Trinitrobenzenesulfonic acid (TNBS; Sigma-Aldrich, USA) was prepared by dissolving 1.5 mg 
in 50% ethanol. Unconscious, unresponsive mice were given an enema with 125 mg/kg TNBS with a 
lubricated 20-G soft catheter (Terumo, Japan). TNBS was delivered slowly, in 10 µl increments to ensure 
minimal leakage. Upon delivery of the TNBS mice were inverted for 10 minutes to allow for the TNBS 
to be adequately distributed.  
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Monitoring and scoring 
Animals were examined daily for clinical signs including weight loss, mobility, faecal 
consistency/bleeding and piloerection. Clinical scores were carried out as per below and performed by 
the same person at time points 0, 24 h, 48 h and 72 h (before sacrificing).  
Clinical scoring measures: 
Mobility: 
Normal = 0; Lethargy = 1; Motionless/sickly = 2 
Fur: 
Normal = 0; Mild piloerection = 1; Severe piloerection = 2 
Faeces: 
Normal = 0; Mild diarrhoea/soft stool = 1; Bloody/liquid stool = 2 
Mice were euthanised (CO2 asphyxiation) 72 h post administration of TNBS, and the colons removed 
from the caecum to the rectum. Blinded macroscopic scoring to assess the extent of colitis was carried 
out on the colon as per below, performed by the same person for every colon in each group to ensure 
consistency. Colons were imaged and length recorded.  
Macroscopic scoring of colon: 
Adhesions:  
Normal = 0; Minimal adhesions = 1; Adhesions = 2; Severe Adhesions = 3 
Ulceration: 
None = 0; Minimal ulceration (1 ulcer) = 1; Multiple Ulcers = 2; Severe ulceration/necrosis = 3 
Bowel wall thickening: 
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Normal = 0; Slight thickening in places = 1; Moderate thickening = 2; Severe thickening throughout = 3 
Mucosal oedema: 
Normal = 0; Slight oedema =1; Moderate oedema = 2; Severe oedema = 3 
 
Histology and cytokine quantification 
Pieces of colon were removed in 0.5 cm segments for histological evaluation of inflammation as well 
as cytokine production. Tissue samples were placed in 4% formalin for fixation before being transferred 
to 70% ethanol for storage. Paraffin was used to embed the tissue before it was sectioned longitudinally 
and mounted on a microscope slide. Slides were stained with hematoxylin and eosin (H&E). Scoring of 
pathology was performed from H&E stained slides by the same individual blinded to the experimental 
group. Tissue sections were scored on a scale of 0-5 for each of the following parameters; (1) epithelial 
pathology (crypt elongation, hyperplasia, and erosion), (2) mural inflammation and (3) oedema for an 
overall maximum total histology score of 15. 
Tissue homogenate for measuring cytokine levels was placed into a 2 ml tube containing 500 µl sterile 
PBS and a stainless steel homogenisation bead. The weight of the tube was measured pre- and post- 
addition of the tissue to obtain the net tissue weight. The tube containing the tissue, PBS and bead was 
lysed using a TissueLyser II (Qiagen) at a frequency of 25 for 5 minutes. Samples were centrifuged at 
16,000 g in a pre-cooled microfuge for 10 minutes before supernatant was collected and stored at -
80°C. Supernatant was assayed for IL-6, IL-10, MCP-1, IFN-y, TNF, and IL-12p70 proteins using a 
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4.2.3 HDM asthma 
 
An overview of the procedure employed for HDM asthma is presented in Figure 4.2. 
 
Figure 4.2: An overview of the experimental design for the house dust mite (HDM) asthma model 
including mouse strain, treatment concentrations and outcomes. 
Mice 
Mice used for asthma experiments were the same in all regards to the TNBS trials above except they 
were not weight matched and there were five animals per group. This number of mice was deemed 
adequate to generate enough statistical power based on previous experiments. Age, handling and 
housing conditions were all identical as described. 
Intranasal vs intratracheal injections 
Three mice were assigned to one of three groups: (1) naïve; (2) i.n. food colouring; (3) i.p. food 
colouring. Mice were anaesthetised with 5% isofluorane for 5 minutes using an isoflurane vaporizer 
(VetEquip). Group 1 mice received no injection, group 2 received 30 µl i.n. of 1:5 PBS diluted blue food 
colouring (Queen), group 3 received 30 µl i.t. of 1:5 PBS diluted blue food colouring. All mice were 
Page | 114 
 
immediately euthanised (CO2 asphyxiation) and lungs were removed. Lungs from mice in groups 2 and 
3 were compared for the presence and spread of blue dye throughout the lungs. 
Treatments 
On days 5, 7, 9 and 11 trial compounds in sterile PBS were delivered i.p. at a dose of 1 mg/kg to five 
mice per group. Eight experimental groups were included in the study: (1) healthy naïve; (2) PBS vehicle 
(asthma control); (3) dexamethasone (drug control); (4) recombinant human albumin; (5) NP3; (6) NP4; 
(7) NP12; and (8) NP17. Dexamethasone (1 mg/kg) was administered using an oral gavage in a total 
volume of 100 µl. Recombinant NP proteins (produced from chapter 3) were electrophoresed on a SDS-
PAGE gel prior to administration to check for protein degradation. Endotoxin was confirmed to be 
below the level of detection using a Pierce LAL Chromogenic Endotoxin Quantification Kit.  
HDM-induced asthma 
On day 0 mice were anaesthetised with 5% isofluorane for 5 minutes using an isoflurane vaporizer. 
Groups 2-8 were sensitised with 10 µg house dust mite (HDM) Dermatophagoides pteronyssinus extract 
(Citeq Biologics) i.t. in 30 µl PBS. Beginning on day 6, mice were challenged with 25 µg HDM i.t. once 
per day for 5 consecutive days (days 6-10). On day 14 mice were euthanised (CO2 asphyxiation) and 
blood was immediately collected from the heart using a 23G needle. A bronchoalveolar lavage (BAL) 
was performed by opening up the trachea, inserting a blunt 18G needle and carrying out 3 x 1 ml 
washes with PBS. The total BAL wash (3 ml) was stored immediately on ice for subsequent flow 
cytometry analysis. Upon completion of the dissection blood samples were centrifuged at 10,000 g for 
10 minutes at room temperature before being stored at -80°C. BAL samples were processed 
immediately for flow cytometry.  
Serum IgE 
IgE was measured using the Mouse Ready-SET-Go! ELISA kit (LS885046077, EBioscience) as 
recommended by the manufacturer. In brief, plates were coated with coating buffer and incubated 
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overnight at 4°C. Plates were washed 3 times with wash buffer before blocking buffer was added and 
incubated overnight at 4°C. The plates were washed 3 times before samples (diluted 1:10) and 
standards were added in duplicate and incubated for 2 hours at room temperature. The plates were 
washed 3 times before addition of detection antibody. A final 3 washes were carried out and substrate 
solution was added to each well. The reaction was stopped after 15 minutes with 1 M HCl and 
absorbance read immediately at 450 nm.  
Flow cytometry 
BAL samples were maintained on ice throughout the procedure. Red blood cells were lysed using RBC 
lysis buffer (420301, Biolegend) as per the manufacturer’s recommendation. Cells were washed and 
stained in FACS buffer (PBS containing 1% FCS and 0.01% sodium azide) for 30 minutes in the dark. 
Antibodies used to stain the cells were PE Siglec F (552126, BD), PerCP-Cy5.5 CD11c (560584, BD), Alexa 
Fluor700 CD11b (557960, BD), APC-eFluor 780 CD3 (BD), PE-CF594 CD19 (562291, BD), V450 Gr1 
(560453, BD) and Alexa Fluor647 F480 (564226, BD). Data was collected using an LSR Fortessa (BD) and 
analysed using FlowJo. AccuCheck counting beads (PCB100, Life Technologies) were added to 
determine cell counts.  
4.2.4 Statistical analyses 
 
All data from this chapter were analysed using GraphPad Prism (Version 7; Prism). When two groups 
were compared, a nonparametric Mann-Whitney U test was used. A one-way ANOVA with a Bonferroni 
post-test was utilized for comparisons of three or more groups. In the experiments looking for an effect 
over time, between multiple groups, a two-way ANOVA with Bonferroni post-test was selected. 0.05 
was the P value chosen for statistical significance. Graphed results represent the mean ± standard error 
of the mean. Both pooled results from repeated experiments and representative figures are presented 
throughout, the specifics of which are detailed in figure legends.  
 




4.3.1 TNBS colitis 
 
Weight-loss and clinical scoring 
Mice were pre-treated with one of the four hookworm recombinant proteins before colitis was induced 
with an i.r. injection of TNBS. Weight changes were measured daily and the results are detailed in Figure 
4.3. Naïve mice gained 1-3% of their body weight over the course of the experiment. In comparison, 
TNBS mice which received either PBS vehicle or recombinant human albumin (negative controls) lost 
10-12% of their starting body weight by day 1. This weight loss was maintained so that by day 3, mice 
were still 10-12% lighter than at the beginning of the experiment. The weights of mice treated with 
sulfasalazine (positive control) were not statistically different to those of negative control mice. 
Hookworm protein treated groups NP4, NP12 and NP17 all had significantly greater weight loss than 
the rHA negative control with approximately 15-18% loss over the course of the trial. NP3-treated mice 
were not significantly different to the negative control mice.  
 
Figure 4.3: Three of the four hookworm recombinant excretory/secretory proteins accentuate TNBS-
induced weight loss in mice.  Six week old BALB/c mice were pre-treated with or without Necator 
americanus recombinant proteins before colitis was induced with an i.r. injection of TNBS. Weight-loss 
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was monitored daily for 3 days. Results show two pooled experiments, n = 6 mice for each group in 
each experiment (total 12 mice). * = p<0.05, ** = p<0.01, **** = p<0.0001. 
 
Mice were examined daily and scored based on mobility, fur appearance and stool consistency for a 
combined clinical score (Figure 4.4). Compared with naïve mice, all TNBS colitis groups had significantly 
higher clinical scores across all assessed days post-TNBS-injection. No significant differences in clinical 
features were observed between the time points (days 1, 2, or 3). Of mice that received TNBS, there 
were no significant differences in clinical score between protein-treated groups, the negative controls 
or the sulfasalazine group. 
 
Figure 4.4: Hookworm recombinant excretory/secretory proteins have no effect on clinical 
manifestations in TNBS colitis. Six week old BALB/c mice were pre-treated with or without Necator 
americanus recombinant proteins before colitis was induced with an intrarectal injection of TNBS. Mice 
were examined daily and scored based on mobility, fur appearance and stool consistency for a 
combined clinical score. Results show three pooled experiments, n = 6 mice for each group in each 
experiment (total 18 mice per group).  
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Colon length, macroscopic scoring and histopathology 
Upon sacrificing mice on day 3, colons were excised and measured from the caecum to the anus. All of 
the groups that received TNBS had significantly shorter colons than the naïve controls (Figure 4.5). This 
manifested as 1.5-2 cm reductions in colon lengths. While the sulfasalazine group had slightly longer 
colons on average than the rHA control, statistical significance was not achieved. For the hookworm 
recombinant proteins, only NP12 showed a significant difference compared with the rHA control 
(p<0.05). The colons of NP3-, NP4- and NP17-treated mice showed no changes in terms of length 
compared with the negative controls.  
  




Figure 4.5: Hookworm recombinant excretory/secretory proteins do not protect against colon 
shortening in TNBS mouse model of colitis. Six week old BALB/c mice were pre-treated with or without 
recombinant Necator americanus proteins before colitis was induced with an intrarectal injection of 
TNBS. Dissection/colon measurements took place on day 3 (A) and images were taken following 
measurements (B). Single representative images of the colons are shown. Results show three pooled 
experiments, n = 6 mice for each group in each experiment (total 18 mice). * = p<0.05, **** = p<0.0001. 
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Macroscopic scoring was carried out on the colons based on the presence of adhesions, ulceration, 
bowel wall thickening and mucosal oedema. Naïve mice did not have any visible pathology whereas all 
groups of TNBS treated mice had some degree of these features. Due to variation within groups, 
differences between TNBS groups in Figure 4.6 were not found to be statistically significant. None of 
the hookworm recombinant protein groups were significantly different from each other, the negative 
controls or the sulfasalazine group.  
 
Figure 4.6: Hookworm recombinant excretory/secretory proteins have no effect on colon 
macroscopic pathology in TNBS colitis. Six week old BALB/c mice were pre-treated with or without 
recombinant Necator americanus proteins before colitis was induced with an intrarectal injection of 
TNBS. Dissection/colon scoring took place on day 3. Results are reflective of a pooled scoring based on 
the presence of adhesions, ulceration, bowel wall thickening and mucosal oedema. Results show three 
pooled experiments, n = 6 mice for each group in each experiment (total 18 mice). **** = p<0.0001; 
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Removed colons were either fixed and stained with H&E or homogenised and assessed for 
inflammatory cytokines. Representative images for each group are shown in Figure 4.7A. Histology 
images were scored based on inflammation, oedema and hyperplasia individually and these scores 
were pooled for a combined ‘histology score’ (Figure 4.7B). From the images and reflected in the 
scoring, the only significant differences in terms of inflammation, oedema and hyperplasia are 
present between the naïve controls and all TNBS groups.  
  




Figure 4.7: Hookworm recombinant excretory/secretory proteins have no effect on microscopic 
colon pathology in TNBS colitis. Six week old BALB/c mice were pre-treated with or without 
recombinant Necator americanus proteins before colitis was induced with an intrarectal injection of 
TNBS. Dissection took place on day 3 and colons were fixed and stained with H&E. Images (A; 20x 
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magnification) were scored on inflammation, oedema and hyperplasia individually and these scores 
were pooled for a combined ‘histology score’ (B). Stained images show selected single representatives 
of three experiments, n = 6 mice for each group in each experiment (total 18 mice). 
 
Cytokine quantification 
Homogenised pieces of colon were assayed using a cytometric bead array for IFN-γ, IL-6, IL-10, MCP-1 
and TNF-α. IFN-γ and IL-10 were below the level of detection of the assay and therefore these results 
have not been presented. Marked IL-6, MCP-1 and TNF-α were detectable from the CBA (Figure 4.8A-
C respectively). A marked IL-6 response was observed from the colitis groups compared with the naïve 
controls, p<0.01. Between treated groups, no statistically significant differences were observed. A 
similarly distinct increase was seen in MCP-1 levels from colitis groups compared with the naïve 
controls. NP12 treated mice were observed on average to have higher levels of MCP-1 in their colons 
however the variability between mice in this group meant this result did not reach significance when 
compared with the rHA control (p>0.05). TNF-α appeared to be higher in colitis groups in general 
compared with naïve controls however this induction did not reach statistical significance. Variability 
in NP3 and NP12 individual results meant that these results were not significantly different compared 
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Figure 4.8: Hookworm recombinant excretory/secretory proteins have no effect on intestinal 
cytokine expression in TNBS colitis. 6 week old BALB/c mice were pre-treated with or without 
recombinant Necator americanus proteins before colitis was induced with an intrarectal injection of 
TNBS. Dissection took place on day 3 and colons were homogenised and assessed for IL-6, MCP-1 and 
TNF-α. IL-6, MCP-1 and TNF-α (A-C respectively) were quantified with a cytometric bead array. Data 
reflect three pooled experiments, n = 6 mice for each group in each experiment (total 18 mice). ** = 
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4.3.1 HDM asthma 
 
Comparison of i.n. vs i.t. for HDM delivery 
Route of administration of HDM was compared between i.n. and i.t. methods. Figure 4.9 shows an 
example set of lungs from each group of mice from the experiment. Image A reflects a healthy set of 
lungs with no blue food colouring administered while B and C are lungs which received blue food 
colouring i.n. and i.t. respectively. From Figure 4.9C it can be clearly seen that mice that received i.t. 
administration of the colouring have a much greater quantity of colouration in the lungs. This 
colouration is visible in the bronchi and throughout both the left and right lobes progressing towards 
the edge of the lung. By comparison, Figure 4.9B shows some dark colouration close to the base of the 
bronchi without extensive spreading. This effect was reproduced in all 3 mice included in each 
experiment with the i.t. route consistently showing greater delivery to the lungs than i.n. 
 
 
Figure 4.9: Intratracheal (i.t.) administration results in markedly better delivery of solution to the 
lungs compared with the intranasal (i.n.) route. Naïve lungs (A) are shown compared with lungs 
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Mice were sensitised and challenged with HDM as described earlier with or without concurrent 
treatment with hookworm recombinant proteins or dexamethasone. In these experiments the rHA 
treated group was included as the only negative control. This was reasoned from the earlier TNBS 
experiments where PBS vehicle treated mice had the same outcomes as recombinant expression-
matched rHA mice (no protection). On day 14 mice were sacrificed and a BAL performed to collect lung 
cells. Cells were stained and immediately subjected to flow cytometry to analyse cell population 
frequencies. Gating strategy for each of the relevant cell types is shown in Figure 4.10. Figure 4.11A-E 
shows the breakdown of the number of eosinophils, neutrophils, T cells, B cells, and macrophages. 
HDM sensitised and challenged mice had significant increases in the number of eosinophils, T cells and 
B cells. These increases were almost completely ablated with the use of dexamethasone, the positive 
control. The hookworm recombinant proteins tested had no significant effect on any of the responses 
when compared with the rHA treated control. These results were reflected in the serum IgE levels 
(Figure 4.12) whereby only dexamethasone had any effect on HDM-augmented production of IgE.  
 
  




Figure 4.10: Gating strategy for cells collected from bronchoalveolar lavage of healthy vs house dust 
mite (HDM)-treated mice. Six week old BALB/c mice were sensitised and challenged with HDM 
intratracheally while being treated with hookworm recombinant proteins intraperitoneally. Mice were 
sacrificed on day 14 and a bronchoalveolar lavage was performed to collect cells present in the lungs. 
Eosinophils (Siglec F+ CD11c-), macrophages (Siglec F+, CD11c+), B cells (Gr1- CD19+), T cells (SSClow, 
CD3+) neutrophils (Gr1+ CD11b+) were stained and gated as shown above. 





Figure 4.11: Hookworm recombinant excretory/secretory proteins do not protect mice in an acute 
house dust mite (HDM) asthma model. Six week old BALB/c mice were sensitised and challenged with 
HDM intratracheally while being treated with recombinant Necator americanus proteins 
intraperitoneally. Mice were sacrificed on day 14 and a bronchoalveolar lavage was performed to 
collect cells present in the lungs. Eosinophils (Siglec F+ CD11c-), macrophages (Siglec F+, CD11c+), B 
cells (Gr1- CD19+), T cells (SSClow, CD3+) neutrophils (Gr1+ CD11b+) were stained and gated (B). 
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Results are representative of three pooled experiments, n = 5 mice for each group in each experiment 
(total 15 mice). *** = p<0.001, **** = p<0.0001. 
 
 
Figure 4.12: Hookworm recombinant excretory/secretory proteins do not protect mice against 
increased serum IgE in an acute house dust mite (HDM) asthma model. 6 week old BALB/c mice were 
sensitised and challenged with HDM intratracheally while being treated with recombinant Necator 
americanus proteins intraperitoneally. Mice were sacrificed on day 14 and serum was collected. Results 
are a single representative of three experiments, n = 5 mice for each group in each. ** = p<0.01. 
 
  




In this chapter four hookworm recombinant ES proteins were tested for potential therapeutic 
properties in an IBD mouse model of human disease. In these experiments a single i.r. dose of TNBS 
was sufficient to induce significant pathology in these mice. The outcomes measured included weight-
loss and clinical features, as well as colon pathology, cytokine responses and histology. While vehicle-
treated mice administered TNBS were significantly unwell across these categories, in general, the 
tested outcomes were unaffected by pre-treatment with hookworm proteins. I included a 
sulfasalazine-treated group as a positive control. Despite sulfasalazine being an anti-rheumatic drug 
used to treat patients with CD, in this model of colitis it was ineffective at limiting any disease indicators 
in this study. This is in line with other studies which have reported mixed efficacies for sulfasalazine in 
murine models of colitis [314,315]. In the future, a more appropriate positive control to employ would 
be AIP-1 or AIP-2, two hookworm ES proteins which have been shown to protect in inflammatory 
mouse models [203,313]. 
The ES products of hookworms contain hundreds of different proteins [195]. Whole mixtures of these 
proteins, from A. caninum and N. brasiliensis as well as the soluble proteins from S. mansoni, were 
shown to effectively limit disease induction in the TNBS mouse model [193,255]. The key outcomes of 
these studies included decreased inflammatory scores and a reduction in the extent of inflammation. 
This effect was attributed to the suppression of pro-inflammatory cytokines in the colon and was 
accompanied by upregulation of regulatory responses. Indeed, A. caninum ES products also suppressed 
pathology in the DSS model of chemically induced colitis [192]. While it would have been ideal to 
include crude ES products from adult N. americanus in the current study, this was not a feasible option 
due to limited accessibility to sufficient material. Given that A. caninum and N. americanus ES products 
were shown in chapter 2 to be highly similar in terms of sequence homology, it is reasonable to 
postulate that they may also protect in colitis models. As these mixtures proved effective across 
multiple models of colitis it was logical to seek individual molecules responsible for protective 
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outcomes. Moreover, a single i.p. dose of recombinant Ac-AIP-1 significantly suppressed colonic 
inflammation in the TNBS colitis mouse model [313]. Recombinant Ac-NIF, another protein from A. 
caninum ES products, was shown to potently bind neutrophils, inhibiting chemotaxis, adhesion and 
transmigration of inflammatory cells across the epithelium [316]. 
The previously mentioned Ac-NIF belongs to the SCP/TAPS family, attesting to the role for these 
proteins in immune regulation. In addition, the vaccine antigen and abundant N. americanus L3 
secreted protein, Na-ASP-2, is a SCP/TAPS family member and was shown to bind to CD79A on human 
B cells and suppress signaling [317]. Unfortunately only four proteins were successfully produced in 
recombinant forms in the current study, reducing the size of the pool for identifying therapeutic 
candidates. Although a therapeutic benefit was not detected for any of the four SCP/TAPS proteins 
screened in this study, inherent limitations in the models employed, as well as dosing and/or routes of 
administration of the proteins might not have been optimal.  
In the HDM asthma model, I showed stark differences in tissue distribution when comparing i.n. and 
i.t. delivery routes. While the i.n. model is widely used, it was prudent to compare it with the i.t. model 
and select the one that worked best. As these differences were so consistent, I opted not to compare 
responses in a true HDM sensitisation and challenge model to spare animals. When a two-week HDM 
mouse model was employed using much greater doses of i.n. instillations than those used in the current 
study, significantly milder inflammatory responses were observed [318]. This comparison attests to the 
improved delivery of allergen to the lung. Sensitisation and subsequent challenge with HDM was 
effective in eliciting a significant increase in lung inflammatory cell populations as well as increased 
serum IgE. The positive control, dexamethasone, potently suppressed the allergic phenotype as seen 
from the significant reduction in eosinophils, as well as T and B lymphocytes. Dexamethasone was 
selected for this experiment as it is a currently recommended systemic steroid for moderate to severe 
asthma exacerbations [319]. Similarly to the colitis experiments, the four tested recombinant proteins 
had no effect at the dose and delivery frequency used.  
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Although I did not show any improvements in disease outcomes in the models tested, there are many 
factors to consider before concluding that the tested proteins have no immunoregulatory capacity. A 
number of variations may prove useful to consider for future experiments including the route of 
administration of test proteins as well as dose and timing. For example, in the HDM asthma 
experiments, it may be beneficial to trial delivery of the proteins specifically to the lung using an i.t. 
injection. This may allow for a more direct interaction between the proteins and the localised 
inflammation. Moreover, oral delivery of protein to the gut might be required for obtaining a 
therapeutic effect in colitis. Other cell populations might also be the target of these SCP/TAPS proteins, 
as seen with the B cell-specific targeting of CD79A by Na-ASP-2 [317]. 
Another factor to consider across both models is whether the proteins were folded correctly and 
subsequently active. When recombinant proteins are overproduced it can lead to errors in endoplasmic 
reticulum folding. When these mechanisms and secretion capacity is impacted the result can be 
misfolded or unfolded proteins [281]. Given that the function of most proteins depends on correct 
folding, it would be prudent to confirm this in future experiments. Even partial incorrect folding in any 
of the proteins tested in this chapter may have played a role in the results obtained. For this reason 
future experiments should clarify that these proteins are indeed correctly folded and active. Circular 
dichroism and nuclear magnetic resonance are two methods for determining the folding properties of 
recombinant proteins. These methods are useful to highlight if any potential mutations that might 
affect a protein’s conformation or stability and can also be used to study protein interactions [320].  
While there is a plethora of factors which could be explored in the mouse models, I was interested to 
see whether the proteins may have a human-specific effect. This was a logical next step as N. 
americanus naturally infects humans and not mice. To test this theory, in the next chapter I co-culture 
the recombinant proteins with human peripheral blood mononuclear cells (PBMCs).  
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5  Chapter 5 – Effect of hookworm 
recombinant SCP/TAPS proteins on human 




Limited clinical efficacy and side effects are key problems associated with immunosuppressive drugs 
such as corticosteroids in the treatment of allergic and autoimmune diseases. Subsequently there is a 
need for simple, cheap and rapid screening tools to test the anti-inflammatory capability of novel 
molecules. One such system utilises purified human peripheral blood mononuclear cells (PBMCs) ex 
vivo from the blood of healthy donors. PBMCs are blood cells which have a round nucleus including 
lymphocytes, monocytes and macrophages [321]. These cells make up a critical component of the 
immune system and play roles in the pathogenesis of allergic and autoimmune diseases. When 
stimulated, innate immune cells begin to release pro-inflammatory cytokines such as IL-12 and IFN-γ 
[322]. IFN-γ is produced by both innate cells NK and NKT cells) and adaptive cells (CD4 and CD8 T cells) 
as part of the innate immune response [323]. IFN-γ plays a key role in host-defence mechanisms 
through the regulation of more than 30 genes which lead to a variety of cellular and physiological 
responses, such as reactive oxygen species production by macrophages [323]. This immune cascade 
involves activation of NFκB resulting in, among others, production of TNF-α [323], a key cytokine that 
drives pathogenesis of many inflammatory diseases including IBD. 
Such screening platforms often utilise a stimulus to activate certain cell types. For example, in this 
chapter PBMCs are stimulated with either lipopolysaccharide (LPS) or a mixture of phorbol myristate 
acetate (PMA) and ionomycin. LPS is found on the outer layer of gram-negative bacteria and serves as 
a pathogen-associated molecular pattern (PAMP) binding to TLR4 [324]. TLR4 activation plays a 
significant role in immune responses to bacteria through recognition of LPS [324]. In contrast, PMA 
activates protein kinase C, a signal transduction enzyme which along with ionomycin stimulates 
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production of IL-2 and IL-4 [325]. In this way, LPS primarily activates monocytes and macrophages while 
PMA and ionomycin stimulate T cells [325]. As mentioned in chapter 1, dysregulation of these varying 
cell types and the corresponding cytokine profiles are key contributors to IBD. Indeed, the levels of 
cytokines such as IL-6, IL-8, IL-12, and TNF-α have been shown to be markedly increased in people with 
IBD. Moreover, TNF-α concentrations are positively correlated with IBD disease severity [92,93]. Any 
drug that displays a suppressive effect on these pro-inflammatory cytokines may have a beneficial 
effect in terms of IBD clinical pathology. By treating PBMCs with the recombinant proteins in this 
chapter I was able to gain insight into their direct effects on immune cells ex vivo without the 
complexity of an animal model. 
Later in this chapter a human protein microarray was used to identify interactions between the 
hookworm SCP/TAPS proteins of interest and putative host cell targets. Microarrays are useful tools 
for identifying proteins that are the targets of a protein of interest. Typically, protein arrays are probed 
with serum antibodies, but they can also be used to identify host-pathogen protein-protein interactions 
[317]. Microarrays have been used to reveal new interactions between humans and a number of 
pathogens. The binding partners of a protein kinase from T. gondii were explored using a human 
proteome array which lead to further validation of specific candidates [326].  This approach has been 
employed for non-worm pathogens such as Legionella pneumophila whereby a human protein 
microarray was used to find novel interaction candidates [327]. This method is particularly useful when 
there are known targets of a tested protein which act as controls when looking for new targets.  
These arrays are an ideal platform for which to identify protein-protein or ligand-receptor interactions, 
particularly for proteins of unknown function [328]. Using these two approaches (the PBMC culturing 
and arrays) the aim of this chapter was to elucidate putative functions of these N. americanus SCP/TAPS 
proteins. 
 




5.2.1 PBMC isolation  
 
Blood was collected from three healthy, hookworm-negative, male donors aged 34-39. This work was 
covered by human ethics application H7010. PBMCs were isolated from whole blood using Lymphoprep 
(07801, Stemcell) as per the manufacturer’s instructions. In brief, blood was collected from donors into 
EDTA tubes (BD, 367861) before diluting 1:1 with dPBS + 2% Fetal Bovine Serum (Stemcell). Up to 30 
ml diluted blood was carefully layered on 15 ml Lymphoprep. The tube was centrifuged at 800 g for 20 
minutes at room temperature with no brake before the PBMC layer was collected. PBMCs were washed 
once with washing media (RPMI Media 1640 (ThermoFisher), 10% FBS, 1% Penicillin-Streptomycin 
(ThermoFisher); and GlutaMAX (ThermoFisher)). Cells were used immediately or frozen in washing 
media with 10% dimethyl sulfoxide (DMSO) under liquid nitrogen. 
5.2.2 PBMC stimulation and cytokine quantification 
 
Cells were used immediately post isolation or thawed in a 37°C water bath. Cells were diluted with 
washing media, mixed gently and centrifuged at 500 g for 5 minutes at 4°C. The supernatant was 
aspirated and the cell pellet was resuspended in fresh wash buffer for counting. One hundred thousand 
cells were added to each well of a 96-well U bottom plate such that each condition could be tested in 
triplicate. The experiment was carried out a total of three times, each with a different donor’s PBMCs. 
Cells were split into three main groups: (1) untreated, (2) stimulated with PMA and ionomycin (Cell 
Stimulation Cocktail (500x) diluted to 1x, 00497093, ThermoFisher), and (3) stimulated with LPS from 
Escherichia coli (10 ng/ml; L6529, Sigma-Aldrich). Before stimulation, cells were treated with either PBS 
(vehicle control), cyclosporine A (CsA) (10 µg/ml; positive control for group 2; 30024, Sigma-Aldrich), 
dexamethasone (25 mg/ml; positive control for group 3; D4902, Sigma-Aldrich), or one of the four 
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hookworm recombinant ES proteins from chapter 3. Three hours post-treatment, cells were stimulated 
as described above.  
Cells were incubated overnight at 37°C with 5% CO2. Following incubation plates were centrifuged at 
500 g for 5 minutes and the culture supernatants were collected for cytokine analysis. Cytokines were 
quantified using a human inflammatory cytometric bead array (551811, BD) as per the manufacturer’s 
instructions. This array measured detectable levels of interleukin-6 (IL-6), interleukin-8 (IL-8), 
interleukin-10 (IL-10), interleukin-1β (IL-1β), tumor necrosis factor (TNF), and interleukin-12p70. 
 
Statistical analyses 
All data were analysed using GraphPad Prism (Version 7; Prism). When two groups were compared, a 
nonparametric Mann-Whitney U test was used. A one-way ANOVA with a Bonferroni post-test was 
utilized for comparisons of three or more groups. 0.05 was the P value chosen for statistical 
significance. Graphed results represent the mean ± standard error of the mean. Both pooled results 
from repeated experiments and representative figures are presented throughout, the specifics of 
which are detailed in the respective figure legends.  
 




Five millilitres of 1 M HEPES, 4 ml 5 M NaCl, 800 µl 10% Triton X-100, 50 ml 50% glycerol, 610 mg 
glutathione powder, and 10 ml 10X Synthetic block were combined before adjusting the pH to 7.5 with 
NaOH. One hundred microlitres 1 M DTT and dH2O were added to obtain a total volume of 100 ml. 
Blocking buffer was stored on ice until use and discarded after 24 hours.  
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Washing buffer 
One hundred millilitres 10X PBS pH 7.4, 100 ml 10X Synthetic block and 10 ml 10% Tween-20 were 
mixed and made up to 1 L with dH2O 
Biotinylation of recombinant proteins 
Biotinylation was carried out using a Biotin-7-NHS Protein Labelling Kit (11418165001, Roche) as per 
the manufacturer’s instructions without modification.  
 
Array 
The ProtoArray selected included approximately 8,000 ORFs expressed as N-terminal GST fusion 
proteins, purified, and printed on a nitrocellulose-coated glass slide in duplicate. Probing of ProtoArray 
human protein microarrays (PAH0524011, ThermoFisher) was carried out as per the manufacturer’s 
instructions with minor modifications. In brief, microarrays were removed from storage and allowed 
to equilibrate to 4°C for 30 minutes. Arrays were then blocked with 5 ml blocking buffer (detailed 
above) in a 4-chamber incubation tray for 1 hour with gentle shaking. Blocking buffer was aspirated 
before 5 washes of 5 minutes each were carried out at 4°C with gentle shaking. Five millilitres of 3 µM 
biotinylated hookworm recombinant protein was added to each array and incubated for 90 minutes at 
4°C with gentle shaking. Proteins were removed and the arrays were washed 5x as described above. 
Five millilitres ml of Alexa Fluor 647-streptavidin-conjugated antibody (1 µg/ml) in washing buffer and 
incubated for 90 minutes at 4°C with gentle shaking. Arrays were washed again 5x as above before they 
were dried using centrifugation as per the manufacturer’s instructions. Each array was scanned using 
a GeneArray 4000B scanner (Molecular Devices) at 625 nm. The generated multi-TIFF files were 
analysed with Genepix Propsector software v7.  
 




5.3.1 Human PBMC cytokine responses 
 
Human PBMCs were treated with hookworm recombinant proteins before being stimulated with 
endotoxin-free PBS (negative control), LPS or PMA/ionomycin. In the absence of cell stimulation, NP4 
elicited a significantly greater IL-6, IL-8, and TNF-α response when compared with the untreated 
controls (p<0.001; Figure 5.1). NP12 and NP3 both induced a slight but nonetheless significant increase 
in IL-8 responses. NP-4 was the only protein which did not induce any cytokine responses that were 
statistically different from the untreated control. The cytometric bead array used also included IL-1β, 
IL-10, and IL-12, none of which were detectable in unstimulated cells.  
 
 
Figure 5.1: Hookworm recombinant excretory/secretory protein NP4 induces an inflammatory 
response in peripheral blood mononuclear cells (PBMCs). PBMCs were isolated from the whole blood 
of healthy donors before being treated with or without recombinant Necator americanus proteins at a 
concentration of 20 µg/ml. Supernatant was collected 24 hours later and assayed for inflammatory 
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cytokines. Graphs show a selected single representative experiment (from a total of three 
experiments), n=3-4 for each group in each experiment. Error bars are indicative of four technical 
replicates from the blood sample. **** = p<0.0001;** = p<0.01; * = p<0.05 
 
When PBMCs were stimulated with PMA/ionomycin, strong IL-6, IL-8 and TNF-α responses were 
detected in the supernatant compared with unstimulated controls. Figure 5.2A and 5.2C show that CsA 
was highly effective at limiting the production of IL-6 and TNF-α respectively (p<0.001). NP-2 
significantly increased IL-6 production (p<0.001) while the other hookworm proteins had no effect 
compared with the PMA/ionomycin only group. IL-8 production was reduced by 30% in cells treated 
with NP17 (p<0.0001) while none of the other treatments had any effect on IL-8 production. CsA 
reduced the production of TNF-α below the level of detection (p<0.0001) (Figure 5.2C). NP-2 increased 
TNF-α production while NP-4 treatment reduced production by approximately 60% compared with the 
PMA/ionomycin group (p<0.0001). Cells treated with PMA/ionomycin did not produce detectable 
levels of IL-1β, IL-10, and IL-12 and so this data is not presented.  
  
Page | 140 
 
     
 
 
Figure 5.2: Hookworm recombinant excretory/secretory protein NP17 significantly reduces 
production of TNF-α from PMA/ionomycin stimulated peripheral blood mononuclear cells (PBMCs). 
PBMCs were isolated from the whole blood of healthy donors, treated with or without recombinant 
Necator americanus proteins (20 µg/ml) and stimulated with PMA/ionomycin 3 hours later. 
Supernatant was collected 24 hours later and assayed for inflammatory cytokines Graphs show 
selected single representatives of experiments carried out three times (each experiment was a 
different individual), n=3-4 for each group in each experiment. Error bars are indicative of four technical 
replicates from the sample blood sample. **** = p<0.0001;** = p<0.01; * = p<0.05 
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When PBMCs were stimulated with LPS, strong IL-6, IL-8, IL-10, IL-1β and TNF-α responses were elicited. 
All of these responses were diminished to varying degrees by dexamethasone treatment (p<0.001; 
Figure 5.3A-E). None of the hookworm protein treatments had an effect on IL-6 or IL-10 production. 
Similarly to the unstimulated group, NP3, NP4 and NP12 all augmented IL-8 release into the 
supernatant (Figure 5.3B). NP3 and NP4 both increased IL-1β production (Figure 5.3E). NP17-treated 
cells had cytokine levels similar to the LPS-only stimulated group with the exception of TNF-α which 
was reduced to the same level as dexamethasone-treated cells (p<0.0001). NP4 and NP12 also reduced 
TNF-α production (p<0.001), although the suppressive effect was less than that achieved for NP17. 
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Figure 5.3: Hookworm recombinant excretory/secretory protein NP17 significantly reduces 
production of TNF-α from LPS stimulated PBMCs. PBMCs were isolated from the whole blood of 
healthy donors, treated with or without recombinant Necator americanus proteins (20 µg/ml) and 
stimulated with LPS 3 hours later. Supernatant was collected 24 hours later and assayed for 
inflammatory cytokines. Graphs show single representatives of experiments, each data point is a 
technical replicate. Experiments were repeated three times. **** = p<0.0001;** = p<0.01; * = p<0.05  
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5.3.2 ProtoArray human protein microarray 
 
Four ProtoArray human protein microarrays were probed individually with a single biotinylated 
hookworm recombinant protein (NP3, NP4, NP12, NP17). Each of the proteins elicited a different 
profile of hits; the top 10 hits for each protein are summarised in Table 5.1. The alpha subunit of 
propionyl-CoA carboxylase (PCCA), a biotin-binding protein control was a significant hit for all of the 
proteins (data not shown), however was only a top 10 hit for NP17.  
 
Figure 5.4: Example image of one array from the four tested recombinant proteins, highlighting a 
significant hit. All proteins on the array are printed in duplicate. Blue boxes denote hits. Yellow spots 
in the magnified image on the right denote orientation controls that are replicated across the array. 
 
A variety of proteins involved in RNA processing, signaling pathways, mitosis, and immunity were 
identified in the top 10 binding partners for each of the proteins (Table 5.1). NP4 most significantly 
bound to TRAF3 interacting protein 1, a protein which binds to and forms part of the TNF receptor 
complex. NP3 and NP4 both bound to SH2 Domain Containing 2A (SH2D2A), a T cell adapter protein. 
NP17’s second most significant hit was to leukocyte receptor cluster member 1. 
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  Rank Protein name Gene Brief description Database ID Z-Score 
NP3 
1 Heterogeneous Nuclear Ribonucleoprotein K HNRNPK  Pre-mRNA processing in nucleus NM_002140.2  15.5651 
2 Dematin Actin Binding Protein DMTN  Actin binding - structural role in erythrocytes BC052805.1 13.6899 
3 Wiskott-Aldrich Syndrome Protein WAS 
Transduction of signals from cell surface receptors to actin 
cytoskeleton 
BC002914.1 13.2461 
4 Alpha Tubulin Acetyltransferase 1 ATAT1 Acetylates alpha tubulin on lysine 40  BC006105.1 11.8336 
5 SH2 Domain Containing 2A SH2D2A   T-cell signal transduction NM_003975.1  11.0692 
6 Splicing Factor 1 SF1 Spliceosome assembly NM_201998.1  10.5161 
7 Proline And Serine Rich Coiled-Coil 1 PSRC1  Mitosis NM_032636.2  10.3568 
8 hypothetical protein MGC2731 - - NM_024068.1  10.2271 
9 G-Patch Domain And KOW Motifs GPKOW  RNA-binding protein - plays role in pre-mRNA splicing NM_015698.2  9.19348 
10 Thyroid Hormone Receptor Interactor 6 TRIP6 Signalling from cell surface to nucleus BC002680.1 9.10054 
NP4 
1   TRAF3 Interacting Protein 1 TRAF3IP1  
Tethers TNF receptor-associated factor 3 to cytoskeletal 
microtubules 
BC059174.1 8.38278 
2 Cortactin CTTN  Actin branching NM_138565.1  6.96568 
3 Ubiquitin Like Modifier Activating Enzyme 6 UBA6 Alters proteins with ubiquitin BC031637.1 5.88249 
4   Polyglutamine Binding Protein 1 PQBP1 
Scaffold protein for pre-mRNA splicing, transcription regulation, 
innate immunity 
NM_005710.1  5.77709 
5 SERPINE1 mRNA Binding Protein 1 SERBP1 mRNA stability BC020555.1 5.71155 
6 Small Nuclear Ribonucleoprotein Polypeptide C SNRPC Spliceosome assembly NM_003093.1  5.62476 
7   Musculoskeletal, Embryonic Nuclear Protein 1 MUSTN1 Development and regeneration of the musculoskeletal system NM_205853.1  5.60881 
8 SH2 Domain Containing 2A SH2D2A  T-cell signal transduction NM_003975.1  5.58579 
9 Sciellin SCEL Regulation or assembly of cornified envelope BC047536.1 5.28643 
10 Proline Rich 16 PRR16 Regulates cell size and mitochondrial respiration BC038838.1 5.27314 
NP12 
1 Alpha Tubulin Acetyltransferase 1 ATAT1 Acetylates alpha tubulin on lysine 40  BC006105.1 10.3024 
2 Thyroid Hormone Receptor Interactor 6 TRIP6 Signalling from cell surface to nucleus BC002680.1 8.55641 
3 Proline Rich 16 PRR16 Regulates cell size and mitochondrial respiration BC038838.1 7.39087 
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4 Polyglutamine Binding Protein 1 PQBP1 
Scaffold protein for pre-mRNA splicing, transcription regulation, 
innate immunity 
NM_005710.1  6.52483 
5 Cell Division Cycle Associated 3 CDCA3  Mitosis NM_031299.2  6.13117 
6 Erythrocyte Membrane Protein Band 4.1 Like 4A EPB41L4A  Regulates interactions between plasma membrane and cytoskeleton NM_022140.2  5.8641 
7   Arginine And Glutamate Rich 1 ARGLU1 Required for ESR1 target gene expression BC050434.1 5.71436 
8 Small Nuclear Ribonucleoprotein Polypeptide C SNRPC  Spliceosome assembly NM_003093.1  5.71127 
9 Single Stranded DNA Binding Protein 3 SSBP3  Transcriptional regulation of alpha 2 collagen gene NM_018070.2  5.56153 
10 CUE Domain Containing 1 CUEDC1  - NM_017949.1  5.47662 
NP17 
1 Propionyl-CoA carboxylase (PCC) PCCA Biotin binding NM_000282.1  20.3827 
2 Leukocyte Receptor Cluster Member 1 LENG1 Leukocyte expressed receptors of the immunoglobulin superfamily NM_024316.1  18.7357 
3 Dead-box helicase 42 DDX42 RNA helicase BC015505.1 13.5748 
4 RD RNA-binding protein NELFE Regulates RNA polymerase II transcription NM_002904.4  11.307 
5 Alpha Tubulin Acetyltransferase 1 ATAT1 Acetylates alpha tubulin on lysine 40  BC006105.1 11.2321 
6 Actin Binding LIM Protein 1 ABLIM1 Binds actin filaments mediating cytoplasmic and actin interactions BC002448.2 10.8754 
7 Nuclear speckle splicing regulatory protein 1 NSRP1 Mediates alternative splicing regulation of pre-mRNAs NM_032141.1  9.9507 
8 Polyglutamine Binding Protein 1 PQBP1 
Scaffold protein for pre-mRNA splicing, transcription regulation, 
innate immunity 
NM_005710.1  9.91107 
9 Proline Rich 30 PRR30 Variable function NM_178553.2  9.40026 
10 Erythrocyte Membrane Protein Band 4.1 Like 4A EPB41L4  Regulates interactions between plasma membrane and cytoskeleton NM_022140.2  8.98633 
 
Table 5.1: Top 10 hits from Protoarray human protein microarrays probed with individual human hookworm recombinant proteins. Results are listed based 
on Z-score.




In this chapter I exposed PBMCs from healthy donors to the four hookworm recombinant proteins. A 
marked increase in IL-6, IL-8, and TNF-α production was observed from cells exposed to NP4, as well as 
an increase in IL-8 from NP-1- and NP-3-treated cells. IL-8 is most prominently produced by monocytes 
and has been shown to be triggered by numerous ligands, metabolic stimulants, bacterial products, 
and cytokines [329,330]. Given that it is broadly implicated in many inflammatory responses, it is 
difficult to conclude why most of the proteins elicited some IL-8 release. PBMCs exposed to NP3, NP12 
and NP17 had IL-6, IL-8 and TNF-α levels similar to untreated controls. These findings highlight the 
differences between individual SCP/TAPS, notably that one of them was pro-inflammatory while the 
others were less so, or even capable of suppressing production of some inflammatory cytokines. 
The key finding from this chapter was that NP17 consistently, across multiple donors, inhibited TNF-α 
release from PBMCs stimulated with either LPS or PMA/ionomycin. The primary TNF-α-producing cells 
from the PBMC mixture are monocytes and M1 macrophages [331]. This means that the TNF-α-limiting 
effect of NP17 must involve these cells in some fashion. Under normal circumstances TNF-α is rapidly 
released following exposure to bacteria-derived LPS or trauma [331]. It plays a pivotal role in the 
regulation of many pro-inflammatory cytokines and is a key orchestrator of the immune response to a 
multitude of infections [331]. Anti-TNF-α mAb drugs such as infliximab and adalimumab are frequently 
used to treat IBD and other immune dysregulated diseases [332]. These drugs are highly effective in 
treating both UC and CD due to their inhibitory effect of TNF-α [332]. Given that IBD is not curable, the 
goal is to send patients into remission by restricting the inflammatory responses that drive disease 
pathology. The finding that NP17 limits TNF-α production is promising and warrants further 
investigation as a potential therapeutic for treatment of IBD. 
When PBMCs were isolated from N. americanus infected individuals and stimulated with adult A. 
caninum ES, a reduced capacity to produce IL-6 and TNF-α was observed [333]. Given that this study 
used mixtures of hookworm antigens, it is unsurprising that a multitude of effects were observed. In 
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contrast, I have shown a single human hookworm ES protein which specifically suppresses TNF-α rather 
than affecting the other cytokines tested. The benefits of this specific targeting of TNF will be discussed 
later in chapter 6.  
I then went on to use human protein microarrays to determine potential binding partners for the 
hookworm proteins. This was a useful tool for garnering insight into the human host targets to which 
the proteins might bind. A large number of hits were identified for each of the proteins with varying 
binding efficacy as measured by a Z score. As each of the proteins were biotinylated, the biotin-binding 
enzyme, PCCA, was an important control to consider. Each of the proteins significantly bound PCCA 
(full data not included), while NP3, NP4, and NP12 had numerous more significant binding partners 
than this protein interaction. Some of the top hits involved immune-related pathways, including 
TRAF3IP1 (for NP4), a protein which interacts with the TNF-α receptor. NP3 and NP4 also bound 
SH2D2A which has been implicated in the control of T cell activation. One of the most significant hits 
for NP17 was binding to the LENG1, a complex involved in a range of immune-related pathways. A 
majority of the top 10 binding partners for each protein were intracellular targets. This result may be 
explained by protein endocytosis, with the key hits being present in the cytosol and cell nucleus [334]. 
Indeed, SCP/TAPS have been shown to be present on N. brasiliensis exosomes which were internalised 
by host cells [255]. The implications for these results in interpreting the PBMC data will be discussed in 
chapter 6. While array technology is useful, a key limitation should be considered when interpreting 
the results here. Normally membrane-bound proteins may not adopt correct conformation in the 
absence of a cell environment or cell membrane [335]. This may mean some of the extracellular targets 
for the tested proteins may have been affected. To overcome this, future experiments should explore 
using RNA-Sequencing (RNA-Seq) which would look at expression levels influenced by real interactions 
between the ligand and their cellular target – this too will be discussed in chapter 6. 
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The key conclusions from probing the human proteome arrays are that these hookworm proteins bind 
(at least in vitro) to a number of human proteins, some of them immune related, highlighting their 
potential mechanisms of action and providing leads for targeted validation of these defined pathways.  
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6  Chapter 6 - General discussion 
 
Humans and other animals across the globe exist in environments heavily populated by pathogenic and 
non-pathogenic microorganisms, as well as toxic and allergenic substances. These include not only 
infectious, disease-causing microbes, but also beneficial commensals. The latter must be kept in check 
and tolerated, while the former is targeted for elimination to ensure optimal health and homeostasis 
are maintained. Interactions between the host immune system and microbes are both unavoidable 
and essential for normal development of the immune system. The observed rise in the prevalence of 
allergic and autoimmune diseases in the developed world, both of which are associated with 
inappropriate immune responses to harmless stimuli, supports the notion that something is out of 
balance with immune development in people from these regions. Societies in general have moved 
towards improved sanitation, cleaner water and superior healthcare, including rapid development of 
screening tools and anti-infective drugs. These practices have had a dramatic impact on the prevalence 
of soil-transmitted helminths and other parasites, to the point where many have now been eliminated 
in most developed nations. In line with increasingly sterile living conditions and decreased exposure to 
infectious diseases, the incidence of inflammatory conditions has exploded. This effect has led many 
researchers to propose that these two phenomena are linked, and research efforts are now focused 
on mechanisms by which to re-establish immune homeostasis without the need for infectious 
exposures.  
Parasites have coexisted with humans throughout our evolution. The eggs from intestinal helminths 
have been found in both human faeces dating thousands of years and in fossilised dinosaur coprolites 
[336,337]. Our bodies and our immune systems have been shaped to manage infestations with 
helminths, while simultaneously some helminths have evolved to manage the pressures imposed on 
them by the immune system, to ensure their survival. Indeed, hookworms in particular are able to live 
for long periods of time within their host without provoking protective immunity or serious pathology 
when present in small numbers. In line with this and through research on related hookworm species, 
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there is strong evidence that hookworms can modify host immune responses. This is thought to occur 
primarily through the release of immunomodulatory molecules in the worm’s ES products. Thus, these 
products derived from natural human hookworm pathogens represent a substantial untapped resource 
of molecules that could be turned into novel therapeutics to treat human inflammatory diseases.  
Before beginning to elucidate any protein functions, I first needed to characterise the N. americanus 
ES proteome. As detailed in chapter 2, reannotation of the genome improved the quality of the ES 
proteome description and was therefore an important first step in this process. The majority of 
published genomes are first-drafts which have frequent missing data, gaps, and errors in reported 
sequences [338]. We found 3,425 fewer genes than the original model with increases in gene lengths 
and the percentage of the genome covered by genes. This new annotation represented a more 
accurate and refined hookworm draft genome. Not only did this improve the quality of the ES proteome 
but it also serves as an upgraded reference tool to study numerous aspects of N. americanus biology 
such as genome evolution and pathogenesis. Using the re-annotated genome, nearly 200 ES proteins 
were identified by LC-MS/MS. Upon analysis I found that SCP/TAPS proteins were the predominant 
protein family. This finding reflects the published data for closely related species including N. 
brasiliensis, A. caninum, and H. polygyrus [194,195,248]. SCP/TAPS proteins have been described from 
various eukaryotic organisms including many helminths [339].  
To date, SCP/TAPS proteins have been reported to have substantial variation in structure and sequence 
which accordingly reflects their diversity of function. These proteins have been implicated in host-
pathogen interactions, defence mechanisms and immunoregulatory roles to name a few. The dominant 
SCP/TAPS subfamily reported in plants is the PR-1 protein family which falls under the category of 
pathogenesis-related proteins. PR-1 proteins, identified in every investigated plant species to date, are 
synthesized in response to stress-inducing factors such as infection with pathogens and plant cutting 
[340]. In vitro, tomato PR-1c impaired growth of Phytophthora infestans, a water mould that causes 
disease in these plants [340]. Similarly, when PR-1 genes in tobacco were selectively expressed, 
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transformed plants showed greater resistance to certain moulds, but not to other fungus, bacteria or 
viruses [340].  In animals, SCP/TAPS make up major components of the venom allergens from biting 
insects such as fire ants and yellow jacket wasps, as well as in the venom of snakes [197]. In the latter, 
two different SCP/TAPS with ~50% homology to mammalian SCP/TAPS were able to block ion channels 
and the depolarisation of smooth muscle membranes [341,342]. Indeed, SCP/TAPS have been reported 
from snakes across five continents [343]. While the mechanism of a few of these proteins have been 
described, most are yet to be elucidated. In vertebrates, SCP/TAPS have been identified in rats, mice, 
rhesus monkeys, and horses. Due to their high expression in the epididymal lumen, they have been 
hypothesised to be involved in sperm-oocyte binding [344]. This aligns with the early finding that 
particular SCP/TAPS are expressed specifically in the human testes and have been implicated in sperm 
maturation [345].  
SCP/TAPS gene orthologues and protein homologues have been frequently reported in helminths. Not 
just in the aforementioned species related to the human hookworm, but also in various other 
nematodes. Three SCP/TAPS proteins - Ov-ASP-1, Ov-ASP-2, and Ov-ASP-3 - have been described from 
Onchocera volvulus, a filarial nematode. Each of these ASPs has been shown to have distinct 
transcription patterns at various stages of parasite development [346,347]. While little is available on 
their function, Ov-ASP-1 was shown to afford some anti-larval immunity in mice [348]. A single 
SCP/TAPS protein from Brugia malayi called Bm-VAL-1 has been identified and found to be specifically 
restricted to larval stages, highlighting the probability for a role in the invasion of the host [349].  
Comparing the expression of SCP/TAPS between free living and parasitic hookworms, the importance 
of these proteins in parasitism becomes clear. SCP/TAPS were the most abundantly represented group 
of mRNAs in activated L3 A. caninum [266]. Ac-ASP-1 and Ac-ASP-2 were found to be a key components 
of the ES proteins of serum-activated L3 larvae [198,199]. Further study showed these proteins to be 
localised to the granules in the glandular oesophagus, indicating a role in host invasion [200]. This was 
expanded on in adult A. caninum worms when four adult-specific ASPs (Ac-ASP-3-6) were described. 
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Ac-ASP-3, like Ac-ASP-1 and Ac-ASP-2, was found to localise to the oesophageal glands of adult worms. 
Ac-ASP-4, 5 and 6 were found to localize to the cuticular surface, intestinal brush border membrane, 
and excretory glands respectively [350]. All four proteins were found in the ES products, supporting the 
notion that they are released by the parasite [350].  Ac-NIF, belonging to the SCP/TAPS family and 
upregulated in adult A. caninum, was reported to block neutrophil recruitment and limit ROS release 
[351]. SCP/TAPS have also been studied from trematodes that infect humans including S. mansoni. Of 
the thirteen identified SCP/TAPS isolated from S. mansoni, transcriptional analysis showed higher 
expression in the invasive stage of the parasite [196]. From this, roles of these proteins in protease 
modulation of the immune response have been suggested [196]. SCP/TAPS have been the focus of a 
large body of research (some of this just described) into understanding host-parasite interactions. The 
vast number of these proteins, the diversity in stage-specific production and localisation, and the small 
number which have had their function explored highlights the importance and potential in choosing 
these proteins to investigate. Of particular importance is the unprecedented expansion of SCP/TAPS 
found in the N. americanus [169]. More than half of the 137 SCP/TAPS proteins were overexpressed in 
adult worms, with only 6 having orthologues in C. elegans [169]. This attests to the notion that 
nematode SCP/TAPS are likely to have developed before parasitism. 
The proteomics data generated in this chapter has implications beyond the scope of this thesis. 
Analyses of other helminth proteomes have shown that ES products are not only a rich source of 
potential immunoregulators but also contain promising vaccine candidates and diagnostic markers. For 
example, SCP/TAPS from both A. caninum and N. americanus have been used in vaccine studies in mice 
and humans respectively [200,201,207]. More recently, a cysteine protease from A. caninum was 
shown to induce high levels of antigen-specific antibodies and confer protection against the parasite in 
a hamster model [352]. I identified 6 cysteine proteases in the ES proteome which could be explored 
for their vaccine potential in rodents and humans. In places where they are endemic, hookworms 
contribute significantly to poverty through their devastating effects on childhood nutrition, mental and 
physical development, productivity, and pregnancy outcomes [353,354]. Given these effects, a vaccine 
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would have a huge impact on the health and economic prosperity of these communities. While no 
vaccines currently exist for any human helminths, research into antigen discovery (including this thesis) 
has undergone exponential growth in the age of systems biology and ‘omics’ [355].  
Given the lack of success in producing an effective vaccine for human helminths thus far, it is unlikely 
that a single parasite antigen will offer sufficient protection as a protein vaccine. Many parasites have 
multi-stage lifecycles that utilize a plethora of strategies to evade immune system detection. To add to 
the complexity, not all individuals elicit immune responses to specific antigens in natural infections 
[169]. With this in mind, the right combination of antigens in the form of a multivalent vaccine may be 
key to a successful vaccine for hookworm and other helminths. Indeed, a vaccine against the blood-
feeding nematode Teladorsagia circumcincta in sheep found that a cocktail of recombinant parasite 
antigens could be used as an effective vaccine [356]. While vaccine-related studies were outside the 
scope of this dissertation, it should be noted that the catalogue of ES products generated may be 
explored for this purpose. The ES molecules are of particular vaccine-relevance due to their direct, 
frequent interaction with the host.  
I also assessed the individual and combined diagnostic potential of each of the four recombinant 
proteins produced in this study. This was carried out by assaying serum IgG levels from individuals in a 
hookworm endemic area of Brazil. For individual proteins the highest score was 60% FoR which 
improved to 82% when 3 of the proteins were combined. This combined score greatly exceeded the 
FoR of the L3 extract, highlighting the diagnostic potential of ES proteins. Indeed, helminth ES products 
from a number of species have been shown to hold immunodiagnostic potential [357,358]. 
Conventional microscopy is the most frequently used method of detecting hookworms. It is however 
limited by the fact that many nematode eggs require specific expertise to diagnose accurately, it can 
be time consuming and may be less accurate in cases of low intensity infections. Given that the four 
recombinant proteins produced in this study were recognized by serum antibodies, the remaining ES 
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proteins offer a database of potentially new immunogenic targets to overcome the drawbacks of 
microscopy-based diagnoses.  
In addition to the soluble proteins identified in the N. americanus ES products, there are other 
components of the ES milieu that should be explored in future work. Extracellular vesicles (EVs) and 
metabolites sourced from ES products have been shown to suppress TNBS colitis and impact on 
cytokine secretion by mammalian host cells [255,359]. Moreover, H. polygyrus EVs were shown to 
suppress eosinophilia and Type 2 innate responses in mice [360]. Recent work demonstrated that a 
single i.p. injection of EVs from N. brasiliensis afforded protection against colitic inflammation in a 
mouse model of disease [255]. These works collectively support exploration of human hookworm EVs. 
Indeed, some of the proteins identified in the ES proteome herein are known to be found in EVs, and 
the ES products were not subjected to ultracentrifugation to remove EVs from the crude prep prior to 
preparation for LC-MS/MS. 
In chapter 3 I successfully expressed 4/18 SCP/TAPS proteins. The remaining 14, despite 
troubleshooting, were unable to be produced using the P. pastoris expression system. This poor rate 
of expression may be overcome in the future using any number of other systems including E. coli, 
Saccharomyces cerevisiae, insect or mammalian cells, or even cell-free expression. Each of these has 
advantages and drawbacks including cost, complexity, scalability, protein yields, endotoxin content and 
more [361-363]. Sometimes certain proteins are expressed better in particular systems, however the 
scope of this project precluded exploring other expression hosts due primarily to time constraints.  
Given that I was still able to produce workable quantities of four proteins, I tested their therapeutic 
efficacy in acute mouse models of inflammatory diseases. I commenced with a chemically-induced 
colitis model which utilised a single i.r. injection of TNBS with ethanol and was able to successfully 
induce many of the clinical features of IBD in mice, including weight-loss and colonic inflammation. The 
TNBS model of colitis was ideal for the purpose of this thesis as it is well characterised in the literature 
and allows for high throughput screening of multiple proteins.  
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The outcomes measured from the TNBS experiments included: weight-loss and clinical scores, colon 
lengths and macroscopic scoring, histology, and colon cytokine profiles. In these experiments none of 
the four hookworm proteins tested were effective at preventing the induction of TNBS colitis. The TNBS 
model has been shown to be a valuable tool for identifying molecules from parasites with immune 
regulatory effects [255,313]. To further explore potential regulatory effects of the recombinant 
SCP/TAPs proteins identified herein, additional studies need to be undertaken, including dosage and 
frequency and route of administration. In support of this, a dose-dependent decrease in inflammation 
was observed in mice treated with A. caninum ES products. Similarly, daily i.p. administration of A. 
caninum ES products also produced a dose-dependent decrease in colon inflammatory cytokines in the 
DSS model of colitis [192]. It may be as simple as adjusting the dose or increasing the frequency of 
dosage of the recombinant proteins.  
No single mouse model encompasses the complexity of human IBD [302]. For this reason, a multitude 
of mouse models have been established, each providing insight into a particular aspect of the disease 
[301]. Other models which could be considered for testing the recombinant proteins include: (1) 
dextran sulfate sodium (DSS), (2) adoptive transfer colitis, and (3) IL-10 KO mice to name a few. In 
comparing the mechanisms underlying each of these models, it is possible to hypothesise varying ways 
in which hookworm ES products may be used to treat colitis, despite not being effective in the TNBS 
model used herein with the current dosing and route of administration schedules. For example, DSS 
and TNBS colitis both employ chemicals to disrupt the colon surface epithelium. Bacteria and other 
large molecules are rendered immunogenic and can translocate and provoke inflammation and 
necrosis [303,364]. In contrast, the IL-10 KO or adoptive transfer colitis models use mice with 
compromised capacity to produce regulatory responses in the form of Tregs and alternatively activated 
macrophages [365,366]. If any of the tested proteins exerted their functions by augmenting adaptive 
immune responses, particularly regulatory cell responses, then the acute nature of the TNBS model 
may not have been sufficient to capture this effect. Indeed, helminth ES products from a number of 
species have been shown to promote Treg cell expansion and limit pathology across multiple models 
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of disease [367]. Moving forward, if future studies were able to produce greater numbers of N. 
americanus recombinant ES proteins and conduct similar studies, it is likely that new 
immunomodulatory molecules would be found. These molecule/s could be characterised by examining 
various immune populations – e.g. effector T cells, DCs, macrophages, Tregs – both at the site of 
inflammation and in lymph nodes. If certain cell types were specifically regulated, this might indicate 
which pathways to explore further. For instance, if regulatory cells were upregulated in mice 
administered with a particular ES protein, it would be prudent to use KO mice to test which receptors 
or pathways might be involved. The alternative to this theory is that these particular proteins have a 
distinct mechanism of action that may not be captured by the model employed. These proteins might 
also need to act in concert with other ES proteins to exert an anti-inflammatory effect.  
To maximise delivery of HDM to the lungs for the asthma model, route of administration was compared 
between i.n. and i.t. A mixture of PBS with blue food colouring was prepared and delivered to mice 
under anaesthetic. Following dissection and using visual inspection the i.t. instillation showed markedly 
greater delivery to the lungs. This was important to confirm as I was utilising one of the most acute 
asthma models, with the smallest number of HDM administrations [307,310]. Following sensitisation 
and challenge with i.t. injections of HDM, I successfully observed HDM-induced airway inflammation 
and a corresponding increase in serum IgE. In particular, eosinophils as well as T and B lymphocytes 
were significantly augmented in HDM mice. This compared well with other studies of OVA and HDM 
mouse models which found increases in these cell populations [203,318]. None of the four hookworm 
recombinant proteins had any effect on the inflammatory response when administered throughout the 
challenge phase of the experiment. This model was selected because it allowed for testing molecules 
in the shortest experimental timeframe as well as requiring a relatively lesser quantity of hookworm 
protein than if employing a chronic model. While I did not see differences with the tested indices, 
others have reported a multitude of factors which are differentially expressed in similar asthma 
models. One study of HDM-challenged mice found 31 mRNAs which were significantly upregulated in 
lung tissue [310]. This included genes linked with human asthma (e.g. ear11, il-10, il-21, clca3) and with 
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leukocyte recruitment in the lungs (e.g. ccl11, 12 and 24). The same study also identified a panel of 
cytokines including IL-4, IL-5, IL-6, IFN-γ, IL-1β, TNF-α, IL-13 and IL-33 which were elevated in the BAL 
and lung tissue. I observed in this study that key markers of inflammation (immune cells and IgE) were 
upregulated in allergen-treated mice. Although there were no differences between protein-treated 
and untreated groups in terms of these inflammatory markers, this does not necessarily mean that 
other factors weren’t affected. Future studies with these proteins would benefit from a more 
comprehensive analysis of disease indicators including gene regulation and lung cytokine levels.  
Earlier in this thesis the sequence similarities were compared between the human hookworm 
secretome and those of published similar species. A key outcome from this comparison was that the 
majority of ES proteins from N. americanus had a significant match to a compared species. Despite the 
relatively high sequence conservation, these matches still contained large tracts of sequence variation. 
It is difficult to draw convincing conclusions as to whether the variation in sequence – and therefore 
folding and function – could be a factor in why the proteins from the human hookworm weren’t 
effective in mouse models of disease. The vast majority of published roundworm-derived immune 
regulatory molecules have come from species which infect non-human animals which have been tested 
in their relevant hosts. Furthermore, the ES products of N. americanus and A. caninum have been 
reported to have varying protein patterns and bind to distinct leukocyte populations [368]. This may 
mean that the human hookworm ES molecules may have distinct effects on the human immune system 
[369]. To rule out host-specific differences it may be useful for future work to utilise more human 
applicable models, building on the ex vivo findings herein using human PBMCs or even intestinal biopsy 
tissue co-cultured with hookworm recombinant proteins.  
As there were no successful therapeutic outcomes from mouse inflammatory models described in 
chapter 4, I moved on to ex vivo screening of the hookworm proteins with human PBMCs. This assay is 
frequently used in the selection of biotherapeutics for its potential to predict immunomodulatory 
compounds as well as test molecule toxicity [321,370]. Initially I sought to determine whether any of 
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the proteins had an inherent pro-inflammatory effect by culturing them for 24 hours with unstimulated 
PBMCs. NP4 induced potent IL-6, IL-8, and TNF-α release into the supernatant when compared with 
untreated cells. Given that all of the proteins were screened for endotoxin prior to the assay, the 
presence of an endotoxin contaminant can be ruled out in interpreting this result. Furthermore, the 
absence of an IL-1β response supports the notion that LPS is unlikely to be present [371]. Further 
purification to remove other contaminants, such as yeast derived zymosan, would be useful in better 
attributing the cytokine responses to the hookworm protein. However, given that these yeast derived 
contaminants were likely present in all samples, the cytokine responses are most likely caused by the 
hookworm proteins. It is likely, therefore, that NP4 through some undetermined mechanism causes 
the release of IL-6, IL-8 and TNF-α. IL-6 is produced by multiple cell types and is involved in a number 
of anti- and pro-inflammatory processes [372]. These processes include the activation and 
differentiation of macrophages and lymphocytes [373,374]. A study of IL-6 KO mice infected with H. 
polygyrus showed that IL-6 limits the Th2 response, modifies regulatory responses and increases host 
susceptibility to infection [374]. While this doesn’t reveal a mechanism for NP4, it does provide a 
possible rationale for an ES protein from N. americanus that causes increased IL-6 production. 
When PBMCs from healthy donors were stimulated with PMA/ionomycin, significantly elevated 
amounts of IL-6, IL-8 and TNF-α were released into the supernatant compared to buffer-treated cells. 
This result was expected, as PMA/ionomycin-stimulated cytokine responses have been well 
characterised [370,375]. As with unstimulated cultures, IL-6 and TNF-α were further augmented for 
cells treated with NP4. Interestingly, both IL-8 and TNF-α were significantly diminished in cells treated 
with NP17 before being stimulated with PMA/ion. TNF-α is a particularly important pro-inflammatory 
cytokine which has been implicated in both Th1 and Th2 mediated immune responses [376]. As 
mentioned earlier, TNF-α upregulation is significantly linked with the development of IBD, but it also 
plays a role in allergic airway inflammation. This has led to the development and use of anti-TNF 
molecules for the treatment of these and other immunological conditions [97]. Furthermore, blocking 
TNF-α in IL-4 KO mice delayed Trichuris muris expulsion, implicating this cytokine in defence against 
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parasitic infections [377]. Given the central role TNF-α plays in immunity against parasitic infections, as 
well as in immune diseases, it makes sense that a hookworm ES molecule would selectively inhibit its 
release. The follow up experiments to determine the molecular mechanism by which NP17 inhibits 
TNF-α release will be discussed later in this chapter. 
When PBMCs were stimulated with LPS, I observed an increase in a number of cytokines. Significant 
levels of IL-1β, IL-6, IL-8, IL-10, and TNF-α were observed from PBMCs 24 hours post-stimulation with 
LPS. This profile of cytokines has been observed in other studies [378,379]. None of the hookworm 
recombinant proteins had an effect on LPS-induced IL-6 or IL-10 production. NP3 significantly increased 
IL-1β, a pro-inflammatory cytokine predominantly released by monocytes and macrophages with a 
protective role against viral and bacterial infections [380,381]. This IL-1β release is dependent on nod-
like receptor (NLR) family, Pyrin Domain Containing 3 (NLRP3) inflammasome activation which can be 
triggered by various PAMPs [380]. In the case of helminth infections, H. polygyrus and T. muris 
infections increased activation of NLRP3 and IL-1β production [382,383]. In contrast to the usually 
protective role, T. muris NLRP3 activation inhibited Th2 immunity [383]. When NLRP3 was ablated, a 
reduction in IL-1β followed, with increases in Th2 responses as well as accelerated helminth expulsion 
[383]. Interestingly, helminth ES products were sufficient in vitro to induce NLRP3 and the 
corresponding IL-1β release [383,384]. This result aligns with my finding that NP3 selectively 
augmented IL-1β release from PBMCs. A rationale for this outcome is that helminths have evolved to 
manipulate these immune pathways, dampen host responses, and prolong their longevity. 
As with the PMA/ionomycin-stimulation experiments, LPS-induced TNF-α release by PBMCs was 
significantly reduced by NP17. Similarly, the TNF-α response from LPS stimulated cells was also 
significantly reduced by NP4 and NP12 but to a lesser degree than NP17. While NP17 decreased TNF-α 
from PMA/ionomycin stimulated cells, NP4 and NP12 did not have this same effect. This result draws 
attention to the differences in cell activation and the corresponding immune signalling pathways 
activated by PMA/ionomycin vs. LPS, and their eventual impact on TNF-α secretion. PMA activates 
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protein kinase C while ionomycin regulates calcium influx [325]. Together these molecules lead to 
activation of intracellular signalling from T cells and increased TNF-α [325]. In contrast, LPS binds to 
TLR4 on monocytes, activates NFκB signalling and consequently augments TNF-α gene expression 
among other pro-inflammatory cytokines [385]. NP4 and NP12 selectively reduced TNF-α production 
from LPS-stimulated cells, indicating that these proteins are affecting monocytes specifically in some 
way. I cannot however draw meaningful conclusions as to the subsequent cell-cell interactions which 
may also be having an effect on cytokine production. For example, TNF-α produced by LPS-activated 
monocytes can cause T cell proliferation and increased cytokine production by those proliferating cells 
[386,387].  
It is important to consider the next steps, as well as limitations of the current study, so that future 
experiments can elucidate the mechanisms of action by which these N. americanus SCP/TAPS proteins 
regulate human immune responses. One of the main limitations of this experiment is that I used whole 
PBMCs rather than specific cell subsets. PBMCs are a heterogeneous cell population made up of many 
immune cell types including, but not exclusively, lymphocytes (70%), B cells (15%), NK cells (10%) and 
monocytes (5%) [388]. This breakdown is highly variable and as such the interpretation of results from 
mixed populations can be challenging. This is due to the fact that certain cell populations communicate 
with and affect other cell responses. For example, LPS-activated macrophages release cytokines that 
can act on lymphocytes to induce more inflammatory cytokines. In this way, the use of stimulants (LPS 
or PMA/ionomycin) in this chapter did not exclusively target specific cell responses. Another point to 
consider is that in a PBMC mixture, as noted above, the ratios of different cell populations can change 
substantially. For this reason, lymphocyte responses (70% of PBMC total) may mask monocyte 
responses (5% total). These complications can be overcome through the isolation of individual 
populations of immune cells prior to experimentation [388,389]. For example, monocyte populations 
can be isolated with positive and negative magnetic sorting techniques using markers such as CD14 
[390]. The same sorting systems could be employed to selectively remove the monocytes and culture 
the lymphocytes specifically. Another option would be using whole PBMCs, to capture cell-cell 
Page | 161 
 
interactions, and using intracellular staining to look at cytokine production from defined cell subsets. 
It would also be prudent to compare immune cells isolated from humans with those from mice. This is 
particularly important due to the frequent use of murine-infecting helminths as a model for the human 
hookworm. It may also add to the overall understanding for the lack of efficacy of these proteins in 
mouse models of disease. Indeed, there are dissimilarities between gene expression profiles of human 
and mouse monocyte subsets [391].  
Isolation of cell populations would be particularly beneficial for future experiments into the mechanism 
of action of these proteins, particularly for exploring gene expression. RNA sequencing (RNA-seq) is the 
gold standard for characterisation of gene expression changes and would be instrumental in further 
characterisation of the proteins and informing future work [392]. By comparing the expression levels 
of specific cell populations treated with and without the ES proteins, the immune pathways they affect 
may be elucidated. All of these future experiments are essential for better understanding the function 
of individual ES proteins from the human hookworm. The next steps include manufacturing 
recombinant versions of many more of these proteins and carrying out similar screening as in this 
thesis. The vast majority of the information available for these proteins is theoretical, based on protein 
family analyses and sequence similarities. Future work should build on the experiments as discussed 
here using functional assays to determine potential effects in situ. By looking more thoroughly at the 
underlying potential gene regulation of these proteins on immune cells the mechanisms of action can 
begin to be unravelled. 
In chapter 5 I used human protein microarrays to begin to explore some of possible binding partners 
for each of the recombinant proteins. Given the lack of functional characterisation for these SCP/TAPS 
proteins, this was a useful way to start to explain the immune regulatory effects seen from the in vitro 
work with PBMCs. NP4 notably increased production of IL-6, IL-8 and TNF-α from otherwise 
unstimulated whole PBMCs. Probing the microarray with NP4 revealed that the most significant binding 
partner was TNF receptor-associated factor 3 (TRAF3) interacting protein 1, a protein involved in 
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tethering TRAF3 to cytoskeletal microtubules [393]. TRAF3 is involved in the mediation of CD40 signal 
transduction which plays a role in TNF receptor immune responses [394]. Through its binding with 
TRAF2, this protein has been shown to regulate activation of NFκB and MAPK [393]. While this result 
does not indicate the specific mechanism by which NP4 functions, it validates the in vitro result and 
provides support for this particular SCP/TAPS protein’s regulation of host immunity. Interestingly, NP3 
and NP4 also bound to SH2D2A on the array; SH2D2A is a T cell-specific adapter protein (TSAd) protein 
involved in T cell activation [395]. This protein has been shown to be induced in activated NK cells as 
well as T cells exposed to activated macrophages [395]. This provides a potential mechanism by which 
NP4 upregulated inflammatory responses in whole PBMC mixtures. Interestingly, a protein from N. 
americanus was shown to bind mouse and human NK cells, inducing IFN-γ production [368]. Future 
work with NP3 and NP4 should include purifying NK cells and checking whether they induce IFN-γ. NP17 
conversely downregulated inflammatory responses, specifically TNF-α. When the human proteome 
array was probed with NP17, the second most significant binding partner identified was LENG1, a 
leukocyte expressed immunoglobulin receptor. The leukocyte receptor complex encompasses a wide 
array of different ligands expressed on NK, cytotoxic T, and myeloid cells [396]. This gene family has 
been broadly implicated in many immune recognition pathways [396]. While little information is 
available on the LENG1 receptor in the literature, this does allude to an immune regulatory role for 
NP17. 
This project began with a reannotation of the human hookworm genome as well as a proteomic 
description of the ES products. This is the first report of the N. americanus secretome and will increase 
capacity for future research in the areas of hookworm derived vaccines, diagnostics and therapeutics. 
I used this data to inform my approach in the following chapters, selecting numerous SCP/TAPS to 
express in a yeast expression system. The aim was to begin to characterise some of these proteins 
through the use of mouse inflammatory models as well as in vitro cultures, and microarray screening 
tools. I have identified one candidate protein which robustly downregulates specific cytokine responses 
in vitro with human PBMCs, and begun to identify putative binding partners using human proteome 
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microarrays. This research broadly advances the knowledge of the variable functions of helminth ES 
proteins. It also adds specific insight into the relatively unknown function of SCP/TAPS proteins, and 
some of the hits from the human proteome array studies now need to be validated. Further work 
should aim at exploring more of these proteins given their abundance and seeming importance across 
many parasitic helminths. Given the increasing burden of chronic inflammatory diseases worldwide, 
there is a greater need than ever to better understand, treat and manage these conditions. This project 
offers a novel resource for the biomedical community and ultimately might contribute to improving 
the outcomes for people with hookworm infection as well as those with chronic immune disorders. 
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7  Chapter 7 – Supplementary data 
 
7.1 Supplementary material from Chapter 3 
 
Sequences of selected Necator americanus proteins sent to IDT. 
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NECAME_01369 (NP4) 
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NECAME_16708 (NP13) 
NT sequence optimised without signal peptide or stop codon, with restriction enzyme sites EcoR1 and 
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Lysogeny broth (LB) low-salt media 
10 g Tryptone (Sigma Aldrich), 5 g NaCl and 5 g Yeast Extract (Sigma Aldrich) were combined, made up 
to 950 ml with dH2O, pH adjusted to 7.5 with 1 M NaOH, and topped up to 1 L before autoclaving on a 
liquid cycle at 121°C for 20 minutes. Solution was stored at room temperature until used. 
Lysogeny broth (LB) low-salt agar 
10 g Tryptone, 5 g NaCl and 5 g Yeast Extract were combined, made up to 950 ml with dH2O, pH adjusted 
to 7.5 with 1 M NaOH, 15 g of agar added, and topped up to 1 L before autoclaving on a liquid cycle at 
121°C for 20 minutes. Solution was stored at room temperature until used. 
50% Glycerol 
50 ml Glycerol (Sigma-Aldrich) was added to 50 ml dH2O. Solution was autoclaved on a liquid cycle at 
121°C for 20 minutes or filter sterilized with a 0.22 µm filter (Millipore) before storing at room 
temperature. 
15% Glycerol 
15 ml Glycerol was added to 85 ml dH2O. Solution was autoclaved on a liquid cycle at 121°C for 20 
minutes or filter sterilized with a 0.22 µm filter before storing at room temperature. 
1% Agarose gel 
1.5 g agarose was added to 150 ml of 1X TAE Buffer and microwaved for 30 second intervals until 
dissolved.  
1X TAE Buffer 
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4.84 g Trizma Base (Sigma-Aldrich), 0.372 g Ethylenediaminetetraacetic acid (EDTA) disodium salt 
dihydrate (Sigma-Aldrich) and 1.14 ml Glacial acetic acid (Chem-supply) were combined and made up 
to 1 L with dH2O. 
Yeast Extract Peptone Dextrose Agar with Sorbitol (YPDS) 
10 g Yeast Extract, 20 g Tryptone, 182.2 g D-Sorbitol (Sigma-Aldrich) and 20 g Agar were combined and 
made up to 900 ml with dH2O. The solution was autoclaved on a liquid cycle at 121°C for 20 minutes. 
20 g Dextrose was dissolved in 100 ml dH2O, filter-sterilised with a 0.22 µm filter, and added to the 
solution to make a total volume of 1 L. For YPDS plates with 100 µg/ml Zeocin (Invivogen), agar was 
allowed to cool below 55°C before adding Zeocin. YPDS agar plates with Zeocin were stored in the dark 
at 4°C and used within 1 week of preparation. 
YPD media 
10 g Yeast Extract, 20 g Tryptone were combined and made up to 900 ml with dH2O. The solution was 
autoclaved on a liquid cycle at 121°C for 20 minutes. 20 g Dextrose was dissolved in 100 ml dH2O, filter-
sterilised with a 0.22 µm filter, and added to the solution to make a total volume of 1 L. 
1 M Sorbitol 
18.22 g D-Sorbitol (Sigma-Aldrich) was made up to 100 ml with dH2O before autoclaving on a liquid 
cycle at 121°C for 20 minutes. 
BMGY 
10 g Yeast Extract, 20 g Tryptone were combined and made up to 700 ml with dH2O. The solution was 
autoclaved on a liquid cycle at 121°C for 20 minutes. 100 ml of 1 M Potassium Phosphate Buffer pH6.0, 
100 ml 10X YNB, 100 ml 10X Glycerol and 2 ml 500X Biotin was added before use. Media that was not 
used immediately was stored at 4°C. 
BMMY 
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10 g Yeast Extract, 20 g Tryptone were combined and made up to 700 ml with dH2O. The solution was 
autoclaved on a liquid cycle at 121°C for 20 minutes. 100 ml of 1 M Potassium Phosphate Buffer pH6.0, 
100 ml 10X YNB, 100 ml 10X Methanol and 2 ml 500X Biotin was added before use. Media that was not 
used immediately was stored at 4°C. 
1 M Potassium Phosphate Buffer pH6.0 
174 g Potassium Phosphate Dibasic (Sigma-Aldrich) was dissolved in 1 L of dH2O to make a 1 M solution. 
136 g Potassium Phosphate Monobasic (Sigma-Aldrich) was dissolved in 1 L of dH2O to make a 1 M 
solution. 868 ml of 1 M Potassium Phosphate Monobasic was added to 132 ml of 1 M Potassium 
Phosphate Dibasic. The pH of the solution was adjusted to 6.0 using 10M Potassium hydroxide (KOH). 
The solution was autoclaved on a liquid cycle at 121°C for 20 minutes.  
10X Yeast Nitrogen Base (YNB) 
67 g of Yeast Nitrogen Base without Amino Acids (Sigma-Aldrich) was made up 500 ml with dH2O. The 
solution was filter-sterilised with a 0.22 µm filter. Media that was not used immediately was stored at 
4°C. 
10X Glycerol 
100 ml Glycerol was made up to 1 L of dH2O. The solution was autoclaved on a liquid cycle at 121°C for 
20 minutes. 
500X Biotin 
10 mg Biotin (Sigma-Aldrich) was dissolved in 50 ml dH2O. The solution was filter-sterilised with a 0.22 
µm filter. Media that was not used immediately was stored at 4°C. 
10X Methanol 
25 ml Methanol (Sigma-Aldrich) was added to 475 ml dH2O. The solution was filter-sterilised with a 
0.22 µm filter. Media that was not used immediately was stored at 4°C. 
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Phosphate Buffered Saline 0.05% Tween-20 (PBST) 
500 µl Tween 20 (Sigma-Aldrich) was added to 1 L of PBS. The solution was stored at room temperature 
until used. 
5% Skim milk in PBST 
2.5 g of Skim milk powder (Coles) was added to 50 ml PBST. 
4X SDS Protein loading buffer 
3.1 ml dH2O, 4 ml Glycerol, 0.8g Sodium dodecyl sulfate (Sigma-Aldrich), 4 mg Bromophenol Blue 
(Sigma-Aldrich), 0.5 ml 2-Mercaptoethanol (Sigma-Aldrich) were combined. 0.378 g of Trizma 
hydrochloride (Sigma-Aldrich) was made up to 2.4 ml with dH2O to make a 1 M solution, and the pH 
was adjusted to 6.8. The 2.4 ml 1 M Trizma HCl was added to the other reagents to complete the loading 
buffer.  
10X SDS Running Buffer 
30 g of Trizma Base, 144 g of Glycine (Sigma-Aldrich) and 10 g of Sodium dodecyl sulfate were dissolved 
in and made up to 1 L with dH2O. 
Western transfer Buffer 
200 ml of Methanol was added to 100 ml of 10X SDS Running Buffer and made up to 1 L with dH2O. 
Buffer A 
DPBS (-/-) (1X) (Life Technologies) 
Buffer B 
DPBS (-/-) (1X) with 500 mM Imidazole (Sigma-Aldrich) 
1 M Sodium hydroxide 
40 g Sodium hydroxide (Sigma-Aldrich) was made up to 1 L with dH2O. 
